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Background: The Nanoporation project set out to explore specific solutions to 
overcome the current challenges of targeted drug delivery (TDD) to tumours using 
magnetic resonance imaging guided focused ultrasound (MRgFUS) to cavitate 
microbubbles (MBs) for increasing cell permeability and to open ‘drug nano-capsules’ 
to release proven active anticancer drugs directly to the tumour site with reduction of 
systemic drug dosage needed for the desired therapeutic effect. 
Objective: The work reported here aimed to develop novel nano-carriers for existing 
anticancer drugs, by establishment of human cancer cell models to evaluate the carriers’ 
encapsulation efficiency in vitro and in vivo, by using animal models and a clinical 
MRgFUS system to investigate the carrier-drug vehicles’ in vivo distribution and 
localised drug release / cellular drug uptake. 
Methods: A novel γ-cyclodextrin (γ-CD) based carrier for encapsulation of 
doxorubicin (DOX) was synthesised and fully characterised. The encapsulation 
efficiency was assessed under various temperatures and pH levels by both chemical 
analysis and in vitro human cancer cell modeling with KB and HCT116 cells. A 
high-throughput in vitro FUS device was designed and applied, in combination with 
carrier-DOX inclusion. SonoVue
®
 MBs was used to investigate TDD in cell 
monolayers. Ex vivo and in vivo trials were carried out with a clinically approved 
ExAblate MRgFUS system (InSightec, Israel) to establish a safe and efficient clinical 
TDD protocol on small rodents.  
Results: The desired γ-CD based carrier greatly reduced DOX’s toxicity and the 
carrier-DOX inclusion was highly stable under physiological temperature conditions as 
well as under a wide range of acidic conditions (pH 1.0 ~ 7.0); the encapsulated DOX 
is slowly released under hyperthermic conditions (up to 50 °C). In the presence of MBs, 
application of FUS with low mechanical indexes, under which no thermal effect was 
observed, enhanced the drug uptake into tumour cells for both encapsulated and free 
DOX. Optimal setups of MR parameters and FUS parameters were identified ex vivo 
xxi 
and in vivo, allowing application of MRgFUS treatments to 4 live mice bearing tumours 
(human colorectal carcinoma, up to 1059.71 mm
3
) under anaesthesia with full recovery. 
Conclusions: The study demonstrated the possibility of translation of the constructed 
γ-CD derivative to potential clinical use as a delivery vehicle for DOX using combined 
thermal and mechanical release mechanisms by clinically applicable MRgFUS– 

























Chapter 1  
Introduction 
The main modalities of treatment for cancer patients are conventional surgery, 
chemotherapy and radiation therapy. Chemotherapy is particularly challenging 
primarily because of limited uptake of drugs by the tumour cells and the significant 
systemic toxicity. Better understanding of tumour biology in recent years and new 
targeted drug delivery (TDD) approaches that are being explored using different 
nanosystems, bioconjugates, administration routes and controlled delivery devices 
provide optimism in developing successful targeted and well controlled cancer therapy 
(Vasir and Labhasetwar 2005). 
In spite of that, the current drug delivery systems exhibit many specific problems: 
1) potencies and therapeutic effects of drugs are limited or otherwise reduced because 
of the partial degradation that occurs before drugs reach a desired target in the body; 2) 
time-release dependent drugs deliver treatment continuously once ingested, rather than 
providing relief of symptoms and protection from adverse events solely when 
necessary; and 3) in vivo circulation and distribution of drugs cannot be well monitored 
and controlled for their targeted delivery and release. Methods are not yet established 
to safely target drugs to specific areas of the body. Therefore, the purpose of reliable 
drug delivery systems is to deploy drugs intact to specifically targeted parts of the body 
through a medium that can control the therapy’s administration by means of either a 
physiological or chemical trigger combined with a visualised monitoring tool 
(Vogelson 2001). To achieve this aim, nanotechnology (nanocarrier) and 
energy-mediated delivery with real-time visualisation based monitoring systems were 
proposed and developed to improve TDD by many researchers during the last decade. 
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1.1 Targeted Drug Delivery (TDD) 
TDD is an intensive research area encompassing several engineering branches, 
physics, physical chemistry, and biology, combined with molecular pharmaceutics and 
etc. It essentially involves connecting a drug release site to a predetermined anatomical 
site with the objectives of high efficacy and safety via controlled drug release location, 
timing, dosage and transport (Kleinstreuer, Childress et al. 2013). The key 
requirements of an effective TDD system include retention, evasion, targeting and 
release. However, many obstacles exist to the purpose of strengthening the therapeutic 
index of a TDD system by selectively delivering it to target areas. Some of these 
concerns have been addressed by recent developments in areas such as liposomes, 
prodrugs, external targeting, controlled gene expression and antibodies (Mills and 
Needham 1999).  
In the various TDD systems, the physico-biochemical properties of the drug carrier, 
the delivery device and optimisation of targeting methodology are the most critical 
factors for successful TDD (Kleinstreuer, Childress et al. 2013). To improve the 
efficiency of TDD, various targeting mechanisms have been proposed. The most 
widely used TDD strategies are passive targeting by accumulation of nanomedicines 
through the leaky vasculature of a tumour or enhancement of permeability and 
retention effects, and active targeting by attaching specific ligands on the surface of 
the carriers to increase affinity towards the site of interest (Torchilin 2000; Farokhzad 
and Langer 2009). 
Besides, researchers have investigated a number of physical energy triggers to 
improve the efficiency of in vivo TDD, which are (Figure 1.1): ultrasound-mediated 
sonoporation, light intervention optoporation, electric field impelled electroporation, 
magnetic field forced magnetoporation, and temperature gradient triggered 
thermoporation, by using, for example, thermal effects or mechanical forces to enhance 
drug delivery within the targeted cells or tissues and to activate the drugs using a 




Figure 1.1 Different physical energy modalities used for drug delivery. Drug 
delivery enhancement through sonoporation, optoporation, electroporation, 
magnetoporation, and thermoporation are illustrated  
(Lakshmanan, Gupta et al. 2013). 
1.2 Nanocarrier 
A nanocarrier is a nanomaterial that is used to transport another substance, such as 
a chemotherapy agent. Widely used nanocarriers include micelles, polymers, 
dendrimers, carbon-based materials, liposomes and some other substances (Qian, Sun 
et al. 2012). Nanocarriers have the potential to improve the therapeutic effect of drugs 
that suffer from poor solubility and poor stability. This is done by improving their 
pharmacokinetics by tailoring the release rate (Blanco, Hsiao et al. 2011; Grazú, Moros 
et al. 2012; Venditto and Szoka Jr 2013), thereby reducing unwanted toxicity and 
changing the distribution of the drug in tissue. Sarker and Workman (Sarker and 
Workman 2007) stated that many existing cytotoxic agents discovered during the 
1960s such as the platinates, camptothecins and adriamycins, which all suffer from 
poor solubility, poor pharmacokinetics, reduction of therapeutic efficacy and various 
harmful side effects, are currently being improved by researchers through the use of 
nanomedicine for anticancer treatments (Davis, Chen et al. 2008). Therefore, 
nanocarriers are increasingly being used to improve the solubility and 
pharmacokinetics of the drug and show promising reductions of adverse side effects 
(Blanco, Hsiao et al. 2011). Figure 1.2 shows advantages of nanocarriers. 
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Figure 1.2 Advantages of nanocarriers for cancer nanomedicines  
(Mousa and Bharali 2011). 
1.3 Motivation 
 TDD trigger: Why focused ultrasound (FUS) and magnetic resonance guided 
FUS (MRgFUS)?  
One of the recently developed physical TDD drivers is focused ultrasound (FUS) 
(Dromi, Frenkel et al. 2007; Ibsen, Benchimol et al. 2011) that allows the deposition of 
ultrasound bio-effects including heating, cavitation and radiation force in deep tissues 
in order to: 1) enhance the permeability of pathological cells; 2) localise drug release 
from nanocarriers; 3) increase extravasation of drugs from carriers; and 4) improve 
diffusivity of drugs (Husseini and Pitt 2008; Deckers and Moonen 2010). For example, 
certain tumour microenvironments are characterised by mild hyperthermia (1 – 2 °C 
above physiological temperature) (Vaupel, Kallinowski et al. 1989; Venditto and 
Szoka Jr 2013) where thermo-responsive drug-carrier nanosystems can be used. In 
addition, ultrasound contrast agent (USCA) microbubbles (MBs) are playing an 
important role in diagnosis of cancer. Nowadays, USCA can not only help to 
distinguish tissues and improve imaging, but can also induce local drug delivery by 
enhancing accumulation of drugs at a targeted tumour site and by increasing tumour 
vascular permeability because of cavitation and oscillatory effects such as 
microstreaming within the sonic field (Lin, Li et al. 2012).  
Based on the treatment strategy of FUS, a new method developed very recently in 
5 
TDD is the combination of magnetic resonance guidance with FUS such that, by 
using MR imaging (MRI) as a tool, the safety profile of FUS-mediated targeted drug 
release and uptake (Dick and Gedroyc 2010) can be improved. Clinical MRgFUS 
systems have been developed by InSightec (work with GE MRI, Haifa, Israel) and 
Philips Healthcare (Amsterdam, The Netherlands). Specifically, many reports state that 
TDD applications to overcome the blood-brain barrier (BBB) can be applied safely, 
reliably and in a controlled manner on rhesus macaques by using an ExAblate 
MRgFUS system (from InSightec) (Vykhodtseva 2010; McDannold, Arvanitis et al. 
2012; Burgess and Hynynen 2013; Jolesz and McDannold 2014). Additionally, Treat et 
al. (Treat, McDannold et al. 2012) have reported their in vivo work using MRgFUS for 
TDD with liposomal doxorubicin in which result in rats have shown that FUS can 
temporarily permeabilise the BBB but without causing evident tissue damage (Figure 
1.3). This indicates that the approach may significantly increase the antineoplastic 
efficacy of the cytotoxic agent in the brain. Further authors have proposed that the 
therapeutic benefit of combined MRgFUS-enhanced chemotherapy, achieved with a 
single treatment, is an important step forward in the development of this technique for 
the improved treatment of patients with malignancies. 
 
Figure 1.3 T2-weighted MR images of a rat brain with implanted 9 L gliosarcoma 
(outlined) before and 1, 2 and 3 weeks after treatment with focused ultrasound 
and liposomal doxorubicin (FUS+DOX; top row) and treatment with liposomal 
doxorubicin (DOX only; bottom row). While the tumour in the rat treated with 
DOX only continued to grow exponentially (R
2
 = 0.999) even after treatment, 
tumour growth in the rat treated with FUS+DOX was visibly slowed in 
comparison (Treat, McDannold et al. 2012). 
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Additionally, researchers from Philips reported their advanced TDD study using 
drug release from temperature-sensitive liposomes (ThermoDox) mediated by 
Sonalleve MR-HIFU (high intensity focused ultrasound) in combination with 
gadolinium-based MRI contrast agent. They found the drug uptake in the targeted 
tumour was increased between 2 to 5-fold 
(http://www.newscenter.philips.com/main/research/news/ 
backgrounders/2011/20110207-mr-hifu-backgrounder.wpd#.UxRsE4UyOSr). The 
same scientists also stated that the visualisation results by MR guidance may provide 
an indication if the treatment was effective and may be capable of identifying regions 
within a tumour that are poorly perfused with blood. 
Therefore, MRgFUS system was selected as a TDD tool in this thesis as it has 
benefits of: 1) being completely non-invasive; 2) providing high-resolution tissue 
imaging guidance; and 3) providing real-time temperature mapping feedback of the 
treatment region. 
 Nanocarrier: Why cyclodextrin (CD) modification?  
In terms of drug carrier development, Venditto and Szoka Jr. (Venditto and Szoka 
Jr 2013) summarised the approved nanomedicines for cancer therapy, where the phases 
of invention, innovation and imitation were identified. As can be seen in Figure 1.4, 
monoclonal antibodies (Figure 1.4 C) and liposomes (Figure 1.4 B) have passed the 
invention and innovation phases and entered the imitation phase before 2000. However, 
polymer based nanomedicine (Figure 1.4 A), especially CD synthesis, began after 1980. 
To date, clinical trials are still in the innovation phase for all CD polymer modification 
and CD-based anticancer nanomedicine such as a remarkable nanoparticle assembly 
containing CD-based polymer and camptothecin (CRLX101), reported by Davis’ team 






Figure 1.4 Invention, innovation and imitation timeline on the plot of publications 
per year with seminal publications highlighted. (A) Polymers; (B) Liposomes; (C) 
Monoclonal Antibodies (Venditto and Szoka Jr 2013). 
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For CDs, among the most common three native ones (α-, β- and γ-CD), α-CD and 
β-CD are known to be renally toxic and disruptive of biological membranes while γ-CD 
and some of its derivatives appear to be much safer (Stella and He 2008). Specifically, 
for the most frequently used cancer chemotherapeutic agent, doxorubicin (DOX), Anand 
et al. (Anand, Ottani et al. 2012) studied since the 90s the binding between DOX and 
unmodified natural CDs. Bekers and coworkers (Bekers, Beijnen et al. 1990; Bekers, 
Beijnen et al. 1991) as well as Dromi et al. (Dromi, Frenkel et al. 2007) experimentally 
demonstrated that DOX bonds significantly to γ-CD, whereas it possesses lower affinity 
to α-CD and β-CD.  
To summarise, two factors: 1) the modification of natural CDs is regarded as novel 
and has unexplored potential; and 2) γ-CD appears to be less toxic and exhibits higher 
binding affinity towards the anticancer agent DOX; have served as the motivation for 
undertaking the rational design and chemical modification of γ-CD as the delivery 
nanocarrier for DOX reported in this thesis. 
1.4 Structure of Thesis 
This thesis reports: 
1) The latest research progress in the field of nanocarriers in anticancer therapy 
and FUS-mediated TDD systems;  
2) The design, synthesis and evaluation of a novel γ-CD based nanocarrier for 
encapsulation and delivery of DOX;  
3) In vitro application of the carrier-drug inclusion by establishment of human 
cancer cell modelling through cytotoxicity assays and drug uptake investigations;  
4) In vitro application of a unique high throughput FUS device (a ‘sonicator’) in 
combination with USCA – SonoVue® MBs to release the drug and/or increase cellular 
drug uptake;  
5) Ex vivo and in vivo pre-clinical trials of TDD in nude mice with a clinical 
ExAblate MRgFUS system.  
Chapters 1 & 2: Introduction & Literature review. This first chapter briefly 
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introduces the motivation of this work as well as the outline of this thesis. Chapter 2 
overviews the literature in the field and summarises the latest advances in nanocarriers 
in anticancer therapy and prospective applications of FUS-mediated TDD systems. 
Chapter 3: Development of a novel γ-cyclodextrin (γ-CD) based nanocarrier 
for doxorubicin (DOX). This chapter presents the detailed design, synthesis and 
evaluation of a novel γ-CD derivative: mono-6’-deoxy-6-[3-(naphthalen-2-yl)-2- 
(amino)propionylamino]-γ-cyclodextrin (carrier 3b) with a β-naphthyl alanine 
residue attached to the primary face of γ-CD. DOX encapsulation efficiency by carrier 
3b was evaluated under various temperatures and pH levels and the potential of the 
carrier 3b conjugate as a thermo-sensitive carrier for DOX is discussed. 
Chapter 4: In vitro study by human cancer cell modelling. This chapter 
provides information on in vitro experimental modelling undertaken on two human 
cancer cell lines: KB (human nasopharyngeal epidermal carcinoma) and HCT116 
(human colorectal carcinoma). It reports a series of cytotoxic and cellular drug uptake 
assays carried out to further validate the encapsulation capability of the carrier 3b for 
DOX under normal physiological conditions. Hyperthermia (up to 50 °C) was 
employed to investigate the potential unloading factors of DOX from the carrier 3b. 
The biological observation of the encapsulation capacity of carrier 3b and the 
potential application of the vehicle in TDD are addressed. 
Chapter 5: FUS mediated TDD: application of a unique in vitro sonicator 
device. A high-throughput in vitro sonicator device with FUS transducers was 
designed and implemented, in combination with USCA, in the form of SonoVue
®
 MBs, 
to test cells’ viability, drug release and cellular uptake of DOX from the drug-carrier 
inclusion. The results obtained by application of FUS in the absence and presence of 
MBs with low mechanical indexes, under which no thermal effects were observed, are 
discussed. Atomic force microscopy (AFM) is reported, to analyse membrane 
morphology of cancer cells upon exposure to FUS. A thermal camera and 
thermocouples were employed to monitor the temperature change during the 
application of FUS. This section of the study thus suggests that the constructed γ-CD 
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derivative may serve as a delivery vehicle of DOX with combined thermal and 
mechanical mechanism, e.g., clinically applicable FUS, -triggered TDD.  
Chapter 6: Ex vivo and in vivo trials with a clinically approved MRgFUS 
system. This chapter describes ex vivo and in vivo pre-clinical trials (without injection of 
drug and carriers) which have been carried out with the clinically approved ExAblate 
MRgFUS system, in order to establish a safe and efficient clinical TDD protocol on 
small rodents with subcutaneous human cancer xenografts. The optimal MRI and FUS 
parameters, as well as the setup of in vivo trials, are introduced to explain the possibility 
of allowing application of MRgFUS treatments in live nude mice bearing subcutaneous 
tumours under anaesthesia with full recovery.  
Chapter 7: Conclusions. The final chapter summarises achievements of the entire 
study, and further discusses and raises remaining problems, suggestions and possible 
solutions for future work. 
1.5 Contributions to Knowledge 
 A novel γ-CD based carrier 3b was successfully designed, synthesised and fully 
characterised for molecular encapsulation of the anticancer agent DOX. The evaluation 
by chemical analysis techniques, in vitro cytotoxic testing and cellular drug uptake 
investigation all showed that the carrier 3b had potent encapsulation ability for DOX. 
 Application of a unique in vitro sonicator device as a FUS source to expose cancer 
cells cultivated in 96-well plate. The use of this standardised device and experimental 
method reduced instrument-related variability in reported results, reduced the time 
associated with the FUS exposure of a large number of wells of a 96 well-plate and 
thus increase the accuracy of exposure duration of cells to encapsulated and 
non-encapsulated drugs. Moreover, with this high throughput device, the established in 
vitro protocol provides an important platform for biologists to carry out FUS-induced 
TDD in cell culture.  
 Successful evaluation and validation that the novel carrier 3b is thermally 
sensitive and stable under mechanical forces through bonding constant (Kbinding) 
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investigation of the carrier-DOX inclusion by exposure to hyperthermia / FUS with no 
thermal effects.   
 Ex vivo experiments offered a satisfactory simulation of in vivo studies, 
highlighting a series of questions and potential problems. A safe and efficient clinical 
TDD protocol was successfully established on small rodents. MRI and FUS parameters 
have been optimised. In addition, an optimal setup was identified that will allow the 
application of MRgFUS treatments to live mice with tumours under anaesthesia with 
full recovery.  
 The first in vivo trial provided many insights into the application of MRgFUS for 
targeted drug release in situ in a small animal model. The presented experiment tested 
and confirmed the feasibility of the MRI and FUS sonication modes.  
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Chapter 2  
Literature Review 
2.1 Introduction 
Cancer remains one of the leading causes of mortality worldwide, affecting over 10 
million new patients every year (Jemal, Siegel et al. 2010). At present, cancer 
treatments include surgical resection, chemotherapy and radiation. However, although 
over 90 chemotherapeutic drugs have been approved for clinical use, their efficacy has 
been severely hindered by dose-restriction toxicity and patient morbidity (Blanco, 
Kessinger et al. 2009). Since two decades ago, nanoscale (10 – 200 nm) therapeutic 
systems have emerged as one of the most novel therapeutic modalities for cancer 
treatment (Duncan 2003; Ferrari 2005; Peer, Karp et al. 2007). 
This chapter reviews the arsenal of nanosystems and molecules available in TDD 
systems for cancer therapy and emphasises the challenges for these nanosystems in the 
same applications. Cyclodextrin derivatives discussed particularly, as they are still 
regarded as novel excipients of unexplored potential (Brewster and Loftsson 2007). In 
addition, factors that may trigger release of anti-cancer agents from nano-vehicles, 
such as temperature, physiological pH environments and ultrasound, are introduced, 
focusing particularly on the MRgFUS mediated TDD that has been proposed as a 
powerful strategy. Finally, a summary discusses the contributions of the literature to 
the field of TDD in cancer therapy and the overall strengths and weaknesses of current 
progress as well as future research directions.  
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2.2 Nanosystems for TDD in Cancer Therapy: 
Potential and Challenges 
Nanotechnology has the potential to revolutionise cancer diagnosis and treatment. 
Pioneers’ contributions from protein engineering and materials science have given new 
hope to novel nano-scale targeting approaches that may bring benefits to cancer patients. 
To date, however, only a few clinically approved nanocarriers exist, incorporating 
anti-cancer molecules to selectively target and bind to cancer cells (Peer, Karp et al. 
2007). These include organic nanocarriers such as liposomes, micelles, polymer-based 
carriers and dendrimers; inorganic particulates like metal (gold and iron oxide) particles; 
and carbon nanotubes (Figure 2.1). In comparison to conventional small molecule-based 
therapies, nanotherapeutic systems have many potential advantages for cancer therapy, 
including higher payload capacity, prolonged blood circulation times, reduced toxicity 
to healthy tissues and improved anti-tumour efficacy (Blanco, Kessinger et al. 2009). 
 
Figure 2.1 Different nanocarriers for cancer nanomedicines  
(From: http://wichlab.com/research/)  
2.2.1 Organic Nanosystems for Cancer Treatment 
Liposomes 
Liposomes are one of the most attractive nanosystems. The interesting property is 
their natural ability to target cancer. Liposomes of certain sizes, typically less than 
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400 nm, can rapidly enter tumour sites from the blood, but are kept in the bloodstream 
by the endothelial wall in healthy tissue vasculature. Anti-cancer drugs such as 
doxorubicin (Doxil
®
, Ben Venue Laboratories, Bedford, Ohio, USA), camptothecin and 
daunorubicin (DaunoXome
®
, Nexstar Pharmaceuticals (Gilead Sciences), Foster City, 
California, USA) are currently being marketed in liposome delivery systems in cancer 
therapy. 
Most of the medical applications of liposomes that have reached the preclinical 
stage are in cancer treatment (Gregoriadis and Wiley 1988; Gregoriadis 1995; Lasic and 
Papahadjopoulos 1998). Kobayashi et al. (Kobayashi, Tsukagoshi et al. 1975), and 
Mayhew et al. (Mayhew, Papahadjopoulos et al. 1976) first demonstrated in vivo 
application of a liposome-encapsulated anti-cancer agent, cytosine arabinoside, in 
animal models, showing that liposome-protected cytosine arabinoside prolonged the 
survival time of mice suffering from L1210 leukemia. Presant et al. (Presant, Proffitt et 
al. 1988) first revealed human solid tumours (Kaposi's sarcoma and malignant 
lymphoma) to be successfully imaged by accumulation of indium 111-labeled 
liposomes in regions of enhanced vascular permeability (Presant, Blayney et al. 1990). 
Gabizon et al. (Gabizon, Peretz et al. 1989) presented the first clinical trial, in which 
liposome-associated DOX improved the tolerance of liver cancer patients by reducing 
side-effects such as nausea and vomiting.  
In contrast, Lasic (Lasic 1998) proposed that most early studies showed that 
liposome-entrapped drug molecules were only poorly bioavailable, which caused 
reduction of cytotoxicity but with a severe negative effect on efficacy. For instance, 
Lasic and Papahadjopoulos (Lasic and Papahadjopoulos 1998), Gabizon et al. (Gabizon, 
Chisin et al. 1991) and Barenholz et al. (Barenholz, Amselem et al. 1993) showed in 
several clinical studies that liposome-associated drugs were rapidly cleared by the 
reticuloendothelial system and had drug leakage during circulation. Therefore, the 
concept of ‘stealth liposomes’ was suggested to revive targeted liposomal drug delivery 
(Lasic 1998).  
Stealth liposomes, also known as long-circulating liposomes, are stabilised by 
polymers such as polyethylene glycol (PEG) (Allen and Cullis 2013). Several studies 
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(Blume and Cevc 1990; Klibanov, Maruyama et al. 1990; Allen, Hansen et al. 1991; 
Maruyama, Yuda et al. 1991; Papahadjopoulos, Allen et al. 1991; Senior, Delgado et al. 
1991) demonstrated that PEG-associated liposomes reduced the mononuclear phagocyte 
system (MPS) clearance. Senior et al. (Senior, Delgado et al. 1991) further reported that 
stealth liposomes have dose-independent pharmacokinetics. Following this, other 
studies demonstrated the therapeutic improvement of PEG-liposomes in animal models 
(Bakker-Woudenberg, Lokerse et al. 1992; Mayhew, Lasic et al. 1992; T.M. Allen 1992; 
Vaage, Mayhew et al. 1992; Woodle, Allen et al. 1992; Woodle, Storm et al. 1992). 
Gabizon et al.(Gabizon, Catane et al. 1994) first published the use of stealth liposomes 
in human studies, followed by a study by James et al. (James, Coker et al. 1994) that 
reported the first clinical trials of PEG-liposomes as DOX carriers (Doxil
®) for Kaposi’s 
sarcoma treatment in HIV patients.  
In parallel, receptor-mediated endocytosis liposomes were demonstrated by 
Leserman  et al. (Leserman, Weinstein et al. 1980), Straubinger et al. (Straubinger, 
Hong et al. 1983) and Leamon and Low (Leamon and Low 1991), and developed by 
Heath et al. (Heath, Fraley et al. 1980) and Martin et al. (Martin, Hubbell et al. 1981). 
Shortly after these publications, Heath et al. (Heath, Montgomery et al. 1983) showed 
that antibody-targeted liposomes improved selective cytotoxicity of liposomal 
anti-cancer drugs to cancer cells. However, Papahadjopoulos and Gabizon 
(Papahadjopoulos and Gabizon 1987) proved that antibody-targeted liposomes could 
not overcome rapid clearance by the mononuclear phagocyte system as well, which 
restricted their in vivo distribution. Therefore, more coupling techniques such as newer 
attachment of antibodies, their fragments and some other ligands to the terminus of PEG 
molecules were investigated to develop the stability of liposomes-drug system (Ahmad 
and Allen 1992; Blume, Cevc et al. 1993; Allen, Agrawal et al. 1994; Lee and Low 
1994; Allen, Brandeis et al. 1995; Hansen, Kao et al. 1995; Maruyama, Takizawa et al. 
1995; Suzuki, Watanabe et al. 1995). Ahmad et al. (Ahmad, Longenecker et al. 1993) 
introduced the improved in vivo survival of targeted-liposomes in a mice lung tumour 




Figure 2.2 The evolution of liposomes: a) Simple liposomes are vesicles that have a 
shell consisting of a lipid bilayer; b) ‘Stealth’ liposomes developed for TDD 
applications, contain target specific biological targets (blue rectangle); c) Cationic 
liposome: DNA complexes have an onion-like structure, with DNA (purple rods) 
sandwiched between cationic membranes; d) Liposome bilayer are assembled 
from cavitands: vase-shaped molecules, with attached hydrophobic and 
hydrophilic chains which can trap angstrom-sized guest compounds (yellow 
diamonds)  
(Safinya and Ewert 2012). 
 
Overall, liposomes have been developed innovatively from the very simple bilayers 
through stealth targeted liposomes and cationic liposomes, to the very recent deep 
cavitand vesicles as drug carriers for anti-cancer agents (Figure 2.2). Notably, liposomes 
have many advantages because of their potency to encapsulate both hydrophobic and 
hydrophilic drugs to achieve reduction of unwanted cytotoxicity.  
In contrast, techniques for developing targeted liposomes are tedious and difficult 
to control. Moreover, liposomes are often cleared out by blood circulation rapidly 
(Allen and Cullis 2013). As mentioned in Chapter 1, Venditto and Szoka Jr. (Venditto 
and Szoka Jr 2013) reported that liposome-mediated nanomedicine had entered an 
imitation stage and that many liposomal anti-cancer nanomedicines have obtained FDA 
approval since mid-1990s. However, from 2000 to 2012, only a couple of anti-cancer 
liposomal-medicines, Lipo-Dox (Allen and Cullis 2013) and Marqibo (Sarris, 
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Hagemeister et al. 2000; Rodriguez, Pytlik et al. 2009) have been approved by the FDA 
Conversely, many other liposomes-based anti-cancer medicines are in the clinical trial 
stage. Therefore, more efforts are needed in order to improve the ‘targeting ligand’ on 
the surface of liposomes to promote the clinical approval.  
Micelles 
Polymeric micelles are supramolecular (Figure 2.3), core-shell nanoparticles that 
offer considerable advantages for cancer diagnosis and therapy. They are relatively 
small (typically in the range of 10 – 100 nm), and have the capacity to solubilise 
hydrophobic drugs as well as imaging agents. In addition their improved 
pharmacokinetics provide a useful bioengineering platform for cancer applications 
(Blanco, Kessinger et al. 2009).  
 
Figure 2.3 Schematic representation of supramolecular structure of polymeric 
micelles (Lu and Park 2013).  
 
Ringsdorf et al. (Gros, Ringsdorf et al. 1981) reported the first use of micelles for 
cancer treatment in the early 1980s and they were first proposed by Bader at al. as drug 
carriers in 1984 (Bader, Ringsdorf et al. 1984). During the next three decades, 
micelle-mediated anti-cancer drug delivery developed rapidly. For example, Tokoama’s 
group (Yokoyama, Inoue et al. 1987; Yokoyama, Inoue et al. 1989; Masayuki, Mizue et 
al. 1990) found DOX-conjugated PEG-b-poly (aspartate) copolymers spontaneously 
formed polymeric micelles in an aqueous environment. Yokoyama et al. (Yokoyama, 
Okano et al. 1991) and Kwon et al. (Kwon, Suwa et al. 1994; Yokoyama, Okano et al. 
1999) then concluded that polymeric micelles significantly prolonged the blood 
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circulation time of associated anti-cancer agents. Shortly after, Kohori et al. (Kohori, 
Sakai et al. 1998) and Kim et al. (Kim, Kim et al. 2004) reported micelle-associated 
paclitaxel (Genexol-PM
®
) which has been approved for the treatment of breast, lung, 
and ovarian cancers in South Korea. At the same time, Matsumura et al. (Matsumura, 
Hamaguchi et al. 2004; Matsumura and Kataoka 2009) published micellar anti-cancer 





 (Hamaguchi, Matsumura et al. 2005; Hamaguchi, Kato et al. 2007), and 
NC6004
®
. Furthermore, several biodegradable micellar anticancer drugs, NK012 
(Hamaguchi, Doi et al. 2010), NC4016 (Gilchrist, Bunemann et al. 1999; Gong, Chen et 
al. 2012) and BIND-014 (Hrkach, Von Hoff et al. 2012) also have been approved in 
different phase clinical trials in Japan, USA and UK recently. Blanco et al. (Blanco, 
Kessinger et al. 2009) noted that polymeric micelles provided a unique and 
complementary nano-platform to the nanosystems including liposomes, polymer-drug 
conjugates and dendrimers in anti-tumour drug delivery applications.  
Nevertheless, many challenges still exist, despite the fact that polymer micelles 
have shown many advantages in drug delivery applications, with an active field of 
research to address them,. Allen et al. (Allen, Maysinger et al. 1999) and Gaucher et al. 
(Gaucher, Dufresne et al. 2005) indicated that the small size of micelles restricts the 
amount of drug that can be loaded in the core. Higher drug loading requires increasing 
micelle size and aggregation. Thus, Kim et al. (Kim, Shin et al. 1998) suggested that 
drugs would be released faster from the micelles because of their small size and limited 
drug loading, causing to premature release before the micelle reaches its desired 
targeted site. Additionally, Jones and Leroux (Jones and Leroux 1999) have raised 
several questions regarding the long-term stability of polymer micelles. In response to 
these concerns, several groups such as Bontha and coworkers (Bontha, Kabanov et al. 
2006) and Xu et al. (Xu, Tang et al. 2004) started examining core-cross linked micelles 
to improve micelle-drug stability in vivo. Finally, problems of anti-tumour efficacy of 
micelles in the clinical setting have been raised as well. To solve these issues, many 
researchers have explored new methods to ensure the accumulation of the micelles at 
the tumour site and release of their contents in a controlled, predetermined fashion 
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(Blanco, Kessinger et al. 2009).  
Dendrimers 
A dendrimer is tree-like polymer, generally described as a spherical body with a 
high degree of surface functionality and versatility (Holister, Vas et al. 2003). Two 
approaches have been developed to synthesise dendrimers. The first, called ‘divergent 
synthesis’ was reported by Vögtle’s group (E.Buhleier 1978). Pioneers, including 
Denkewalter’s team (Denkewalter, Kolc et al. 1981) from Allied Corporation, Tomalia 
and coworkers (James R. Dewald 1983; Tomalia, Baker et al. 1985) at The Dow 
Chemical Corporation and Newkome et al. (Newkome, Yao et al. 1985), described the 
first generation of dendrimers independently. Shortly after, Fréchet et al. (Hawker and 
Frechet 1990) introduced another new approach named ‘convergent synthesis’ of 
dendrimers.  
The family of dendrimers has been greatly developed by the above two methods 
and especially in applications of drug delivery, gene delivery and chemotherapy. From 
2000, Bosman et al. (Bosman, Janssen et al. 1999), Fréchet (Fréchet 2001), Donald  
(Donald 2005) reported over 100 compositionally different dendrimer families as well 
as over 1000 surface chemical modification methods (Nanjwade, Bechra et al. 2009).  
Lee and coworkers (Lee, MacKay et al. 2005), Svenson and Tomalia (Svenson and 
Tomalia 2005) and Yang and Kao (Yang and Kao 2006) identified and reviewed the 
potency of dendrimers as nanocarriers, particularly in biological and pharmaceutical 
applications. Gillies and Frechet (Gillies and Frechet 2005), Khan et al. (Khan, 
Nigavekar et al. 2005), and Tomalia et al. (Tomalia, Reyna et al. 2007) raised the 
increasing significance of dendrimer-based nanosystems in oncological applications as 
dendrimers’ unique properties are highly suitable for effective delivery of anti-cancer 
agents. In 2008, Wolinsky and Grinstaff (Wolinsky and Grinstaff 2008) described more 
dendrimer derivatives developed for greater specificity and functionality in 
pharmacokinetics and targeted delivery as the relationships between architecture, 
biocompatibility, retention and delivery of dendrimer families have become clearer. 
Wolinsky and Grinstaff further showed substantial progress in dendrimers applications 
for cancer diagnosis and treatment, including advances in the delivery of both 
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anti-neoplastic and contrast agents.  
After dendrimers started to be used clinically, in the early 1990s, Wu et al. (Wu, 
Brechbiel et al. 1994) and Wiener et al. (Wiener, Brechbiel et al. 1994) introduced the 
application of dendrimers conjugates in MRI of tumours. Kukowska-Latallo et al. 
(Kukowska-Latallo, Candido et al. 2005) reported preliminary results showing that 
methotrexate-containing polyamidoamine (PAMAM) dendrimers significantly reduced 
subcutaneous tumours in mice. In the same year, Patri et al. (Patri, Kukowska-Latallo et 
al. 2005) and Choi et al. (Choi, Thomas et al. 2005) further reported PAMAM with 
methotrexate-containing / generation 5 (G5) that was covalently conjugated with folic 
acid specifically to target high folate receptor-expressing cancer cells after intracellular 
delivery of the drug through receptor-mediated endocyctosis. Independently, Quintana 
et al. (Quintana, Raczka et al. 2002) synthesised an ethylenediamine core PAMAM of 
G5 dendrimer which was covalently attached to folic acid, fluorescein, and 
methotrexate. Kasai et al. (Kasai, Nagasawa et al. 2002) and Shimamura et al. 
(Shimamura, Kasai et al. 2006) provided research data relating to novel arginine-rich 
dendrimers, TX-1943 (with 8 Arg residues) and TX-1944 (16 Arg residues), that can be 
used to suppress the growth and metastasis of solid tumours. To date, many researchers 
(Hu and Zhang 2012; Lim and Simanek 2012; Mattheolabakis, Rigas et al. 2012) 
reported frequent employment of DOX and paclitaxel that were covalently bonded to 
dendrimers in cancer treatment research.  
Cheng et al. (Cheng, Wang et al. 2008) and Bawarski et al. (Bawarski, Chidlowsky 
et al. 2008) discussed the ideal size, tenability, and multifunctional capability that make 
dendrimers an excellent nanocarrier to enhance multiple drug interactions to deliver 
chemotherapeutic agents to specific tumour sites for tumour targeting and therapy. 
Those advances achieved in dendrimer-based delivery systems over the last two decades 
have led to development of large number of dendrimer technologies in oncology 
applications (Wolinsky and Grinstaff 2008). However, the continued research in the 
area of targeting to a specific cancer (Figure 2.4) still needs to be improved to increase 
specificity and efficacy towards the diagnoses and treatment of cancer in the clinic. 
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Figure 2.4 Dendrimer-based, cancer-targeted drug delivery.  
(a) Dendrimers with multiple surface functional groups can be directed to cancer 
cells by tumour-targeting entities. (b) The next step is intake into the cell, which 
occurs by membrane receptor-mediated endocytosis in the case of targeting group. 
(c) Once inside the cell, the drug generally must be released from the dendrimer. 
(d) Finally, the dendritic scaffold disintegrates.**TAAs refers to tumor associated 
antigens (Sampathkumar and Yarema 2007). 
2.2.2 Inorganic Nanosystems 
Inorganic nanosystems are attracting increasing attention in nanomedicine since 
many investigations on metal / metal oxide nanoparticles (NPs), quantum dots (QDs) 
and carbon nanotubes (CNTs) have shown that the biocompatibility of these 
nanosystems might be determined by functionalisation rather than by size, shape or the 
material, as summarised by Son et al. (Son, Bai et al. 2007). Specifically, Son et al. 
addressed the fact that inorganic nanosystems permit a wide range of functionality 
arising from their unique optical, electrical and physical properties, and that they might 
also provide novel solutions to overcome many physical barriers into the cell that 




Metallic NPs are versatile agents with a variety of biomedical applications 
including: highly sensitive diagnostic assays (Baptista, Pereira et al. 2008; Selvan, Tan 
et al. 2009); radiotherapy enhancement (Hainfeld, Slatkin et al. 2004; Huang, Jain et al. 
2007); and drug and gene delivery (Thomas and Klibanov 2003; Han, Ghosh et al. 
2007). The nanostructured metal powders are typically reduced to the necessary particle 
size using metal salts or some type of corrosive alcohol. Metallic NPs include Au, Fe, 
Cu, Ag, Pt, Ru and Re etc. as well as their oxides, Al2O3, MgO, ZrO2, CeO2, TiO2, ZnO, 
Fe2O3, SnO and so on. The most popular are gold NPs (AuNPs) and iron oxide NPs. 
AuNPs, also known as colloidal gold, are nanosized Au particles in suspension. 
Specifically in cancer diagnosis and therapy, for example, El Sayed et al. (Huang, Jain 
et al. 2007) established that AuNPs assist cancer imaging through selectively 
transportation into the nuclei of cancer cells. Shortly after, Qian et al. (Qian, Peng et al. 
2008) introduced the development of cancer targeted AuNPs as a probe for Raman 
scattering in vivo and suggested that the highly specific recognition and detection of 
human cancer cells and active targeting of epidermal growth factor receptor 
(EGFR)-positive tumour xenografts in animal models can be made using 
surface-enhanced Raman scattering. Moreover, as previous spherical AuNPs 
absorptions were not optimal for applications in vivo, the invention of rod-shaped 
AuNPs by Murphy’s team (Busbee, Obare et al. 2003) circumvented the issue by tuning 
the absorption peak of the AuNP rods then making them selectively accumulate in 
tumours under laser light (IR region). Surrounding tissue is barely warmed as nanorods 
convert light into heat to kill the malignant cells. Several types of AuNPs were able to 
do this, up to 70 °C through near-IR light excitation or oscillating magnetic field 
stimulation, reported by Paciotti et al. (Paciotti, Myer et al. 2004), Visaria et al. (Visaria, 
Griffin et al. 2006) and Cheng et al. (Cheng, A et al. 2008), respectively. 
Iron oxide NPs include three main oxides of Fe2O3, FeO and Fe3O4 that are reddish 
brown and usually magnetic. Their biomedical applications in cancer treatment include 
TDD, gene delivery and stem cell tracking due to their ultrafine size, magnetic properties 
and biocompatibility (Mody, Siwale et al. 2010). For example, Sun and coworkers (Sun, 
Veiseh et al. 2008) developed a chlorotoxin (CTX)-conjugated superparamagnetic iron 
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oxide nanoprobe coated with PEG, which permits detection of glioma tumours via the 
surface-bound targeting peptide. Johannsen et al. (Johannsen, Gneveckow et al. 2007) 
presented another Phase I clinical study in which magnetic iron oxide NPs locally killed 
prostate tumour cells. Furthermore, iron oxide coated with aminosilane (Nanotherm M01) 
has been in Phase II clinical trials in Germany for treatment of brain cancer and recurrent 
prostate cancer using hyperthermia as well as thermal ablation methods (Alexis, Pridgen 
et al. 2010). Further development and modification of iron oxide is possible in 
combination with dendrimers, polymer-based NPs and liposomes. However, the toxicity 
of these magnetic NPs to certain types of neuronal cells is still a matter of concern 
(Pisanic, Blackwell et al. 2007). 
Quantum Dots (QDs) 
QDs, nanoscale light-emitting particles, are emerging as a new class of fluorescent 
probe for in vivo biomolecular and cellular imaging (Gao, Yang et al. 2005). Major 
advances have been made in their use for highly sensitive cellular imaging applications 
because of the particular properties of narrow and size-tunable emissions with superior 
signal brightness and greater resistance to photobleaching. QDs can also be 
functionalised with targeting ligands such as antibodies (Howarth, Liu et al. 2008), 
peptides (Akerman, Chan et al. 2002), DNA (Farlow, Seo et al. 2013), and small 
molecules that simultaneously passivate the inorganic core and provide the particles with 
additional functionalities (Kim, Tonga et al. 2013). These properties make QDs versatile 
nanoscale bases for designing multifunctional NPs with both imaging and therapeutic 
functions (Smith, Duan et al. 2008).  
Many attempts have been made to use QDs for tumour targeting under in vivo 
conditions. In the case of active targeting, QDs were functionalised with tumour-targeting 
molecules to selectively bind to cancer cells (Gao, Yang et al. 2005). While QDs 
involving passive targeting use the enhanced permeation and retention of tumour cells 
(Jain 1999; Jain 2001) for delivery, the first use of QD-peptide conjugates for targeting 
tumour vasculatures was reported by Akerman et al. (Akerman, Chan et al. 2002) in 2002, 
but unfortunately the QD probes were not detected in living animals. Shortly after, Gao et 
al. (Gao, Cui et al. 2004) demonstrate successful application of a new class of 
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multifunctional QD probes for simultaneous targeting and imaging of tumours in live 
animals. 
The remaining issue of QDs is their cytotoxicity in vivo. For example, Derfus et al. 
(Derfus, Chan et al. 2004) reported that CdSe nanocrystals were highly toxic to cultured 
cells under UV illumination, as the QDs can be dissolved under the energy of UV 
irradiation which is close to the covalent chemical bond energy of CdSe nanocrystals. In 
contrast, Ballou et al. (Ballou, Lagerholm et al. 2004) found that QDs with a stable PEG 
coating showed no toxicity in mice. Finally, many other questions such as how to find the 
optical and electrical properties to explain QDs’ energy states in theirs structures is an 
essential step (Mohammadi and Bahrami 2014) and must be carefully evaluated before 
QD applications in tumour or other diseases can be approved for human use. 
Carbon Nanotubes (CNTs) 
CNTs are the leading inorganic nanosystem for biomedical application. Kostarelos’ 
group (Lacerda, Bianco et al. 2006; Kostarelos, Lacerda et al. 2007) discussed their 
toxicology and pharmacology properties extensively. As the electrical conductance of 
CNTs is sensitive and changes with their surface adsorption, CNTs have been proposed as 
a sensor element for detection of biological molecules such as cancer markers (Collins, 
Bradley et al. 2000; Kong, Franklin et al. 2000; Shim, Javey et al. 2001). Specifically, a 
bio-molecular detector based on single-wall CNTs (SWCNTs) has been reported as a 
highly specific electronic sensor to detect important bio-molecules in the human body 
(Chen, Bangsaruntip et al. 2003). In 2005, Li et al. (Li, Curreli et al. 2005) introduced 
another type of biosensor based on SWNTs which were integrated into a biosensor for the 
detection of prostate cancer and, in the same year, Li et al. (Li, Zhang et al. 2005) 
successfully detected prostate-specific antigen (PSA), an interesting target for both 
imaging and therapeutic intervention in prostate cancer (Schülke, Varlamova et al. 2003), 
using SWCNTs. 
Although CNTs have attracted particular growing attention as new vectors for the 
delivery of therapeutic molecules because of their ease of translocation across cell 
membranes and the low toxicity demonstrated by many researchers (Bianco and Prato 
2003; Pantarotto, Singh et al. 2004; Vardharajula, Ali et al. 2012), issues of ultimate 
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biocompatibility of CNTs have limited their widespread use in biomedical applications. 
For instance, SWCNTs’ pulmonary toxicity was proved by Lam et al. (Lam, James et al. 
2004) who showed, through animal models, that they are much more toxic than carbon 
black and can be more toxic than quartz. 
 
Figure 2.5 Conceptual diagram of (A) single-walled carbon nanotube (SWCNT) 
and (B) multi-walled carbon nanotube (MWCNT), showing typical dimensions of 
length, width, and separation distance between graphene layers in MWCNTs 
(Reilly 2007). 
2.2.3 Summary 
To sum up, non-specific accumulation into healthy tissues is always a concern for 
NP drug delivery systems. Typically, inorganic nanosystems such as metallic NPs use 
local sensitisation through light or temperature which may reduce overall toxicity but 
are expected to damage adjacent healthy tissues as well. In most applications, organic 
bio-nanosystems such as liposomes (Park 2002) and biodegradable polymers (El-Sayed, 
Hoffman et al. 2005) have played key roles in nanomedicine because they are 
considered to be safer in the human body. Inorganic nanosystems such as metals and 
metal oxide NPs as well as CNTs have been limited by safety issues and may not 
provide advantageous over organic nanosystems as they are not biodegradable, have 
low payloads, and have no controlled release properties (Alexis, Pridgen et al. 2010). 
On the other hand, Ferrari (Ferrari 2005) and Hillebrenner et al. (Hillebrenner, 
Buyukserin et al. 2006) have suggested that inorganic nanomaterials have fundamental 
advantages over bioorganic nanosystems such as liposomes, dendrimers, and 
biodegradable polymers in terms of size, shape control and surface functionalisation. 
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2.2.3 Cyclodextrin (CDs) Based Nanocarriers 
Overview 
CDs are natural, cyclic torus-shaped oligosaccharides mostly composed of 6, 7, or 
8 D(+)-glucose units, named α-, β-, and γ-CD, respectively (Szejtli 1988; Allegre and 
Deratani 1994). CDs have a variety of applications in the pharmaceutical industry due 
to their complexation ability and other versatile characteristics (Arun, Ashok et al. 
2008). One of the most noteworthy of these is the application of CDs as drug 
encapsulants in controlled release systems. As drug encapsulants, Uekama et al. 
(Uekama, Hirayama et al. 1998; Uekama 2004) noted that, because of the unique 
capability of forming inclusion complexes in the inner cavities and many other 
favourable physicochemical and biological properties, natural CDs and their 
derivatives have been applied in drug delivery systems to improve the solubility, 
stability, bioavailability, therapeutic index, efficacy, pharmacokinetics and biosafety of 
many hydrophobic drugs, with many concomitant pharmacological benefits such as 
reducing unwanted side effects.  
The interior cavity of a CD molecule is considerably more lipophilic than the 
aqueous environment while its exterior surface is relatively hydrophilic. These 
properties account for its capability to act as a complexing agent to increase solubility 
of lipophilic drugs, to further assist in increasing their stability and bioavailability 
(Brewster and Loftsson 2007; Tafazzoli and Ghiasi 2009). Generally, CDs do not 
penetrate lipophilic membranes as they are large, with a number of hydrogen donors 
and acceptors (Arun, Ashok et al. 2008) and they normally carry and transport 
non-covalently bound drugs to the targeted cells (Yamanoi, Kobayashia et al. 2006). 
Figure 2.6 summarises the characteristics of natural CDs. 
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Figure 2.6 Characteristics of natural CDs; a: Stability constants (K1:1) of 1:1 
guest/CD complexes in aqueous solutions at 25 ± 5 °C  
(Connors 1995; Brewster and Loftsson 2007). 
 
Research studies in animals and humans have shown that CDs and their derivatives 
can be used to improve drug delivery for almost any type of drug formulation from 
anti-cancer drugs to anti-viral drugs (Tiwari, Tiwari et al. 2010). When some cancer 
drugs are combined with CDs, their bioavailability increases. It takes far less of a drug 
to produce cancer killing effects if its bioavailability can be controlled in the 
bloodstream and acceptable drug levels are reached more effectively and precisely. CDs 
can thus make cancer treatment far less debilitating for a patient undergoing 
chemotherapy: less of a toxic drug in a person’s system may lead to fewer side effects.  
History of CD development 
CDs were first introduced in 1891 (Villiers 1891). Schardinger (Schardinger 1903; 
Schardinger 1911) then laid the foundation of CD chemistry and identified both α-and 
β-CD during the period 1903 – 11. In the 1930s, γ-CD was discovered by Freudenberg 
and Jacobi (Freudenberg and Jacobi 1935), and the hypothesis that larger CDs might 
exist was suggested in 1948 (Freudenberg and Cramer 1948). This hypothesis was later 
verified by French (French 1965) in 1965. Freudenberg et al. further demonstrated that 
CDs are cyclic oligosaccharides formed by glucose units, and shortly after, Cramer and 
coworkers described their ability to form inclusion complexes (Cramer 1954). By the 
early 1950s, the basic physicochemical characteristics of CDs had been discovered, 
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including their ability to solubilise and stabilise drugs. The first CD-based patent was 
issued in 1953 (Freudenberg 1953). However, pure CDs suitable for pharmaceutical 
applications did not become available until about two decades later, when the first 
CD-containing pharmaceutical product was marketed in Japan. CD-containing products 
appeared on the European market later and in 1997 also in the US. New CD-based 
technologies are constantly being developed and, thus, 100 years after their discovery, 
they are still regarded as novel excipients of unexplored potential (Brewster and 
Loftsson 2007).  
Chemical and Biological Properties of CDs 
CDs are relatively large, with molecular weight (MW) 1000 – 2000. They are 
chemically stable in aqueous alkaline solutions but are susceptible to hydrolytic 
cleavage under strong acidic conditions (Bender and Komiyama 1978; Hirayama, 
Yamamoto et al. 1992). CDs and their complexes will penetrate hydrophobic 
bio-membranes only with considerable difficulty under normal conditions. 
Arima et al. (Arima, Adachi et al. 1990) and Uekama et al. (Uekama, Adachi et al. 
1992) concluded stratum corneum was the main barrier to percutaneous absorption of 
CDs, and that penetration enhancers which decreased the barrier properties would 
enhance penetration of hydrophilic CDs into skin. For instance, Gerlóczy et al. 
(Gerlóczy, Antal et al. 1988) demonstrated that the absorption of 
heptakis(2,6-di-O-methyl)-β-CD (14C-DIMEB/DMβCD) was negligible even it was 
assumed that the absorption might be greater into skin. Another study reported by 
Tanaka et al. (Tanaka, Iwata et al. 1995) in 1995 showed that only 0.02% of topically 
applied radio-labelled hydroxypropyl-β-cyclodextrin (HPβCD) was absorbed by intact 
skin of nude mice under occlusive conditions. However, within the same study, around 
24% of HPβCD was absorbed into stripped skin. Some other bio-membranes were 
found to be slightly more permeable towards CDs, as summarised by Irie and Uekama 
(Irie and Uekama 1997) and Merkus et al. (Merkus, Verhoef et al. 1999). For example, 
Reeuwijk et al. (Reeuwijk, Irth et al. 1993) illustrated that 2.5 – 4% of nasally 
administered DMβCD was recovered in the urine in one clinical study. Another 
example addressed by Szatmári and Vargay (Szatmári and Vargay 1988) showed that 
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less than 10% of orally administered DMβCD was absorbed in rat trials.  
In terms of CDs becoming drug carriers, Bergeron (Bergeron 1984) proposed that, 
in theory, water molecules entrapped in CD’s interior cavity cannot satisfy their 
hydrogen-bonding potential and have higher enthalpy than bulk water molecules located 
in the aqueous environment. Therefore, in the aqueous environment, CDs can form 
inclusion complexes with many hydrophobic drugs through a process in which Loftsson 
and Masson (Loftsson and Masson 2001) suggested that water molecules located inside 
the central cavity are replaced by either the whole drug molecule, or more frequently, by 
some hydrophobic part of the drug. The driving force of complex formation was 
suggested by Loftsson and Brewster (Loftsson and Brewster 1996) to be enthalpy-rich 
water molecules releasing from CD’s interior cavity and thus lowering the energy of the 
whole system. However, Loftsson and Brewster also proposed that other forces may 
also be involved in CD-drug inclusion complexes including van der Waals interactions, 
hydrogen bonding, hydrophobic interactions, release of structural strains and changes in 
surface tension. Figure 2.7 shows CD-based nanocarriers carrying anti-cancer drug to 
bio-systems.     
 
Figure 2.7 Schematic representation of the systemic absorption of drug from its 
CD complex through biological membranes (Uekama, Hirayama et al. 1998). 
 
In summary, with regard to CDs’ permeability, it is generally believed that drug 
uptake by tissues is not possible with CD-drug complexes or free CDs, as stated by 
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Loftsson and Bodor (Loftsson and Bodor 1995), Rajewski and Stella (Rajewski and 
Stella 1996), and Uekama et al. (Uekama, Hirayama et al. 1998), respectively. On the 
aspect of the form of CD-drug inclusions, Stella and Rajewski (Stella and Rajewski 
1997) proposed that no covalent bonds were involved in CD-drug complex formation 
and drug molecules located within the interior cavity were in a very dynamic 
equilibrium with free drug molecules in the solution.  
Modification of CDs as anticancer drug carriers 
With the properties of drug-CD inclusion as a basis, from 2000, more and more 
modified CDs have been employed to improve the native CDs’ efficacy in 
transportation of anticancer agents and reduction of unwanted side-effects in TDD 
system for cancer therapy.  
Bhardwaj et al. (Bhardwaj, Dorr et al. 2000) reported the result of increased 
binding between the anticancer drug Mitomycin C and 2-hydroxypropyl-β-CD 
(2-HPβCD) and an attempt to reduce skin necrosis by employing the complex. Two 
years later, Xiang and Anderson (Xiang and Anderson 2002) found that the generation 
of supersaturated solutions of another anti-cancer agent, Silatecan, was possible by 
converting a precursor to the lactone at an appropriate pH in a sulfobutylether-β-CD 
(SBEβCD) solution. Shortly after, Sætern et al. (Sætern, Nguyen et al. 2004) proved 
that the solubility of Camptothecin had been increased by 30 to 50-fold by adding 
HPβCD-complexation. In parallel, Cheng et al. (Cheng, Khin et al. 2003) redesigned the 
linear β-CD polymer as a protection carrier for camptothecin on the basis of a linear CD 
copolymer patent obtained by Davis et al. (Davis, Gonzalez et al. 2004) in 2003. A year 
later, Cheng’s team (Cheng, Khin et al. 2004) further reported optimised conditions for 
β-CD polymer-camptothecin conjugates including HGGG6, LGGG10, HG6 and 
HGGG10 in small animal studies.  
In 2006, Phase I clinical trials with the CD-based polymer CRLX101 were first 
reported, then Davis (Davis 2009) took Insert Therapeutics-101 (IT-101, a CD 
polymer-camptothecin conjugate) into a Phase II trial in 2008 and was expected to 
complete the entire trial in 2013. At the same time, Yurkovetskiy and Fram 
(Yurkovetskiy and Fram 2009) also introduced another CRLX101-containing 
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camptothecin (XMT-1001) into a Phase II clinical study with Cerulean Pharma Inc. 
Since then, Davis et al. and their industrial partners have taken CD-based carrier 
transport anti-cancer agent/siRNA conjugates into clinical study (Venditto and Szoka Jr 
2013).    
As can be seen, β-CD is the most commonly applied medical research (Giordano, 
Novak et al. 2001; Loftsson and Masson 2001; Singh, Sharma et al. 2002; Loftsson 
and Duchene 2007) taking in 83.9% of all CD applications, while the application of 
γ-CD is only 6.5% (Kurkov and Loftsson 2012). However, as γ-CD is constituted by 8 
glucopyranoside units, it has the largest toroid compared to α- and β-CD and has 
demonstrated the highest solubility, the lowest toxicity and better complexing ability 
(Giordano, Novak et al. 2001). Additionally, both α-CD and β-CD and a number of 
alkylated CDs are known to be renally toxic and disruptive of biological membranes. 
γ-CD and some of its derivatives appear to be much safer (Stella and He 2008). These 
are key issues in the present study and are the reasons why native γ-CD has been 
selected as the modification model for delivery of DOX. 
Overall, CDs are potent nanocarriers to overcome some of the formulation and 
delivery limitations of highly hydrophobic drugs. However, just as with other 
nano-systems, they have both strengths and weaknesses. The major strengths of CDs 
are: 1) the specific form of the equilibrium interaction between CDs and drug 
molecules; and 2) their capability to deliver a number of intractable and cytotoxic drug 
molecules safely. However, this specific nature of their interaction is also a weakness, 
in that the inclusion complex of drug-CD is applicable only to those molecules with 
suitable size, geometry, and intrinsic solubility properties. This is also the reason that 
modifications are essential for improving CD’s encapsulation ability towards different 
drug molecules. 
Binding constant determination of CD-drug inclusion by fluorescence spectroscopy 
CDs and their derivatives can behave as fluorophore quenchers for fluorescent drug 
molecules such as DOX, under the premise of the drugs being trapped by CDs 
dynamically. This property and the binding constant between CDs and different guest 
molecules were validated and calculated, respectively, by Yorozu et al. (Yorozu, 
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Hoshino et al. 1982; Yorozu, Hoshino et al. 1982).  
As discussed in the above section, the complexation interaction between CDs and 
their guests is a dynamic process because no covalent bonds exist during the CD-guest 
complex formulation (Tafazzoli and Ghiasi 2009). Moreover, the rates of fluorophore 
entry into and exit from CD cavities are considered much slower than the rate of 
fluorescence decay of the fluorophore. For example, the fluorescence decay of free 
DOX in aqueous solution corresponds to a lifetime of 1.1 nsec, independent of its 
concentration (Dai, Yue et al. 2008). Thus, there is very little possibility for fluorophore 
guests to enter or exit CD cavities during the lifetime of their excited state. Therefore, 
fluorescence intensity change of CD-fluorophore inclusion is in the steady-state 
fluorescence of the fluorophore upon complexation with CDs. 
The above interaction model makes it possible to analyse binding affinity of 
CD-fluorophore complexation by steady-state fluorescence theory (Park 2006) through 
modified Stern-Volmer correlation (Equation 2.1) (Lehrer 1971; Yorozu, Hoshino et al. 
1982; Yorozu, Hoshino et al. 1982; Lee and Okura 1998; Lee, Shin et al. 2001; Lo, Chu 











Equation 2.1 Modified Stern-Volmer equation. 
 
In Equation 2.1, Io is the fluorescence intensity of fluorophores in the absence of 
CD carriers, Ix is the fluorescence intensity of fluorophores in the presence of different 
concentrations (x) of CDs, [H]x is the concentration of CD carriers as a host compound, 
and 1 / f should be one in the study if only one fluorescence quencher is employed (Lee 
and Okura 1998). In this thesis, only one fluorophore, DOX, was employed and the 
corresponding K binding was calculated by the relationship of the intercept / slope value 
which is equal to (1 / f) / (1 / fK) and derived from the linear plot y = ax + b generated 










Equation 2.2 Calculation of binding constant K. 
To summarise, the fluorimetric properties of a fluorophore are affected by its 
encapsulation by CDs. Hence, the binding affinity between CDs and guest molecules 
with fluorimetric characteristics can be evaluated by measuring their fluorescence 
intensities. It should be noted that this method has to be applied at low concentrations of 
a fluorophore to afford information on the monomer complexation, since the dimer is 
known to be not emissive at all (Agrawal, Barthwal et al. 2009).  
2.3 Triggers Involved in TDD for Cancer Therapy 
2.3.1 Temperature 
Topical temperature increases, also called hyperthermia, are a type of cancer 
treatment by exposure of body tissue to high temperatures, up to 45 °C. However, 
hyperthermia treatment by itself is still under clinical trial and is not widely available 
(Wust, Hildebrandt et al. 2002). Instead, it is usually combined with other forms of 
cancer therapy as warmer temperatures can make the cells more likely to be affected by 
treatments such as chemotherapy and radiation therapy (van der Zee 2002; Wust, 
Hildebrandt et al. 2002). Hence, hyperthermia was also highlighted as a useful trigger 
tool in nanosystem-associated anti-cancer agents in chemotherapy / radiation therapy in 
order to: 1) enhance the effects of certain anticancer drugs; 2) enlarge the pore size of 
tumour microvessels (Lefor, Makohon et al. 1985) to increase tumour perfusion (Karino, 
Koga et al. 1988); and 3) control release of drugs from thermally-sensitive 
drug-protection carriers (Gaber, Wu et al. 1996; Kong, Braun et al. 2000; Kong, Braun 
et al. 2001) at targeted tumour sites.  
Thermo-sensitive nanosystems in cancer TDD include thermo-sensitive liposomes 
(Drummond, Noble et al. 2008; Koning, Eggermont et al. 2010), thermo-responsive 
polymers (Schmaljohann 2006) and thermo-sensitive nanoparticles (Rahimi, Kilaru et al. 
2008). For example, the development of thermo-responsive liposomes for cancer 
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therapy was first introduced in 1999 (Anyarambhatla and Needham 1999), when a novel 
method for preparing thermo-sensitive liposomes was described, which significantly 
enhanced the release of entrapped contents at mild hyperthermia temperatures, 39 – 
40 °C.  
A year later, Needham and coworkers (Needham, Anyarambhatla et al. 2000) 
introduced a new lipid formulation of liposome-encapsulated DOX in combination with 
mild hyperthermia which appeared to be much more efficient than free DOX or other 
existing liposomes at reducing tumour growth in a human squamous cell carcinoma 
xenograft line. Then Celsion Corporation developed ThermoDox which can be triggered 
to release DOX by any heat-based treatment including radiofrequency ablation (RFA) 
and microwave hyperthermia as well as FUS. Apart from thermo-sensitive liposomes, 
Chilkoti et al. (Dreher, Raucher et al. 2003; Furgeson, Dreher et al. 2006) have designed 
a thermally responsive elastin-like polypeptide-DOX (ELP-DOX) conjugate for cancer 
therapy; Purushotham et al. (Purushotham, Chang et al. 2009) have presented a range of 
thermo-responsive polymer-coated magnetic NPs loaded with anti-cancer drugs and 
suggested they are of considerable interest for novel multi-modal cancer therapies. 
2.3.2 pH 
In most tumour tissues, the phenomenon of increased aerobic glycolysis (Gatenby 
and Gillies 2004) named the Warburg effect (Kim and Dang 2006), leads to lower 
extracellular pH (6.5 to 7.2) of cancer cells  (Schmaljohann 2006; Alfarouk, Muddathir 
et al. 2011). The relative acidity of the extracellular / interstitial milieu of tumours 
compared to normal tissues provides a basis for the selective treatment of cancer 
(Gerweck and Seetharaman 1996). This has been actively exploited to develop drug 
carriers that can specifically respond to cancer cells with low pH values while staying 
inactive under normal physiological conditions (Gatenby, Gawlinski et al. 2006).  
Many pH-triggered NP / nanocarrier-drug delivery systems have been developed 
during the last decade. Lim et al. (Lim, Huh et al. 2011) reported that pH-responsive 
drug-delivering magnetic nanoparticles (DMNPs) successfully released DOX under 
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acidic conditions within cancer cells. Schmaljohann (Schmaljohann 2006) introduced 
several types of thermo-responsive polymer-conjugated drugs such as pH-sensitive 
polymeric-micelles composed of poly(L-histidine) (polyHis)/PEG and poly(L-lactic 
acid) (PLLA)/PEG block copolymer associated-adriamycin (Lee, Na et al. 2003), with 
the drug released under acidic environment.  
In summary, pH sensitive drug delivery system can effectively release drugs 
according to physiological pH levels in the local environment of diseases including 
tumours and are a promising TDD system in the future (Balamuralidhara, Pramodkumar 
et al. 2011). 
2.3.3 Focused Ultrasound (FUS) 
FUS allows the deposition of thermal and mechanical energies deep inside the 
human body non-invasively. One of the remarkable advantages of FUS is that it can be 
focused within pathological tissue in a region of about diameter 2 mm. 
Ultrasound-mediated techniques were proposed for TDD in the mid-1990s (Miller, 
Miller et al. 1996; Greenleaf, Bolander et al. 1998). The bio-effects of US can lead to 
local tissue heating, cavitation, and radiation force, which in TDD applications can be 
used to: 1) increase extravasation of drugs and / or carriers and enhance diffusivity of 
drugs; 2) increase the permeability of tumour cell membranes; and 3) control localised 
drug release from nanocarriers circulating in the blood stream.  
When exposed through FUS to temperature / mechanical forces through oscillating 
ultrasound pressure waves, in sensitive nanocarrier-drug inclusion systems, entrapped 
drugs can be released locally. For example, thermo-sensitive liposomes have been 
suggested for targeted drug release in combination with local hyperthermia more than 
25 years ago and MBs can be designed specifically to induce cavitation effects in order 
to cause sonoporation in pathological cell membranes. Moreover, real-time imaging 
methods, such as MRI, have led to insights and methods for ultrasound TDD. The 
following content discusses detailed thermal effects, cavitation and radiation force 
generated by FUS and MB-assisted TDD as well as therapeutic applications of 
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MRgFUS mediated TDD.  
Heat 
When US propagates through tissue, absorption of acoustic energy occurs and this 
energy normally will be converted into heat (Fry 1950). One widespread application of 
US heating is HIFU-induced solid tumour ablation. A HIFU pulse with several seconds 
duration generated by a high intensity ultrasound transducer is the basis of HIFU 
ablation. Because of the highly localised concentration of acoustic energy in the focused 
spot, the tissue in that small region is heated rapidly and a sharply-circumscribed lesion 
caused by thermal coagulation is induced. At the same time, tissue penetrated by 
unfocused ultrasound remains completely unaffected or shows negligible temperature 
rise. The temperature reached within the focal region during a single sonication should 
be between 60 to 95 °C to induce tissue lesions and necrosis.  
To date, many clinical studies using HIFU ablation technique have been performed 
to treat solid tumours in different organs (Al-Bataineh, Jenne et al. 2012). HIFU therapy 
has been successfully employed in patients with prostate cancer (Lee, Hong et al. 2006; 
Ahmed, Zacharakis et al. 2009; El Fegoun, Barret et al. 2011), uterine fibroids 
(Fruehauf, Back et al. 2008; Okada, Morita et al. 2009; Zhang, Chen et al. 2010), breast 
cancer (Gianfelice, Khiat et al. 2003; Furusawa, Namba et al. 2007; Wu, Wang et al. 
2007), liver (Li, Sha et al. 2007; Zhang, Zhu et al. 2009; Zhu, Zhou et al. 2009), kidney 
(Wu, Wang et al. 2003; Illing, Kennedy et al. 2005; Klingler, Susani et al. 2008) and 
pancreas tumours (Wu, Wang et al. 2005; Li, Sha et al. 2007; Xiong, Hwang et al. 
2009). 
Current methods of ablation can result in marginal recurrences of larger lesions and 
in difficulty treating tumours located near large blood vessels. The novel approach of 
applying FUS for the purpose of TDD to extend treatment out to the margins where 
temperatures do not provide complete treatment with ablation alone may be useful, by 
combining thermal ablation with drug-loaded thermo-sensitive nanocarriers (Dewhirst, 
Landon et al. 2013). Hence, the heat may cause the augmented inflow of drugs / 
drug-carriers and a significant enhancement of drug extravasation from the carriers. It is 
worth taking this into consideration for the potential application of low power of FUS in 
40 
TDD for cancer therapy. The approach is suitable for those thermal-responsive drug / 
drug-carriers combined with techniques such as chemotherapy and radiation therapy, as 
well as those patients with cancers that cannot be treated by thermal ablation.  
To date, many heat-sensitive nanosystems for delivering anti-cancer agents in 
cancer therapy have been developed as discussed earlier in this chapter. Overall, the 
heating effect from US has been traditionally employed in physical therapy to warm up 
tissues (Draper, Castel et al. 1995), in TDD to melt drug-containing nanocarriers 
(Tacker and Anderson 1982) and in medical therapy to ablate pathological tissues 
(Huber, Jenne et al. 2001; Kennedy, Ter Haar et al. 2003; Madersbacher and Marberger 
2003). Thus, US induced heating, especially mild hyperthermia in TDD, accomplishes 
the role of heating drugs / drug carriers and tissues to enhance drug efficient. 
Cavitation 
Acoustic cavitation is defined as the formation and / or activity of gas-filled 
bubbles in a medium exposed to US (Barnett, ter Haar et al. 1994). When the pressure 
wave passes through the medium, gas bubbles of any size will expand at low pressure 
and contract at high pressure. If the resulting oscillation within the bubbles is fairly 
stable and reversible, the cavitation is called stable or non-inertial cavitation (Leighton 
1994). In contrast, if the amplitude of oscillation in the bubble increases with the sonic 
intensity up to a point that it cannot reverse the direction when the acoustic pressure 
reverses, the gas bubble will be continuously compressed to a very small volume until it 
collapses, creating extremely high pressures and temperatures (May, Allen et al. 2002). 
This type of cavitation is called transient or inertial cavitation (Leighton 1994).  
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Figure 2.8 Cavitation bubbles are created when ultrasonic energy input is 
initiated. Bubbles require several cycles of sound waves to grow to a size which 
will result in an implosive collapse (A and B). The population of bubbles in the 
growth stage interferes with the transmission of sound waves thereby producing a 
diminished number of cavitation bubble implosions.  
(From 
http://www.ctgclean.com/tech-blog/2012/03/ultrasonics-pulse-more-about-pulsed-
ultrasonics/, created by John Fuchs). 
 
As US induced cavitation causes the permeability of cell membranes to increase the 
cellular drug uptake (Klibanov 2006; Deckers, Rome et al. 2008; Frenkel 2008), this 
property has led to US-mediated drug delivery as a novel strategy to assist 
non-permeable therapeutic agents to be internalised so as to enhance the cellular uptake 
of conventional drugs in cancer therapy (Deckers and Moonen 2010). US radiation is 
known to be the mechanism which induces cavitation (Larina, Evers et al. 2005) and in 
vivo application of US-mediated TDD is highly attractive as US radiation can be 
focused at almost any part of the body. Again, localised US induced cavitation may lead 
to highly selective and efficient drug delivery in vivo.  
US-induced cavitation to deliver macromolecules in vitro has been considered by 
many research groups since the 1980s. In 1989, Kost et al. (Kost, Leong et al. 1989) 
first studied the effect of US on the degradation of polymers and the release rate of  
molecules incorporated within the polymers. The examination revealed 5-fold reversible 
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increases in degradation rate of polymers and 20-fold reversible increases in the release 
rate of incorporated molecules, with the authors observing that the release rate increased 
in proportion to the intensity of US and proposing that cavitation appeared to play a 
significant role. In 2003, Schaaf et al. (Schaaf, Langbein et al. 2003) reported that naked 
plasmid DNA can be easily and effectively delivered to malignant urothelial cancer 
cells in vitro upon exposure to acoustic shock-waves. Moreover, Guzman et al. 
(Guzman, Nguyen et al. 2002) measured the effects of cellular uptake of several 
different sizes of molecules including caicein (623 Da), bovine serum albumin (66 kDa) 
and two kinds of dextrans (42 Da and 464 kDa) by exposure of DU145 prostate cancer 
to 500 kHz US, with the results suggesting that the cellular uptake of all molecules were 
correlated with applied acoustic energy and thus providing a means to use US cavitation 
for laboratory and possibly clinical drug delivery applications.  
As regards in vivo studies, Esenaliev et al. (Esenaliev, Larina et al. 2001) proposed 
an in vivo cavitation-induced drug delivery trial in nude mice bearing KM20 human 
colon tumours. They investigated the delivery of a macromolecular rhodamine-dextran 
and anti-cancer drug 5-FU under low cavitation US exposure in combination with 
radiation. The results showed significantly enhanced penetration of 5-FU in irradiated 
tumours and improvement of cancer therapy.  
As US cavitation-enhanced drug delivery has a great potential for in vivo 
application in cancer chemotherapy and radiation therapy, optimisation of 
ultrasound-mediated cavitation in delivery of macromolecular drugs in vitro may 
provide a basic protocol that could routinely be employed in anti-cancer nanomedicine 
design and in vivo applications (Larina, Evers et al. 2005).  
Microbubbles (MBs) 
MBs are bubbles smaller than 1 mm in diameter but larger than 1 µm. They are 
used in medical diagnostics as USCA to assist imaging (Agrawal, Barthwal et al. 2009) 
because they oscillate and vibrate when applying an acoustic energy field. This 
behaviour helps to distinguish the MBs from surrounding tissues. MBs have gas cores 
and are usually entrapped by solid shells such as lipids, polymers or proteins (Bekers, 
Beijnen et al. 1991) as unshelled gas bubbles lack of stability in liquid environment.  
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With the exception of enhancement of molecular imaging through their use as 
functionalised contrast agents, MBs’ utilisation as targeted delivery vehicles is one of 
the most popular research topics related to USCAs. As discussed above, cavitation 
generated by bubbles in an acoustic field can increase the permeability of endothelial 
vasculature, allowing small molecules to enter into tissues more easily from the blood 
stream; this technique is one form of sonoporation (Bekers, Beijnen et al. 1990). 
However, the exact mechanisms of induction of sonoporation are still unclear. It is 
generally believed that sonoporation is due to either direct penetration by inertial 
cavitation (Yorozu, Hoshino et al. 1982) or microstreaming around stable cavitation 




Figure 2.9 Sonoporation process on cell membrane for drug delivery  
(Lentacker, De Cock et al. 2013). 
 
A range of in vitro exposures of US to prostate cancer cell suspensions in the 
presence of gradient concentrations of Optison MBs (see Table 2.1) were reported by 
Guzman et al. (Husain, Ndou et al. 1992). The results suggested extensive molecular 
uptake into cells at high viability occurs for low-energy US applied at a high 
cell-to-bubble ratio. Many studies have demonstrated that a combination of US 
sonication and MBs with chemotherapeutics may provide a promising way to treat 
animal tumours (Price, Chappell et al. 2006; Rapoport, Kennedy et al. 2009). For 
example, Anand et al. (Anand, Ottani et al. 2012) confirmed that MB-induced cellular 
44 
release of pre-loaded fluorescent dextrans evoked transient pore formation of primary 
endothelial cells after US exposure. Moreover, Lin and coworkers (Lin, Li et al. 2012) 
reported that US sonication with MBs significantly enhanced the accumulation of DOX 
in the sonicated tumour positions in animal models. 
US-mediated drug delivery with MBs could also non-invasively enhance the 
transport of therapeutic agents to overcome the difficulties of drug delivery posed by 
vascular walls, which can provide a better transport for nanomedicines in tumour tissues 
and permit specific and effective cellular uptake to targeted tumours (Primeau, Rendon 
et al. 2005; Bohmer, Chlon et al. 2010; Lin, Huang et al. 2010). 
Table 2.1 Commercially available ultrasound contrast agents  
(Frenkel, Etherington et al. 2006; Reilly 2007) 
Contrast 
agent 































SonoVue Phospholipids Sulfur 
hexafluoride 





Imagent Phospholipids Perflexane IMCOR USA 2003 
 
 
Figure 2.10 Schematic illustration of SonoVue MBs (Reilly 2007). 
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Table 2.1 lists commercially marketed MBs with their compositions and approved 
medical application year and regions. Figure 2.10 is the schematic picture of SonoVue
®
 
MBs, which was the type applied in this thesis. A detailed description of SonoVue
®
 and 
its application is further introduced in Chapter 5. 
FUS-mediated TDD and MRgFUS-TDD 
FUS can be focused at defined locations in living tissues to generate thermal or 
mechanical effects as described in previous sections. During the last decade, a wide 
range of research has been conducted to demonstrate the concept of FUS-induced TDD 
in vitro and in vivo. In terms of FUS-mediated drug delivery, Frenkel et al. (Frenkel, 
Etherington et al. 2006) first applied pulsed HIFU, followed by tail vein injections of 
Doxil (liposomal DOX) in murine breast cancer tumours grown in the bilateral flanks of 
mice. However, the FUS exposure was not found to enhance the release of Doxil, nor 
did it allow for lower doses to obtain tumour regression. Nevertheless, this trial was the 
first to show that pulsed-HIFU exposure was safe in vivo and it also demonstrated that 
blood vessels treated with HIFU were dilated, as observed by using fluorescent dextran.  
A year later, Dromi et al. (Dromi, Frenkel et al. 2007) reported both in vitro and in 
vivo studies using low temperature sensitive liposomes (LTSLs) in combination with 
pulsed HIFU at a thermal dose of 42 °C for 2 min, which resulted in 50% release of 
DOX from LTSLs and enhanced anti-tumour effects.  
Therapeutic FUS induced thermal and mechanical effects have shown novel and 
potential trigger advantages for drug release at target tumour sites. Proper monitoring 
and guidance to control the acoustic treatment region is a useful adjunct to minimise 
unwanted damage to adjacent healthy structures (Thanou and Gedroyc 2013). Therefore, 
the combination of nanomedicines and non-invasive FUS triggering from outside the 
body together with techniques such as MR-guidance are providing novel approaches to 
achieve spatio-temporal control of drug delivery.  
MRgFUS refers to FUS treatment within an MRI scanner. This setup allows tumour 
targeting and real-time treatment monitoring by MRI. In FUS-induced TDD, MRI 
guidance allows better control of the drug's bio-distribution, the pharmacokinetics and 
pharmacodynamics. Specifically, an MRgFUS system in the field of TDD can be used 
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for:  
1) Real-time manipulation of drug guidance within the targeted area;  
2) Spatio-temporal guidance of actions to control release or activate the drugs and / 
or permeabilise membranes;  
3) Evaluation of a drug’s bio-distribution, pharmacokinetics and 
pharmacodynamics;  
4) Physiological readouts to evaluate therapeutic efficacy precisely (Thanou and 
Gedroyc 2013). 
Kamaly et al. (Kamaly, Kalber et al. 2009) observed the effective accumulation of 
folate-targeted and fluorescent liposome delivery to solid tumours (IGROV-1 cells) 
induced in nude mice monitored by dynamic real-time MRI, providing MR-guided 
insight into the kinetics of nanoparticles targeted to solid tumours. Negussie and 
coworkers (Negussie, Yarmolenko et al. 2011) developed an MR imageable LTSL 
(MR-iLTSL) by co-loading liposome with the MRI contrast agent 
ProHance
®
Gd-HP-DO3A and DOX. MR-HIFU triggered experiments have been done 
both in vitro and in vivo, with the results showing that MR imaging had the greatest 
effect in the heated tumour region. A year later, Ranjan et al. (Ranjan, Jacobs et al. 2012) 
reported their MR-HIFU drug delivery trials in rabbits bearing tumours by injection of 
LTSL-based DOX. LTSL + MR-HIFU treatment suggested an improved distribution, 
with DOX found in both the tumour periphery and core.  
The MRgFUS TDD technique is non-invasive, has excellent penetration depth with 
FUS and can be applied to different organs. It has real-time imaging as a guidance tool 
to provide accurate temperature mapping, high-resolution tissue imaging and precise 
targeting during FUS therapy. Therefore, the MRgFUS system may have an advantage 
over other methods for delivery of drugs to specific sites, especially for solid tumours. 
However, just as with sonoporation, the exact mechanism of FUS-mediated delivery is 
not completely understood. Multiple studies suggest that FUS and agents such as MBs 
facilitate the formation of transient pores in the plasma membrane via cavitation. These 
pores are known to spontaneously reseal within a short time (from seconds to minutes) 
(Schlicher, Radhakrishna et al. 2006; van Wamel, Kooiman et al. 2006; Kudo, Okada et 
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al. 2009). Moreover, MRI equipment is expensive; its use is labour-intensive and its 
spatial resolution is sometimes reduced (Thanou and Gedroyc 2013). Even allowing for 
these issues, the new field of MRgFUS triggered drug delivery opens up opportunities 
to expand applications for existing small drugs in cancer chemotherapy and radiation 
therapy. 
2.4 Conclusions 
To summarise, this chapter reviewed the literature which provided many 
contributions and insights into the invention of novel nanomedicines for TDD in cancer 
therapy, from design, synthesis, and evaluation in vitro and application in vivo, up to 
clinical trials. The improvement of nano-vehicles for carrying toxic and unstable 
anti-cancer drugs has never stopped; in contrast, their structures have been developed 
generation by generation as well as combinations of different nano-systems to improve 
their transportation abilities.  
The combination of anti-cancer nanomedicines with traditional chemotherapy and 
radiation therapy, and with novel non-invasive thermal / ultrasound tumour ablation and 
drug delivery techniques has been successfully applied to many cancer patients. 
Numerous in vivo experiments and clinical trials have revealed valuable references for 
those new generations of researchers and clinicians. 
Notwithstanding that many improvements and innovations have been achieved in 
TDD for cancer treatment, many problems remain, such as non-specific dosage, toxicity 
of nanocarriers themselves, fast clearance from the blood stream, low drug release rate 
and some unclear mechanism of trigger strategies. More efforts need to be made to 
overcome these weaknesses to promote more trustable and potent clinical cancer 
treatment protocols. 
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Chapter 3  
Drug Carrier Development: Chemical 
Modification and Evaluation of a 
γ-cyclodextrin Derivative 
3.1 Introduction 
In aqueous solutions, CDs form inclusion complexes with anthracyclines (Grosse, 
Bressolle et al. 1999) which are potent antitumor antibiotics (Fujiwara, Hoshino et al. 
1985). In present, cancer chemotherapeutic agent DOX, a DNA-intercalating antitumor 
agent, is the most frequently used member of the anthracycline group (Fernandez, 
derpoorten et al. 2001) in spite of being chemically unstable (Bekers, Beijnen et al. 
1990) in aqueous media with major problems of acute and chronic toxicity (Muggia 
and Green 1991) and appearance of cellular multidrug-resistance. The best way to 
overcome serious side-effects associated with DOX administration is to limit the 
amount of DOX intake or alternatively, to encapsulate the drug in various 
drug-delivery systems. An ideal TDD vehicle should be able to solubilise, protect and 
transport the drug specifically to cancer cells and slowly release the drug molecules 
inside the cells to the site of their pharmacological activities. This can be achieved by 
attaching biological signals such as hormones, vitamins or antibodies (Willis and 
Forssen 1998), which can recognise cancer cells, to the surface of the vehicles (Low 
and Antony 2004; Lukyanov, Elbayoumi et al. 2004). Moreover, drug targeting can 
also be achieved by using drug vehicles sensitive to the surrounding enzymes, 
temperature or pH (Soppimath, Tan et al. 2005; Li, Zhang et al. 2006; Liu, 
Wiradharmaa et al. 2007)  
Recently, several studies reported (Yamanoi, Yoshida et al. 2005; Hattori, 
Kenmoku et al. 2006; Yamanoi, Kobayashi et al. 2006; Oda, Kobayashi et al. 2008; 
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Oda, Yanagisawa et al. 2008; Oda, Miura et al. 2009; Kralova, Konak et al. 2010; Li, 
Zhao et al. 2012) that introduction of a suitable substituent (e.g., glucose, galactose, 
arbutin, hydroquinone α-glycoside, porphyrin or β-carboline) to the rim of α- and 
β-CDs, can enhance the binding affinity towards DOX through cooperative 
interactions between the CD’s cavity and guest molecules. Although, α- and β-CD is 
the most exploited CDs, (Sorokin, Fylymonova et al. 2012) little has been published on 
γ-CD as targeted drug delivery system. Having 8 glucopyranoside units thus the largest 
cavity, the γ-CD possesses higher water solubility, better inclusion ability of large-size 
drugs, and orally and is parenterally administered non-toxic (Totterman, Schipper et al. 
1997). 
In the present study, a novel chemically modified γ-CD derivative, 
mono-6’-deoxy-6-[3-(naphthalen-2-yl)-2-(amino)propionylamino]-γ-cyclodextrin(carr
ier 3b), with a β-naphthyl alanine residue attached in the primary face of γ-CD, was 
rationally designed and synthesised. The DOX encapsulation efficiency by this carrier 
was evaluated under various temperatures and pH and the potential of the novel carrier 
3b conjugate as a thermo-sensitive carrier for DOX was discussed. 
3.2 Essential Chemical Synthesis and Analysis Techniques 
3.2.1 Purification Techniques 
3.2.1.1 Precipitation 
Precipitation is a chemical reaction that uses a precipitant (precipitation agent) to 
extract desired substances or impurities, by decreasing their solubility to form a solid 
precipitate.  
Precipitation is used in the applications such as making pigments, removing salts 
from water and in qualitative inorganic analysis, as well as to isolate some products 
during post-reactions. But ideally, the substance of the reaction is insoluble in the 
reaction solvent. Thus, when precipitate is formed, pure crystals is preferably formed 
(Adler, Longo et al. 1967). Precipitation may also occur when the environment is in 
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the presence of an anti-solvent (a solvent in which the substance is insoluble), which 
can drastically reduce the solubility of the desired substance. Therefore, the precipitate 
may easily be separated by filtration, decanting, or centrifugation (Adler, Longo et al. 
1970). Precipitation is also useful in purifying products where it precipitates (Dupont, 
Consorti et al. 2003).  
The precipitation method has been found to be very efficient in the isolation of CD 
based compounds from water, dimethylformamide (DMF) or dimethyl sulphoxide 
(DMSO) (Connors 1997). In particular, the reaction products in the synthesis within 
this thesis report were isolated by pouring the reaction mixture into acetone (Gorin, 
Riopelle et al. 1996). 
3.2.1.2 Recrystallisation 
Recrystallisation (Harwood 1989) is a procedure for purifying chemical 
compounds by dissolving both impurities and desired compound in an appropriate 
solvent. The most commonly used procedure for recrystallisation from a solution 
involves the following steps (Armarego and Chai 2003): 1) A near-saturated solution is 
obtained by dissolving the impure material in a suitable solvent, followed by shaking 
or vigorous stirring at or near its boiling point; 2) Insoluble particles are then removed 
by filtration of the above solution (a heated filter funnel can be used to prevent 
crystallisation during the filtration procedure, or the solution can be diluted with more 
solvent); 3) The solution is then allowed to cool slowly so that the dissolved substance 
can crystallise out; 4) The crystals are separated from the mother liquor, usually by 
filtering under vacuum suction through a sintered glass or a Büchner funnel; and 5) 
The pure crystals are finally washed by a little fresh cold solvent to remove traces of 
the mother liquor, and then dried. 
3.2.1.3 Adsorption chromatography  
Adsorption chromatography is based on the difference in the extent to which 
substances in solution are adsorbed onto a suitable surface. The main techniques in 
adsorption chromatography include thin layer chromatography (TLC), paper and 
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column chromatography (Armarego and Chai 2003). The chromatographic purification 
procedures employed in this thesis are TLC, reversed-phase column chromatography 
(RPCC) and high performance liquid chromatography (HPLC). 
Thin layer chromatography (TLC) 
TLC is a simple and inexpensive separation technique that can quickly reveal how 
many components are in a mixture. TLC is widely used to identifying a compound in a 
mixture by comparing Rf values (Figure 3.1) of a unknown compound to a known 
compound. 
  =
                              
                                       
 
Figure 3.1 Schematic drawing of TLC experiment demonstration and Rf value 
calculation. 
 
A TLC plate can be a sheet of glass, metal (aluminium foil), or plastic which is 
coated with a thin layer (0.2 – 2 mm) of a solid adsorbent (silica, alumina or cellulose) 
(Armarego and Chai 2003). A small amount of the mixture to be analysed is spotted 
near the bottom of the plate. The TLC plate is then placed in a shallow pool of a 
solvent in a developing chamber so that the bottom of the plate is in the liquid with the 
spotted mixture just above the solvent. This liquid, known as the eluent, or mobile 
phase and it slowly rises up the TLC plate by capillary action. At all times, the solid 
phase will adsorb a certain fraction of each component of the mixture and the 
remainder will be in the solution. Depending on different adsorption speed on TLC 
sheet, the components separation is achieved. The separated bands can be visualised 
conveniently by ultraviolet (UV) lamp if they are UV active or by treating the TLC 
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sheet with a suitable visualisation reagent such as iodine vapour (a good general 
reagent for hydrocarbon containing compounds) for few seconds or other more 
selective reagents. 
Reversed-phase column chromatography (RPCC) 
In RPCC, a non-polar or hydrophobic sorbent is usually filled in a vertical glass 
column as stationary phase (McNaught and Wilkinson 2012) leading to the separation 
of the sample components. The mobile phase is typically a mixture of water or aqueous 
buffers and organic solvents are used to elute analytic substrates. The substances to be 
purified are usually placed on the top of the column and the solvent runs down through 
the column by either gravity or external pressure such as vacuum suction. Fractions are 
collected and checked for compounds by using TLC (UV, heat, chemical spray and / or 
other means of visualisation) (Armarego and Chai 2003).  
High performance liquid chromatography (HPLC) 
HPLC is different to traditional liquid chromatography as its operational pressures 
are significantly higher between 50 to 350 bars, while ordinary liquid chromatography 
typically relies on the force of gravity to pass the mobile phase through the column.  
HPLC utilises a liquid mobile phase to separate the components of a mixture. The 
stationary phase can be a liquid or a solid phase. Due to the small sample amount 
separated in analytical HPLC, typical column dimensions are 2.1 – 4.6 mm in diameter, 
and 30 – 250 mm in length. Also, HPLC columns are made with smaller sorbent 
particles size (2 – 50 µm) which gives HPLC superior resolving power when 
separating mixtures. Because of the improved efficiency of the columns, this technique 
has been referred to as high performance, high pressure, or high speed liquid 
chromatography and has found great importance in chemistry and biochemistry 
(Armarego and Chai 2003). 
3.2.2 Characterisation and Analysis Techniques 
3.2.2.1 Mass spectroscopy (MS) 
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MS is a powerful analytical technique that can be used to identify unknown 
compounds in a sample by comparison with a database of known compounds. It is 
particularly useful for identifying components of a mixture when combined with initial 
chromatographic separation: gas chromatography-MS (GC-MS) or HPLC-MS. The 
technique ionises the chemical compounds within a sample generating charged 
molecules (molecular ions) and/or molecule fragments and measures their 
mass-to-charge ratios (m/z) (Sparkman 2000). The distribution of masses (mass 
spectrum) is characteristic of a compound. Ions are generated by inducing either the 
loss or gain of a charge from a neutral species. The ions formed are electrostatically 
directed into a mass analyser where they are separated according to m/z and finally 
detected. The result of molecular ionisation, ion separation, and ion detection is a 
spectrum that can provide molecular mass and structural information (Wilson, Plumb 
et al. 2005; Djukovic, Nagana Gowda et al. 2013). 
In the current study of the modification one hydroxyl proton on the primary rim of 
γ-CD, MS method is an essential tool applied to determine the final substituent, to 
prove the desired modification formula. 
3.2.2.2 Nuclear magnetic resonance (NMR) methodology and spectroscopy 
NMR is the phenomenon of nuclei absorbing and re-emitting electromagnetic 
radiation in a magnetic field (radiofrequency ν = 60 – 600 MHz). NMR spectroscopy is 
a powerful structural technique that provides information about changes in magnetic 




C are the two most 
commonly studied nuclei, among others, for their different environment, and provide 
different signals for magnetically non-equivalent nuclei of the same atom present in the 
same molecule (Kumar 2006).  
Chemical shift 
Unlike infrared or ultraviolet-visible spectroscopy (section 3.2.2.3), where 
absorption peaks are simply located at a frequency or a wavelength, however, in NMR 
spectroscopy, the location of different NMR signals is dependent upon both the 
external magnetic field strength and the reference frequency. The problem here is 
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resonance frequencies always vary as no two magnets have exactly the same field. 
Thus, it is necessary to find a method for characterising and specifying the location of 
NMR signals. 
One suggestion to solve this problem is to report a reference signal from a 
standard compound, added to the investigated sample. Tetramethylsilane (TMS, 
(CH3)4Si), is a chemically inert compound and it can be easily removed from the tested 
sample (Balci 2005), has become the reference compound of choice for both proton 
and carbon NMR. The distance between the TMS signal and the sample signal is called 
the chemical shift (∆ ) (Equation 3.1) of the corresponding proton/carbon.  
 
∆ =         −                
Equation 3.1 Signal distance of the reference signal and the sample signal. 
 
In Equation 3.1,         is the resonance frequency of the sample,                
is the resonance frequency of the standard TMS, ∆  is the distance between the above 
two signals.  
However, the chemical shift given in Hz will vary from on instrument to another 
as different NMR operating systems have different magnetic field strengths (1.4 – 21T), 
therefore, an additional step is needed to provide a uniform location unit which is 
independent of the strength of the external magnetic field. In order to correct these 
frequency differences, ∆  can be divided by the spectrometer frequency (dividing Hz 
by MHz). Since the chemical shifts area always very small number, the factor 10
6 
is 
introduced to simplify the numerical values (Balci 2005), having units of 




             
× 1   
Equation 3.2 Chemical shift calculation. 
 
Where, 𝛿 is the chemical shift,               is the spectrometer frequency in Hz.  
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Two-dimensional (2D) NMR spectroscopy: correlation spectroscopy (COSY) and 
Nuclear Overhauser effect spectroscopy (NOESY) 
Conventional (one-dimensional spectra) NMR, although potent to observe distinct 
peaks for the various functional groups of small chemical molecules, can be limited in 
use for more complex molecules having  many overlapping resonances. The presence 
of overlapping peaks can make the interpretation of an NMR spectrum difficult. 2D 
NMR overcomes this problem by adding additional experimental variables and 
introducing a second dimension to the resulting spectrum, providing data that is easier 
to interpret and often more informative (Giraudeau, Guignard et al. 2007). 
Specifically, one-dimensional NMR spectra are plots of intensity vs. frequency 
while in 2D spectroscopy intensity is plotted as a function of two frequencies. COSY 
and NOESY are two of the most common used 2D NMR methods. COSY is the most 
basic 2D NMR form among others; it is useful for determining the coupling between 
nuclei that are connected through one to three bond lengths. In 2D NOESY, the 
cross-peaks appear between protons that are within 6Å of each other, the closer in 
space the two protons are to each other, the more intense of the cross-peak. The 
NOESY experiment correlates all protons which are close enough. It also correlates 
protons which are distant in the amino acid sequence but close in space due to tertiary 
structure. Thus, 2D NOESY is the most important tool for the determination of protein 
structures. 
NMR spectroscopy is not only a method for the determination of the structure of 
the molecule, but also a very functional spectroscopic method that explains the 
dynamic. Hence, NMR spectroscopy is widely utilised in CD complexation 
determination (Rekharsky and Inoue 1998; Schneider, Hacket et al. 1998). For 
example in the case of 
1
H NMR, the observation of changes in the chemical shift of 
one or more protons on the guest, or those on the CD (host), particularly the hydroxyl 
protons can provide the geometrical information of CD-guest complex inclusion 
(Wagner 2006). 
3.2.2.3 Ultraviolet-visible (UV-Vis) spectroscopy and fluorescence spectroscopy 
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UV-Vis spectroscopy (λ = 200 – 800 nm) studies the changes in electronic energy 
levels within the molecule arising due to transfer of electrons from π- or non-bonding 
orbitals (Kumar 2006). It is often called as electronic spectroscopy or reflectance 
spectroscopy in the ultraviolet-visible spectral region, where it uses light in the visible 
and adjacent (near-UV / near-infrared) ranges. UV-Vis spectroscopy has many 
applications especially in the quantitative determination of solutions of transition metal 
ions highly conjugated organic compounds and biological macromolecules. The 
information provided by UV-Vis spectroscopy when combined with the information 
obtained by NMR and infrared (IR) spectral data leads to valuable structural 
information (Kumar 2006). UV-Vis spectroscopy is a complementary technique to 
fluorescence spectroscopy, where, fluorescence deals with transitions from the excited 
state to the ground state, while absorption measures transitions from the ground state to 
the excited state (Skoog 2007). 
CD / CD-inclusion complexes can be studied by a number of experimental 
techniques including UV-Vis spectroscopy (Busch, Swamidoss et al. 2003) and 
fluorescence spectroscopy (Li, Zhao et al. 2012). In the case of UV-Vis spectroscopy, 
a change in absorbance and/or absorption wavelength of the guest is observed; while in 
the case of fluorescence, a change in the emission intensity and/or emission 
wavelength maximum of the guest is observed (Wagner 2006).  
Fluorescence is the most sensitive method for study of CD complexation and has 
many advantages in comparison to other methods, because: 1) it is high sensitivity and 
is applicable to complexation studies with large binding constant K values (the 










 and UV-Vis spectroscopy is usually 
used for 10
2




) (Wagner 2003); 2) upon complexation with a CD, the 
fluorescent properties usually change more sensitively than the other spectroscopic 
properties; and 3) it requires the lowest concentration of sample. Thus, fluorescence 
spectroscopy is an excellent technique for studying CD inclusion phenomena (Wagner 
2006).  
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3.3 Materials and Methods 
3.3.1 Materials 
3.3.1.1 Reagents and solvents 
Reagents/Solvents Manufacturer and place of origin 
γ-cyclodextrin Mesochem Technology Co.,Ltd, Beijing, 
China 
doxorubicin (DOX) Mesochem Technology Co.,Ltd, Beijing, 
China 
P2O5 Sigma Aldrich, Israel 
4,4-Dimethylaminopyridine (DMAP) Sigma Aldrich, USA 
1-Hydroxybenzotriazole (HOBt) Discovery fine chemicals, UK 
N-Boc-3-(2-naphthyl)-D-alanine Sigma Aldrich, Israel 
1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimidehydrochloride (EDC) 
Sigma Aldrich, Israel 
Dimethylformamide (DMF) Sigma Aldrich, Germany 
Dimethyl sulphoxide (DMSO) Sigma Aldrich, Israel 
trifluoroacetic acid (TFA) Sigma Aldrich, Israel 
dichloromethane (CH2Cl2) Sigma Aldrich, Israel 
deuterated water (D2O) Sigma Aldrich, Israel 
Acetonitrile (AcN) Sigma Aldrich, Israel 
acetone(C2H6CO) YavinYedaa, Israel 
1-butanol Sigma Aldrich, Israel 
sulfuric acid Sigma Aldrich, Israel 
Methanol Sigma Aldrich, Israel 
Ethanol Sigma Aldrich, Israel 
NH3(aq) Sigma Aldrich, Israel 
PBS tablets Oxoid, UK 
dibasic sodium phosphate Sigma Aldrich, UK 
sodium phosphate monobasic Sigma Aldrich, UK 
citrate acid monohydrate Sigma Aldrich, UK 
potassium chloride Sigma Aldrich, UK 
hydrochloric acid Sigma Aldrich, UK 
Distilled/deionized water Millipore, UK 
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3.3.1.2 Glassware, consumables and equipment 
Glassware, consumables 
and equipment 
Manufacturer and place 
of origin 
Specification 
TLC plates Yavin-Yeda, Israel Silica gel 60 
PLC plates Yavin-Yeda, Israel Silica gel 60 F254 
96-well plates Greiner, Austria Black Polystyrene without 
lid 
UV Cuvettes Yavin-Yeda, Israel 4mL volume clear 
Reversed-phased column Merck, Israel LiChroprep RP-18, 40 – 63 
μm 
HPLC Sedere, France UV/Vis & ELSD (Sedex 
75) 




Mass spectroscopy Waters, USA Micromass ZQ 2000 
Melting Point Apparatus Thermo Scientific, Israel Electrothermal IA9100 
Digital 
Lyophilizer Labconco, USA Freezone 2.5 Plus 
500 MHz NMR 
spectrometer 
Bruker, USA Advance III 
400 MHz NMR 
spectrometer 





Varian Cary Eclipse 
pH meter Scientific Laboratory 
Supplies, UK 
SevenEasy pH Mettler 
Toledo 
Multi-mode plate reader Tecan, Austria Tecan infinite M200 
Oven Scientific Laboratory 
Supplies, UK 
INV064 
Vacuum oven Swagelok, Israel  
3.3.2 Methods 
3.3.2.1 Preparation of γ-CD derivative 
a) General coupling reaction of pre-crude product: 
Mono-6’-deoxy-6-[3-(naphthalen-2-yl)-2-(tert-butyloxycarbonylamino)propionyla
mino]-γ-cyclodextrin (3a) 
Native γ-CD was dried at 110 °C/0.1 mmHg in the presence of P2O5 by vacuum 
oven for 24 hr. Dry γ-CD (12.97 g, 10 mmol), DMAP (1.22 g, 10 mmol), HOBt (1.35 g, 
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10 mmol), N-Boc-3-(2-naphthyl)-D-alanine (3.15 g, 10 mmol) and 
1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) (4.12 g, 20 
mmol), were dissolved in DMF (50 mL) and stirred at room temperature for 24 hr. The 
precipitate was removed by paper filtration and the filtrate solution was added drop 
wise with stirring to a hot acetone (500 mL, ~ 40 °C). Then, TLC analysis was 
performed on silica gel plates to figure out the Rf value of 3a. TLC eluent solution was 
prepared by mixing isobutanol: ethanol: NH4OH(aq) at [4 : 5 : 6 (v / v / v)]. Then, spot 
detection was carried out by spraying with 5% (v / v) concentrated sulphuric acid in 
ethanol and heated up at 150 °C by means of hot plate for 5 min. After TLC analysis, 
the precipitate was filtered and dried under vacuum to obtain the pre-crude product of 
3a: mono-6’-deoxy-6-[3-(naphthalen-2-yl)-2-(tert-butyloxycarbonyl amino) 
propionylamino]- γ-cyclodextrin. 
b) Purification of pre-crude product 3a by reversed-phase column 
chromatography 
 The pre-crude product 3a was dissolved in 500 mL hot water (60 – 90 °C) and the 
resulting solution was applied to a reversed-phased column (300 g of LiChroprep 
RP-18, 40 – 63 μm; 50 mm × 260 mm). The column was eluted with 100% ddH2O (500 
mL), methanol: water at 10 : 90 (1000 mL), 20 : 80 (1000 mL), 30 : 70 (1000 mL) and 
100% methanol (500 mL), respectively. Collected column eluted samples 15 mL/tube, 
then, TLC analysis was performed to validate the Rf value of purified 3a. (TLC eluent 
solution and performance were the same as described in section 3.2.2.1a). After TLC 
analysis, fractions of 80 mL volume were collected. The solvent was removed by 
evaporation under reduced pressure affording white crystalline material (yield 50%) to 
obtain crude product of 3a.  
c) Removal of the tert-butoxycarbonyl protecting group from pre-crude product 
3a to obtain final product of mono-6’-deoxy-6-[3-(naphthalen-2-yl)-2-(amino) 
propionylamino]-γ-cyclodextrin (carrier 3b)   
Compound (3a, 5 g) from the above procedure was dissolved in TFA (20 mL) and 
CH2Cl2 (20 mL), and the mixture was stirred at room temperature for 3 hr. Then, the 
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solvent was removed by evaporation under reduced pressure (< 25 °C). The residue 
was dissolved in water (5 mL) and poured in methanol (200 mL). The white precipitate 
was filtered and dried under vacuum (yield 84%). TLC was carried out (the method is 
the same as described in section 3.2.2.1a) and showed one major spot which is the final 
residue of carrier 3b. The pure carrier 3b product was dissolved in ddH2O (10 mL/g). 
The solution was filtered and freeze dried by Lyophilizer for 2 days. 
d) Further purification of carrier 3b by TLC and HPLC 
TLC analysis was conducted the same as mentioned described in section 3.2.2.1a. 
HPLC analysis was performed on a Thermo Electron instrument equipped with UV/Vis 
& ELSD (Sedex 75) detectors. The column was by means of a Gemini 5 μm octadecyl 
carbon chain bonded silica (C18) (110 Å, 250 – 4.6 mm) mobile phase: H2O / 
Acetonitrile (AcN), with a gradient ratios: 98% / 2%, 50% / 50%, 10% / 90%, 98% / 2% 
and 98% / 2% at 0 min, 10 min, 15 min, 20 min and 30 min respectively, under a 
constant flow rate of 1.2 mL/min.  
3.3.2.2 Characterisation of carrier 3b 
a) General characterisation 
The UV spectroscopy signal of carrier 3b was measured at λ = 254 nm. UV 
analysis was performed on a UV spectrophotometer. MS was performed using 
Micromass ZQ 2000 detector, nitrogen flow 500 L/hr, nitrogen cone flow 70 L/hr, 
source temperature 110 °C, desolvation temperature 350 °C, and cone voltage 30 V. 





C-NMR, COSY and NOESY spectra were recorded on 
Bruker 400 MHz Advance III spectrometer with D2O as a solvent. All the chemical 
shifts are expressed as δ units (ppm). 
b) Fluorescence spectrometry analysis 
Inclusion association analysis of carrier 3b with DOX 
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The inclusion association of carrier 3b with DOX was quantitatively evaluated by 
titration method by measuring the fluorescence intensity of DOX at constant 
concentration (5 µM) in the presence of different concentrations (0.67 to 5000 µM) of 
carrier 3b. The carrier 3b : DOX molar ratios, in the tested solutions, varied from 0.13 
: 1 to 1000 : 1. Fluorescence spectra were measured by fluorescence spectrophotometer. 
Experiments were performed in 0.1 M PBS buffer solutions (pH = 7.4) at 37 °C. A DOX 
stock solution (100 mM) was made by dissolving 58 mg DOX powder (purity ≥ 98%) 
by 1 mL DMSO and kept frozen. A solution of 5 µM DOX was prepared by dilution of 
100 mM DOX stock solution (in DMSO) into PBS. The final concentration of DMSO in 
the diluted solution is 0.005%. To 10 mL of the final 5 µM DOX solution, 7.47 mg/mL 
of carrier 3b was added to obtain a carrier concentration of 5000 µM (1000 : 1 molar 
ratio of carrier 3b : DOX). Double dilutions from 1000 : 1 of carrier 3b : DOX 
solution by using 5 µM DOX solution was performed to obtain the various ratios of 
carrier 3b : DOX in the final solutions. Each solution was transferred into a 4 mL 
cuvette (Figure 3.2) and the fluorescence intensity was measured at λexcitation = 480 nm, 
λemission = 500 – 800 nm (λmax = 592 nm) (Kerry K. Karukstis and Rosenfeld 1998; Dai, 
Yue et al. 2008), with excitation and emission slits of 10 nm. 
 
Figure 3.2 DOX at constant concentration of 5 µM in the presence of different 
concentrations (0.67 to 5000 µM) of carrier 3b in cuvette before measuring 
fluorescence intensity. 
 
Thermal-responsivity of the inclusion complex of carrier 3b : DOX  
In thermal-responsivity investigations, DOX concentrations were employed 
constant at 2, 5 and 12.5 µM, respectively. The ratio between carrier 3b and DOX was 
62 
from 0.13 : 1 to 1000 : 1 (20 gradients). Tested solutions were prepared the same as 
described above (the section right above) but were transferred 200 µL/well to a black 
96-well plate (Figure 3.3 A) and test solutions arrangement can be seen from Figure 
3.3 B.  
 
Figure 3.3 Black 96-well plate for fluorescence intensity investigation (A); 
Schematic drawing of test solutions arrangement in 96-well plate (B). 
 
The first fluorescence intensity at room temperature (~ 25 °C) was measured by 
multi-mode plate reader under fluorescence optimal gain mode. Then INV064 oven 
(–10 °C to 50 °C) was used for achieving the higher desired temperatures (37 °C, 42 °C 
and 50 °C) by placing the same plate with the same test solutions 40 min with plate 
cover, fluorescence intensity at each temperature was recorded at the same setting of 
multi-mode plate reader. Then, the same plate was cooled down to room temperature 
again and the final set of fluorescence intensity was recorded. 
pH-responsivity of the inclusion complex of carrier 3b : DOX  
pH dependence of carrier 3b : DOX was assessed by dissolving the complex in 
different buffer solutions. The buffer solutions were prepared by using 0.2 M/0.1 M 
dibasic sodium phosphate (Na2HPO4), 0.1 M sodium phosphate monobasic 
(NaH2PO4∙H2O), 0.1 M citrate acid monohydrate, 0.1 M Potassium chloride (KCl) and 
0.1 M hydrochloric acid (HCl) (Mohan 2003). Table 3.1 shows pH buffers ingredients 
in details and final pH values measured by pH meter at 25 °C and 37 °C, respectively.  
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Table 3.1 pH buffers preparation and their final pH values at 25 °C and 37 °C 


















ddH2O 25°C 37°C 
8.0   10  125   70 8.004 7.970 
7.4 100        7.317 7.214 
7.0  15  45    40 7.047 6.912 
6.5  18.6  36.4    50 6.484 6.407 
5.5  24.2  27.8    50 5.503 5.429 
5.0  25  25    50 5.054 4.974 
4.5  29  23    50 4.532 4.507 
4.0  35  19    50 3.998 3.810 
3.0  48  10    50 3.057 2.980 
2.0      50 12 50 2.051 2.012 
1.0      50 90 90 1.095 1.024 
 
Tested solutions were prepared the same as the above section in a 96 well-plate 
with DOX concentration constant at 5 µM but by using different pH buffers instead of 
PBS. Fluorescence intensities of test solutions at room temperature (~ 25 °C) and 
heated to 37 °C were measured by multi-mode plate reader under fluorescence optimal 
gain mode. 
3.3.3 Calculations of encapsulation efficiency and binding 
constant 
3.3.3.1 Calculation of encapsulation efficiency of carrier 3b to DOX 










Equation 3.3 Encapsulation percentage of DOX by carrier 3b through 
fluorescence intensity measurement. 
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Where, I0 is the fluorescence intensity of DOX in the absence of carrier and Ix is the 
fluorescence intensity of DOX in the presence of different concentrations (x) of carrier 
3b.  
3.3.3.2 Calculation of binding constant K of carrier 3b to DOX 
It has been well reported that in the literature (Emara S 2000), addition of native 
γ-CD added to DOX at a ratio of up to 5000 : 1 can significantly stabilise DOX in 
aqueous solution via complex formation. Some other literatures (Swiech, Mieczkowska 
et al. 2012), where it has been shown that DOX encapsulation within CDs can 
significantly lower the fluorescence and absorbance signals of the guest molecule which 
means CDs can be considered as a fluorophore quencher for DOX molecular. 
Therefore, the binding constant can be calculated according to modified Stern-Volmer 
Equation 3.4 (Sorokin, Fylymonova et al. 2012) (which has been introduced in section 










Equation 3.4 Modified Stern-Volmer equation. 
 
Where, [H]x is the concentration of the host compound carrier 3b and 1 / f is 
equal to 1 since only one fluorescence quencher was employed in the present study 
(Lee 1998). The corresponding K binding, was calculated by the relationship of the 
intercept/slope value which is equal to (1 / f ) / (1 / fK) and derived from the linear plot 
of I0 / (I0 - Ix) vs. 1 / [H]x. 
3.4 Results and Discussion  
3.4.1 Characterisation of Carrier 3b 
Mono-6’-deoxy-6-[3-(naphthalen-2-yl)-2-(tert-butyloxycarbo 
nylamino)propionylamino]-γ-cyclodextrin (3a) was prepared by direct coupling of dry 
γ-CD (1) with 2-((tert-butoxy carbonyl)amino)-3-(naphthalen-2-yl)propanoic acid (2) 
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using HOBt, DMAP and EDC in DMF at 25 °C for 24 hr as shown in Figure 3.4 (step 1). 
Precipitation of the crude product from hot acetone, vacuum filtration of the white solid, 
careful purification by RP-18 column chromatography (H2O / CH3OH), recrystallisation 
from hot water and drying, afforded colourless crystals of pure 3a in 50% yield. 3a was 
converted to mono-6’-deoxy-6-[3-(naphthalen-2-yl)-2-(amino) 
propionylamino]-γ-cyclodextrin (carrier 3b) by removal of the tert-butoxycarbonyl 
protecting group using TFA in CH2Cl2 (1 : 1) at 25 °C (Figure 3.4, step 2). 
Concentration of the solvents under reduced pressure (< 25 °C), precipitation from hot 
acetone, vacuum filtration and freeze drying, afforded colourless crystals of pure 
carrier 3b in 84% yield (overall yield 42%). Compound carrier 3b was then fully 
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Figure 3.5 Dry γ-CD before modification (A); and modified γ-CD derivative 
carrier 3b after purification and freeze-dry (B). 
3.4.1.1 TLC, HPLC, UV, MS and MP characterisation  
To analyse the conjugated product of the carrier synthesis, TLC and HPLC were 
conducted. TLC analysis showed Rf (γ-CD) = 0.18, Rf (3a) = 0.48 and Rf (carrier 3b) = 
0.25, respectively. The chromatogram obtained by HPLC (Figure 3.6) of crude carrier 
3b contains the following peaks: 12.06 min (carrier 3b), 12.9, 13.5, 14.1 min (unknown 
impurities), 17.1, 17.8, 18.8 min (di-substituted γ-CD), 36.6, 37.5, 46.8 min (unknown 
impurities). Where, retention time of the monosubstituted carrier (83% of the product) 
was 12.06 min. The unwanted di-substituted and tri-substituted (14.1% in total) 
retention times were manily three parts happened from 12.9 min to 14.1 min, 17.1 min 
to 18.8 min and 36.6 min to 46.8 min, respectively, which depending on the relative 
position of the substituents to each other. As this is a non-specific reaction, it was 
stopped on purpose after 50% of the reagents had reacted and carefully purified. This 




Figure 3.6 HPLC Chromatogram of crude carrier 3b. It contains the following 
peaks: 12.06 min (carrier 3b), 12.9, 13.5, 14.1 min (unknown impurities), 17.1, 
17.8, 18.8 min (di-substituted γ-CD), 36.6, 37.5, 46.8 min (unknown impurities). 
 
UV spectra found 8 peaks above -3.00 A between started wavelength at 190 nm and 
stop wavelength at 1100 nm which gave a highest peak at absorbance 0.895 of 278 nm 
(Figure 3.7). MS result of ESI-MS m/z calculated for C61H91NO41 (carrier 3b) as 
1494.51, measured as 1494.77 (Figure 3.8). MP (carrier 3b, H2O) = 220 – 222 °C.  
 












C-NMR mesurements were performed to validate the structure of 
desired carrier 3b (Gourevich, Dogadkin et al. 2013). The 
1
H-NMR spectra (Figure 
3.9 A) and especially 
13
C-NMR spectra (Figure 3.9 B) suggested that the chemical 
structure of the carrier is consistent with the desired yield being the monosubstituted 





Figure 3.9 NMR spectra of carrier 3b (20 mM) in D2O. 
1
H-NMR spectrum (A); 
13




H-NMR (400 MHz, D2O) of carrier 3b: 3.20 (d, 4H), 3.52 (d, 2H), 3.86 (s, 6H-6), 
3.79 (t, 5H), 3.97 (d, 3H), 4.41 (d, 9H), 4.50 (s, 8H), 5.10 (d, 1H), 7.39 (s, 19H), 7.57 
(m, 15H), 7.57 (m, 14H), 7.65 (m, 11H), 7.81 (m, 18H), 7.83 (m, 16H), 7.85 (m, 13H). 
13
C-NMR (400 MHz, D2O) of carrier 3b: 36.53 (9C), 53.87 (8C), 59.63-60.15 
(6C), 65.84 (*6C), 69.52 (*5C), 71.56-71.82 (5C), 72.01-72.38 (2C), 72.64-73.06 (3C), 
79.83-80.90 (4C), 100.97-102.17 (1C), 126.59 (15C), 126.73 (14C), 126.81 (18C-18), 
127.31 (13C), 127.53 (16C), 127.94 (19C), 128.35 (11C), 131.69 (17C), 132.23 (12C), 
132.92 (10C), 169.68 (7C). (*Carbon of the substituted ring) 
It is well documented in the literature (Schneider, Hacket et al. 1998) that H-1, H-2, 
H-4 and H-6 protons in γ-CD are located on the exterior surface of the molecule and 
exposed to bulk environments, while H-3 (δ = 3.95 ppm) and H-5 (δ = 3.88 ppm) 
protons are located in the interior cavity of γ-CD. 1H-NMR analysis of carrier 3b 
(Figure 3.9 A), shows that H-3 (δ = 3.97 ppm) and H-5 (δ = 3.79 ppm) protons 
experience magnetic perturbation and have a downfield shift of 0.02 ppm and an upfeild 
shift of 0.09 ppm, respectively. These observations suggest the existence of certain 
cooperative hydrophobic interactions between the CD’s interior cavity and the 
β-naphthalene moeity. Such interaction could be achieved only by partial or fully 
self-assembly inclusion of the β-naphthalene subsituent within the hydrophobic cavity 
of carrier 3b, as suggested by 3D interaction modelling in work reported previously 
(Gourevich, Dogadkin et al. 2013).  
3.4.2 Inclusion Association of Carrier 3b to DOX  
3.4.2.1 NMR analysis of carrier 3b to DOX complexation 
In order to investigate the inclusion behavior of DOX molecule as a guest to the host 
molecule of carrier 3b, further NMR measurements were performed in an aqueous 
solution D2O. The NMR results showed significant changes (black circles positions in 






H-NMR spectra of 10 mM DOX (top), 10 mM carrier 3b (middle), 
1:1 of carrier 3b : DOX (10 mM each) complex (bottom) in D2O with significant 
chemical shifts (black circle areas). 5’-CH3(black arrow) δ = 1.33 ppm and 8-H2 
(red arrow) δ = 2.30 ppm are as indicated. Black circles indicate interations of 
(from left to right): 3H of DOX with protons on β-naphthalene; 1’H of DOX with 
1H of CD’s ring; 3H and 5H interior protons of CD’s ring with 4-OCH3 of DOX 





H-NMR spectra of DOX (2 mM) in D2O. 
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Where, the complex spectrum of carrier 3b and DOX mixture in D2O is not a 
simple superposition of the carrier and DOX spectra (Figure 3.11) (Wang, Wang et al. 
2010), which illustrating that there is indeed an interaction between these two 
molecules. Closer evaluation of the significant amount and manner of DOX and 
carrier 3b’s chemical shifts in aqueous solution suggested the encapsulation of DOX 
happens within carrier 3b’s cavity (Swiech, Mieczkowska et al. 2012). 
As mentioned above in section 3.4.1.2, H-3 and H-5 of carrier 3b are both facing 
the inner space of the cone and are affected by the removal of D2O and DOX entrance 
(Singh 2010). Thus, explanations for the encapsulation might be found from the 




 positions in the γ-CD ring. 
Additional information obtained from the 
1
H-NMR spectrum of the complex can 
indicate the orientation of the DOX within the carrier. Again, as can be seen from 
Figure 3.10, the methyl moiety on the 5
th
 position of the amino sugar ring with the 
peak position of δ = 1.33 ppm (5’-CH3, black arrow in Figure 3.10) and the proton on 
the 8
th
 position of the aromatic ring with peak position of δ = 2.30 ppm (8-H2, red 
arrow in Figure 3.10) of the DOX molecule are not influenced by adding the carrier 
3b, which suggested that moiety of DOX is located outside the γ-CD cavity. 
Additional information on the 3D structure of the complex was achieved by 
NOESY and COSY measurements. Subtraction of the COSY and NOESY full 
spectrums (Figure 3.12, 3.13 and 3.14) provided the information on the non-covalently 
bonded protons present in proximity to each other in the 3D structure of the molecule. In 
the measurement of the 
1
H-NOESY spectra of the carrier 3b and DOX (Agrawal, 
Barthwal et al. 2009) (1 : 1) complex in D2O, the NOE interactions between the proton 
H-3 of DOX (6.9 ppm), which is located on the first phenyl ring next to the methyl group, 
and the β-naphthalene protons (7.6 ppm) of carrier 3b were observed (black arrow in 
Figure 3.13 C). This observation indicated that these protons were located close to each 
other and there was a strong probability of the formation of π-π stacking complex 






H–NMR (A) COSY and (B) NOESY full spectra and (C) their 





Figure 3.13 6 – 8ppm 1H–NMR (A) COSY and (B) NOESY spectra and (C) their 




Figure 3.14 5 – 6ppm 1H–NMR (A) COSY and (B) NOESY spectra and (C) their 
subtraction of carrier 3b : DOX (1 : 1) complex in D2O. 
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Figure 3.15 Interaction model of carrier 3b-DOX inclusion complex 
3.4.2.2 Carrier 3b to DOX complexation analysed by fluorescence spectroscopy 
The inclusion complex created between carrier 3b and DOX in the present study 
was detected through fluorescence measurements based on the DOX fluorescence signal 
at 592 nm. According to the fluorescence studies, the fluorescence intensity of DOX was 
gradually decreased with increasing carrier 3b’s concentrations (Figure 3.16). This 
signal decays in the presence of carrier 3b, suggesting that good coupling between the 
DOX and carrier 3b is formed due to encapsulation, which is allowing energy transfer 
between the guest and host molecule. Therefore, the DOX excited state decays 
non-radioactively leading to lower fluorescence signals. The experimental results also 
validated that carrier 3b is a fluorophore quencher for DOX, because the fluorescence 
intensities of the carrier 3b : DOX samples were constantly lower than those of the free 
DOX. The observed decrease in the fluorescence intensity of DOX is in a good 
correspondence with literatures (Wagner, Fitzpatrick et al. 2003; Park 2006). 
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Figure 3.16 Fluorescence spectrum of DOX in the prescence of carrier 3b. 5 μM 
DOX with increasing concentrations (0.67 to 5000 µM) of carrier 3b in PBS was 
tested at λexcitation = 480 nm, λemission = 500 – 800 nm (λmax = 592 nm) with slits 10 
nm 
 
According to the calculation of encapsulation efficiency (Equation 3.3) between 
carrier 3b and DOX (Figure 3.17), DOX encapsulation efficiency was gradually 
enhanced with increasing concentration of carrier 3b, while no inclusion evidence was 
observed using the non-modified γ-CD with DOX, under similar conditions. Significant 
encapsulation of DOX within carrier 3b was observed at ratios as low as 1 : 1. 
Satisfying encapsulation was obtained of carrier 3b : DOX at the ratio of 10 : 1 which 
will be further discussed in section 3.4.4. 
 
Figure 3.17 Encapsulation of DOX (5 μM) by carrier 3b (0.67 to 5000 µM) and 
γ-CD (0.67 to 5000 µM) analysed by fluorescence spectroscopy. 
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3.4.2.3 Binding constant calculation of carrier 3b to DOX by modified 
Stern-Volmer equation 
Since a good correspondence function between 1 / ([carrier 3b], M
-1
) and 
fluorescence intensity of DOX in the presence of x M carrier 3b was obtained above 
(Figure 3.17), the corresponding K binding value, was calculated by the obtained liner 
plot of y = 5×10
5 
x+1.0263 derived from the correspondence of I0  / (I0-Ix) vs. 1 / [H]x 
(y and x axis in Figure 3.18, respectively) at R
2 
= 0.9936 through the intercept (1.0263) 
/ slope (5×10
5
) value which finally equal to 20,526 M
-1 
at physiological temperature. 
This value is a factor of 102 higher than the fluorescence established Kbinding reported 
by Anand et al. recently (Anand, Ottani et al. 2012) for the native γ-CD with DOX in 
1 : 1 complex formation. The higher value of Kbinding of the modified carrier 3b can be 
attributed to the modification by the naphthalene group, which potentially exhibits π-π 
interactions between the aromatic rings of carrier 3b and DOX molecule. The analysis 
is consistent with the previous carrier 3b to DOX inclusion’s NMR structure 
investigation. 
 
Figure 3.18 Binding constant K of carrier 3b with DOX. Fluorescence intensity of 
DOX (5 μM) mixed with carrier 3b (0.67 to 5000 µM) was measured and K 
binding was calculted as described in the Materials and Methods (K = 20526 M
-1
). 
3.4.2.4 Drug Loading efficiency of the carrier 
An additional important factor in the complex formation is the concentrations of the 
reagents and their molar ratio in solution. As can be seen in the 
1
H-NMR spectra of 
y = 5E-05x + 1.0263 



















1/ [3b], (M-1) 
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carrier 3b : DOX at ratio 1 : 1 and 10 : 1 (Figure 3.19), the top spectrum has broader, 
which has more widely distributed peaks. This variation between the spectra suggests 
that, in the 1 : 1 solution, the created complexation has a more rigid structure than with 
excess of the carrier 3b. In the former case (10 : 1), several carrier 3b molecules can 
encapsulate a certain DOX encouraging it to exhibit a faster dynamic equilibrium 
between the free and encapsulated forms. Additionally, the comparison of the two 
spectra can aid in the attribution of the peaks to the appropriate molecules. The 
appearance of a certain peak (black circle in Figure 3.19) only in the 1 : 1 complex 
spectrum provides a strong indication that the peak belongs to DOX rather than the 
carrier 3b. A good example is the peak at 6.9 ppm which appears only in the 1 : 1 




H–NMR spectra of carrier 3b : DOX complexes at ratios 10 : 1 (top) 
and 1 : 1 (bottom) in D2O, respectively. 20 mM carrier 3b and 2 mM DOX were 
applied for the 10 : 1 complex; and 10 mM carrier 3b and 10 mM DOX were 
applied for the 1 : 1 complex. 
 
The drug loading efficiency was also validated by fluorescence spectroscopy in 
which increasing concentrations of DOX were used while carrier 3b : DOX was kept 
at the same ratio. The results suggested that increasing the concentration of DOX (2, 5 
or 12.5 μM) led to increased drug loading (Figure 3.20), which further confirmed that 
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increasing either the concentration of the carrier or DOX will lead the equilibrium of 
the two molecules to the direction of forming more encapsulation. These results 
demonstrate the potential of this carrier in reducing the dose of DOX in chemotherapy. 
 
Figure 3.20 Loading efficiency of DOX by carrier 3b. The DOX concentrations 
were as indicated (2 μM, 5 μM and 12.5 μM) and carrier 3b was applied at the 
ratios to each concentration of DOX from 26 : 1 down to 0.5 : 1. 
3.4.3 pH Stability of Carrier 3b : DOX Complex  
The pH responsivity of carrier 3b for the inclusion of DOX was investigated by 
fluorescence spectroscopy. The fluorescence emission values of free DOX were found 
to be unaffected in different pH media (Figure 3.21). Therefore, any change in the 
fluorescence intensity of DOX will be a result of the encapsulation. The encapsulation 
efficiency of carrier 3b to the drug was estimated under a wide range of pH values (1.0 
































Figure 3.21 Fluorescence intensity of DOX in solutions of various pH values. 
 
 
Figure 3.22 Encapsulation percentage (%) of DOX by carrier 3b in solutions of 
various pH values and at different carrier 3b : DOX ratios at 37 °C 
 
Since the encapsulation efficiencies are all in the same order of magnitude, the 
results indicate a similar chemical stability of the complex (Bekers, Beijnen et al. 1990; 
Emara S 2000) and comparable encapsulation mode in a wide range of acidic 
environments and at a wide range of carrier 3b : DOX ratios. 
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carrier 3b : DOX=300:1
carrier 3b : DOX=40:1
carrier 3b : DOX=10:1
carrier 3b : DOX=5:1
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3.4.4 Thermal Responsivity of Carrier 3b : DOX Complex 
The same method was utilised to evaluate the thermal responsivity (Schmaljohann 
2006) of the inclusion complex carrier 3b : DOX. Testing temperatures were 25, 37, 
42, 50 °C and then cool down at 25 °C (Figure 3.23). The modified Stern-Volmer plot 
shows a clear correlation between the encapsulation efficiency of carrier 3b with DOX 
and the temperature of the surrounding environment (Figure 3.24).  
 
Figure 3.23 Thermal responsivity of carrier 3b : DOX inclusion complex at pH7.4. 
 
 
Figure 3.24 Modified Stern-Volmer plot showing binding affinities of carrier 3b 
(0.67 to 5000 µM) to DOX (5 μM) at varying temperatures. K25 °C = 34433, K37 °C = 
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Increasing the temperature from 25 to 50 °C led to a decrease of the K binding by ~ 
3.5-fold and release of the DOX from the inclusion complex. In addition, after cooling 
down the testing solutions to 25 °C, a re-encapsulation process of DOX by carrier 3b 
was observed. This phenomenon demonstrated the reversible equilibrium process of 
DOX + carrier 3b  carrier 3b-DOX and further confirmed the dynamic 
complexation interaction between DOX and carrier 3b. It is well known in the literature 
(Tabushi, Kiyosuke et al. 1978) that the complexation process of CDs is driven by 
enthalpy and entropy, typically exhibiting large negative enthalpy changes as well as 
small negative entropy changes. The negative enthalpy changes results from van der 
Waals interaction and hydrogen bonding between guests and the cavities of CDs, while 
the negative entropic change is due to the steric barrier caused by the molecule’s 
geometrical shape and the limit of CD cavity to the freedom of shift and rotation of guest 
molecules (Chen, Xu et al. 2005).   
Optimal (highest) DOX release from the inclusion by temperature changes 
occurred when the carrier 3b : DOX ratio was around 10 : 1 as indicated by the 
release rate (Table 3.2) calculated according to data obtained in Figure 3.23. This ratio 
formation was applied thereafter in in vitro cell culture studies in Chapter 4 and 5. 
 
Table 3.2 DOX (5 µM) release from encapsulation by temperature changes 
 Ratio of carrier 3b to DOX 
39 26 17 11 8 5 3 
Temperature *Release rate (%) 
25 °C to 37 °C 7.3 9.5 11.5 12.3 12.0 12.5 10.8 
37 °C to 42 °C 7.0 8.5 9.0 9.8 9.2 8.6 7.3 
42 °C to 50 °C 8.8 10.3 9.6 10.6 6.6 6.1 4.3 
*Release rates were calculated by deducting the encapsulation efficiency (%) at lower temperature from that of at higher 
temperature. 
3.5 Conclusions  
In conclusion, a novel γ-CD derivative carrier 3b has been successfully designed 
and constructed which showed significantly improved encapsulation ability for DOX. 
The carrier possesses thermo-sensitivity and high pH stability. The delivery system was 
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designed to be used in combination with heat treatments, such as RFA, microwave 
hyperthermia and HIFU (May and Li 2013). However, whether this carrier would be 
efficient in encapsulation of DOX in in vitro and in vivo stages, and how the specific 
transportation and distribution of carrier 3b-DOX inclusion would be, are need to be 
further validated. The further investigation and application of this delivery system, in 















Chapter 4  
Establishment of in vitro Evaluation of 
Doxorubicin Encapsulation by 
γ-cyclodextrin Derivative 
4.1 Introduction 
On the basis of chemical analysis for the encapsulation affinity between the novel 
modified γ-CD carrier and DOX discussed in last chapter, it is essential to establish 
proper human cancer cell models to verify the encapsulation ability of the carrier to 
DOX for potential pre-clinical studies in the future. 
Cell culture plays an important role in the development and evaluation of novel 
anticancer drugs in vitro through carrying out experiments such as cellular drug uptake, 
drug efflux, cellular metabolism and cell proliferation assays. The development of 
methods for culturing human cancer cells in vitro has raised the question of whether it 
might be possible to use cell culture methods to model all of the features important for 
clinical anti-tumour activities. Such approaches might also lead to the development of 
novel nanocarriers for transportation of existing anticancer drugs that are selective for 
human tumour targets (Baguley, Hicks et al. 2002).  
Cell cultures are often used to: 1) screen compounds for carcinogenicity or 
mutagenicity; 2) analyse of the cells themselves; 3) examine cell to cell communication; 
4) assess cell’s response to chemical compounds; and 5) produce cellular-derived 
protein products (Varga 2011).  
The main theme of this chapter is the investigation of encapsulation capacity of the 
novel modified γ-CD carrier to DOX by cytotoxic and cellular drug uptake assays. 
Cytotoxic assays are particularly useful in evaluation of cell survival following 
exposure to novel compounds designed for anti-cancer treatments, while cellular drug 
86 
uptake evaluation is an efficient tool to investigate the encapsulation affinity of 
designed nanocarriers towards existing cytotoxic anti-cancer agents in vitro.  
4.2 Human Cancer Cell Culture and Selection of 
Methodology 
4.2.1 Selection of Suitable Human Cancer Cell Lines: KB and 
HCT116 (Langdon 2003)  
KB, human nasopharyngeal epidermoid carcinoma, is a HeLa (cervical carcinoma) 
contaminant cell line according to American Tissue Culture Collection (ATCC, 
CCL-17). KB cell line is widely used as it contains the highest expression required in 
many studies (Antony, Kane et al. 1989; Elwood 1989; Saikawa, Knight et al. 1993; Lee 
and Low 1994). It is also relatively sensitive to doxorubicin (Shen, Lu et al. 1991; 
Kamimura, Furukawa et al. 2013).  
HCT116 (ATCC, CCL-247) is a human colorectal carcinoma that has wild type p53. 
It carries a RAS mutation in codon 13 and is tumourigenic in nude mice. Cell lines from 
human colorectal cancers are useful tools in the study of cell biology and in the 
development and testing of new therapeutic modalities. In general, colorectal cancer cell 
lines are relatively easy to establish and grow (Langdon 2003).  
4.2.2 Selection of Methodology: Anti-proliferative (Growth 
Inhibition) Assays 
Anti-proliferative assays include cell cytotoxic assays and cellular drug uptake 
assays, which discuss the measurement of growth inhibition rather than cell killing 
(Baguley, Hicks et al. 2002). Cell cytotoxic assays such as the evaluation of the half 
maximal inhibitory concentration (IC50) (Belotti 1996) of a certain drug to different cell 
lines, is a particularly important strategy for DNA-damaging drugs such as DOX which 
was employed in the thesis reported here. DNA damage generally arrests cells in G2 
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phase (Furnari, Rhind et al. 1997) especially when p53 function is present (Abedin and 
King 2010). IC50 determination is the most direct method of measuring cytotoxic 
activity of a drug by in vitro, which may provide useful pharmacokinetic information 
for in vivo application (Fridborg, Nygren et al. 1995). 
Another commonly used anti-proliferative assay is cellular drug uptake. It provides 
a promising evaluation approach for drugs / nanomedicines such as those designed for 
selective activation by specific enzymes in tumour cells; those transportable by 
targeting ligands; and those released by physical or chemical triggers. In the above cases, 
useful activity depends not only on the ability of the drug to act as a substrate for the 
enzyme system but also on its ability to enter the tumour cells. This cell-based method 
is particularly suitable for detecting potential components such as cell targets that are 
difficult to represent in isolated biochemical systems. 
Cytotoxicity investigation by MTT assay  
Mitochondrial reduction of the dye methylthiazoldiphenyltetrazolium (MTT), has 
been first developed and reported as a rapid and quantitative assay for cell survival and 
proliferation investigation by Mosmann (Mosmann 1983).  
In MTT assay, cells should be in their exponential phase of growth and are exposed 
to cytotoxic chemicals. The exposure duration of MTT assay is usually determined by 
the time required for maximal damage to occur but is also depends on the stability of 
the tested drugs. After removal of testing compounds, the cells are usually post-cultured 
to proliferate for two to three doubling times to distinguish between cells that remain 
viable and are capable of proliferation and those that remain viable but cannot 
proliferate (Langdon 2003). Surviving cell numbers are then determined indirectly by 
MTT dye reduction.  
MTT reagent is a yellow water-soluble tetrazolium dye which is reduced by 
mitochondria of live cells (Liu, Peterson et al. 1997) by forming a blue formazan 
product that is insoluble in aqueous solutions (Figure 4.1 A). The amount of produced 
formazan can be determined spectrophotometrically once solubilised in a suitable 
solvent such as DMSO. The advantages of MTT assay are 1) it is a quick and easy 
screening procedure; 2) it allows a large number of assays to be carried out in one batch; 
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3) The results can be read on a multi-well scanning spectrophotometer and show a high 
degree of precision; and 4) No washing steps are used in the assay and lack of any 
radioisotope. But a drawback of the assay is that it cannot distinguish between a 
cytotoxic (cell kill) and a cytostatic (reduced growth rate) effect (Langdon 2003).  
 
Figure 4.1 MTT assay formazan formed by live cells (A) and dead cells (B). 
 
In terms of MTT application, the assay has been adapted successfully to measure 
growth and drug sensitivity of a variety of tumour cell lines by Finlay et al. (Finlay, 
Wilson et al. 1986) and Scudiero et al. (Scudiero, Shoemaker et al. 1988) in the 1980s. 
Moreover, the American National Cancer Institute (NCI) reported MTT dye reduction 
evaluation as a possible endpoint in a rapid screening assay (Alley, Scudiero et al. 1988). 
Shortly after, Berridge and Rao (Berridge and Rao 1993) further investigated the 
cellular reduction including sub-cellular localisation, substrate dependence, and 
involvement of mitochondrial electron transport in MTT reduction.  
Many other tetrazolium salts such as XTT (2, 
3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide), MTS 
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetraz
olium) in the presence of phenazine methosulfate (PMS) (Cory, Owen et al. 1991) and 
water soluble tetrazolium salts (WSTs) have been developed as water soluble 
tetrazolium salts to alternatively replace MTT assay. However, no single cytotoxicity 
assay is ideal and it is always advisable to support results with those obtained from 
alternative assays where possible and applicable. In the thesis reported here, MTT assay 
was adopted to investigate cell viabilities.  
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Cellular drug uptake and cell total protein measurement by the bicinchoninic acid 
(BCA) assay 
Cellular DOX uptake can be observed first of all by fluorescence microscopy. 
When DOX has been up-taken by cells, its fluorescence signal is visible under 
fluorescence microscopy by using a black glass fluorescence filter. The quantitation of 
DOX cellular uptake can be further determined by breaking down cells by lysis buffer 
and measuring cell lysate’s fluorescence intensity. The obtained fluorescence intensities 
of cell lysates need to be normalised further by the total cellular protein using 
bicinchoninic acid (BCA) assay. 
Tuszynski and Murphy (Tuszynski and Murphy 1990) reported BCA assay is a 
rapid and convenient method for the determination of the actual and relative cell 
numbers in tissue culture by using bicinchoninic acid to measure the total cellular 
protein of cultured cells. 
In BCA assay, cells usually are treated by cell lysis buffer to ensure cell protein 
release. By adding BCA reagent to cell lysate, Cu
2+
 firstly oxidises the protein and is 
converted to Cu
1+
, followed by bicinchoninic acid which complexes with the formed 
Cu
1+
 to form a purple colour. The oxidation reaction can be performed at room 
temperature for 2 hr, or at 37 °C for 30 min. The colour generated at the end of the 
incubation period is fairly stable. This assay is rapid and simple to perform. The data 
generated are also very reproducible and the assay is ideal for screening a large number 
of samples.  
As Tuszynski and Murphy finally pointed that the cell-derived absorbance reading 
as determined by BCA protein assay was proportional to the number of cells, in this 
thesis, BCA assay has been adopted for the indication of total cell numbers for 
normalising the fluorescence intensity by DOX in cellular drug uptake assay. 
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4.3 Materials and Methods 
4.3.1 Materials 
4.3.1.1 In vitro cell culture, medium, supplementation and other reagents 
Medium, supplementation and 
reagents 
Manufacturer and 
place of origin 
Specification 
KB cell line American Tissue Culture 
Collection, USA 
CCL-17 
HCT116 cell line American Tissue Culture 
Collection, USA 
CCL-247 
Roswell Park Memorial Institute 
(RPMI)1640 
Gibco® Invitrogen, UK [+] L-Glutamine 
Dulbecco’s Modified Eagle’s 
Medium (DMEM) 
Gibco®  Invitrogen, 
UK 
[+] 4.5g/L D-Glucose 
[+] L-Glutamine 
[+] Pyruvate 
Phenol Red Free Dulbecco’s 
Modified Eagle’s Medium 
(DMEM) 
Gibco®  Invitrogen, 
UK 
[+] 4.5g/L D-Glucose 
[+] L-Glutamine 
[+] 25Mm HEPES 
[−] Sodium Pyruvate 




Gibco Invitrogen, UK 0.05% 
Penicillin Streptomycin 
(Pen-Strep) 
Sigma-Aldrich, UK 10,000 units penicillin 
and 10 mg 
streptomysin/mL 
L-Glutamine Sigma-Aldrich, UK 200 mM 
Sodium Pyruvate Gibco®  Invitrogen, 
UK 
100 mM 
Non-Essential Amino Acids Gibco®  Invitrogen, 
UK 
 
HEPES buffer solution Gibco®  Invitrogen, 
UK 
1 M 
MycoAlert PLUS Mycoplasma 
Detection Kit 
Lonza, USA 10 test kit 
Dimethyl Sulphoxide (DMSO) Sigma-Aldrich, UK Biotechnology use, 
sterile filtered, endotoxin 
tested, hybridoma tested 
Sodium Dodecyl Sulfate (SDS) Sigma-Aldrich, UK 0.05% (w/v) in ddH2O 





Bicinchoninic Acid (BCA) 
Protein Assay Kit 
Sigma-Aldrich, UK Solution A: 
bicinchoninic acid, 
sodium carbonate, 
sodium tartrate, sodium 
bicarbonate in 0.1 M 
NaOH (final pH 11.25). 
Solution B: 4% (w/v) 
copper(II) sulfate 
pentahydrate 
Protein Standard (Bovine Serum 
Albumin-BSA) 
 
Sigma-Aldrich, UK 1.0 mg/mL bovine serum 
albumin in 0.15 M NaCl 
with 0.05% sodium azide 
doxorubicin (DOX) Mesochem Technology 
Co.,Ltd, Beijing, China 
Purity ≥ 98% 
PBS tablets Oxoid, UK Typical Formual (g/L): 
Sodium chloride 8.0; 






7.3±0.2 at 25°C 
4.3.1.2 Complete RPMI1640 and DMEM medium formulation 
Complete RPMI1640 
Supplementation Supplementation 
Fetal bovine serum (FBS) Fetal bovine serum (FBS) 
L-Glutamine L-Glutamine 
Penicillin and Streptomycin (Pen-Strep) Penicillin and Streptomycin (Pen-Strep) 
Sodium Pyruvate Sodium Pyruvate 
Non-essential Amino Acids Non-essential Amino Acids 
HEPES buffer HEPES buffer 
Complete DMEM 
Supplementation Supplementation 
Fetal bovine serum (FBS) Fetal bovine serum (FBS) 
L-Glutamine L-Glutamine 
Penicillin and Streptomycin (Pen-Strep) Penicillin and Streptomycin (Pen-Strep) 
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4.3.1.3 Cell culture consumables and equipment 
Consumables and 
equipment 
Manufacturer and place 
of origin 
Specification 





6-well, 12-well, 24-well 
and 96-well plate 
Techno Plastic Products 
(TPP), Switzerland 
transparent 
Black 96-well plate Greiner, Austria Non cell culture treated 
black base microplates 




Sterile Syringe filters Fisher Scientific, UK 0.45 µm cellulose acetate 
membrane 
Serological pipettes Techno Plastic Products 
(TPP), Switzerland 
5 mL, 10 mL and 25 mL 
Multi-mode plate reader Tecan, Austria Tecan infinite M200 
Oven Scientific Laboratory 
Supplies, UK 
INV064 
Multi-channel pipettes Eppendorf, UK 8-channel/12-channel 
Distilled/deionized water Millipore, UK  
4.3.2 Methods 
4.3.2.1 IC50 evaluation of DOX for KB and HCT116 cell lines 
Cultured KB / HCT116 cells were harvested and seeded at the density of 4000 per 
single well in a 96-well micro-plate 1 day prior to the assay. Cells were not plated in 
columns 1 and 12, rows A and H, but filled with complete medium (CM) because these 
are used as blank controls for the absorbance of the residual medium and MTT in the 
wells.  
DOX stock solution was prepared by dissolving 58 mg DOX powder in 1 mL 
DMSO to obtain the stock DOX concentration at 100 mM and kept the solution frozen. 
A solution of 100 μM DOX was prepared by dilution of the DOX stock solution by CM. 
The final concentration of DMSO in the diluted solution was 0.1%. This solution was 
then filtered by 0.45 µm filter and was diluted by 3/4 dilution method by CM to obtain 
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DOX concentrations from 100 μM to 2.4 μM for KB cell line (14 DOX concentration 
gradients, Figure 4.2 A) experiments, and to obtain DOX concentrations from 100 μM 
to 0.56 μM for HCT116 cell line (19 DOX concentration gradients, Figure 4.2 B) 
experiments, respectively.  
Cells were then exposed to the pre-heated (20 min at 37 °C water bath) test 
solutions by incubation with 100 µL of each solution/well for 30 min in triplicates. 
Experimental arrangement is presented as in Figure 4.2. At the end of incubation, test 
solutions and CM in control wells were removed and cells were washed by pre-heated 
CM twice and replaced with 100 µL/well fresh CM. Cells were then observed under the 
microscope to assess cell loss. Cell in the plate with refilled 100 µL/well fresh CM were 






Figure 4.2 Experimental design for IC50 determination of DOX to KB cell line (A) 
and HCT116 cell line (B) in 96-well plates. 
 
Cell viability was then evaluated by MTT colorimetric assay that uses the 
enzymatic activities of cells as a measure for their viability 48 hr post DOX exposure. 
For the MTT assay, 5 mg/mL MTT powder was dissolved in PBS and 20 µL of the 
prepared reagent was added directly into each well of cultured cells (100 µL CM) and 
A: KB cells 
B: HCT116 cells 
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incubated for 3 hr in a standard incubator. After incubation, the liquid was gently 
aspirated from the wells with a multi-channel pipette without touching the bottom of 
wells. Then, 100 µL/well of DMSO was added to dissolve the formazan, an artificial 
chromogenic product created by the reduction of the tetrazolium salt in metabolically 
active cells. The absorbance for each well, which is proportional to the number of viable 
cells, was read using the multi-mode Infinite M200 plate reader at a wavelength of 550 
nm with 2 min pre-shaking (this step helps to dissolve formed formazan thoroughly). 
Cell inhibition percentages (Inhibition %) by DOX can be calculated based on the 
absorbance values (OD) at 550 nm obtained from MTT assay by Equation 4.1: 
 
𝐼𝑛ℎ𝑖 𝑖𝑡𝑖𝑜𝑛% = (1 −
𝑂𝐷𝑐𝑒𝑙𝑙+𝐷𝑂𝑋 − 𝑂𝐷𝑏𝑙𝑎𝑛𝑘
𝑂𝐷𝑐𝑒𝑙𝑙 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑂𝐷𝑏𝑙𝑎𝑛𝑘
) × 1  % 
Equation 4. 1 Cell inhibition percentage upon exposure to DOX solutions. 
 
Where, 𝑂𝐷𝑐𝑒𝑙𝑙+𝐷𝑂𝑋 is the absorbance of cells exposed to gradient concentration of 
DOX solutions, 𝑂𝐷𝑐𝑒𝑙𝑙 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 is the absorbance of cells with no DOX exposure and 
𝑂𝐷𝑏𝑙𝑎𝑛𝑘 is CM without cells. Then, a correlation between Inhibition% and common 
logarithm of DOX concentrations (Log10 [DOX, M]) (Stewart and Watson 1983; 
Martone, Zhou et al. 2009; Chavez-Gutierrez, Bammens et al. 2012) can be obtained as 
typically showed by Figure 4.3.  
 
Figure 4.3 Determination of IC50 of unlabeled drug 
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As IC50 is the concentration at which the curve passes through the 50% inhibition, 
the inhibition at IC50 concentration  𝐼𝑛ℎ𝑖 𝑖𝑡𝑖𝑜𝑛𝐼𝐶50%  can be then calculated according 
to Equation 4.2: 
 
𝐼𝑛ℎ𝑖 𝑖𝑡𝑖𝑜𝑛𝐼𝐶50% = [𝐼𝑛ℎ𝑖 𝑖𝑡𝑖𝑜𝑛𝑚𝑎𝑥 − 5 % ×  𝐼𝑛ℎ𝑖 𝑖𝑡𝑖𝑜𝑛𝑚𝑎𝑥 − 𝐼𝑛ℎ𝑖 𝑖𝑡𝑖𝑜𝑛𝑚𝑖𝑛 ] × % 
Equation 4.2 Inhibition at IC50 concentration 
 
Where, 𝐼𝑛ℎ𝑖 𝑖𝑡𝑖𝑜𝑛𝑚𝑎𝑥 is the maximum inhibition rate of DOX to this cell line, 
while 𝐼𝑛ℎ𝑖 𝑖𝑡𝑖𝑜𝑛𝑚𝑖𝑛  is the minimum inhibition rate. Thus, the IC50 can be determined 
as the DOX concentration at which inhibition equals to 𝐼𝑛ℎ𝑖 𝑖𝑡𝑖𝑜𝑛𝐼𝐶50value. 
4.3.2.2 Calibration curve of DOX 
Two sets of calibration curves for DOX fluorescence intensity vs. DOX 
concentration were determined by preparation of two sets of gradient concentrations (2 
µM to 0.034 µM and 1 µM to 0.017 µM) of DOX in 0.5% SDS cell lysis buffer. Then 
DOX solutions were transferred to a black plate 200 µL/well in triplicate per sample, 
and fluorescence intensities were obtained by infinite M200 multi-mode plate reader at 
λexcitation = 485 nm, λemission = 500 – 800 nm and the fluorescence intensity at 592 nm 
(λmax) was adopted for the calibration curves. 
4.3.2.3 Cytotoxicity evaluation assays 
Cultured KB / HCT116 cells were harvested and seeded at the density of 4000 per 
single well in a 96-well micro-plate 1 day prior to the assay. Cells were not plated in 
columns 1 and 12, rows A and H, but filled with CM as these are used as blank controls 
for the absorbance of the residual medium and MTT in the wells. 
To test the modified carrier’s cytotoxicity, a solution of 1250 / 2500 μM carrier was 
prepared by dissolving 1.875 / 3.75 mg/mL carrier in CM and filtered by 0.45 µm filter 
for KB and HCT116 cells respectively. For the mixture of carrier and DOX cytotoxic 
assays, a solution of 12.5 / 25 μM DOX (corresponding to the test for KB / HCT116 cell 
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lines, respectively) was prepared by dilution of the DOX stock solution (100 mM) in 
DMSO by CM. The final concentration of DMSO in the diluted solution is 0.0125 / 
0.025%, respectively. To the final 12.5 / 25 μM DOX solution, 0.1875 / 0.375 mg/mL of 
carrier was added to obtain a concentration of 125 / 250μM (10 : 1 of carrier : DOX 
molar ratio). This solution was then filtered by 0.45 µm filter and was diluted by 12.5 / 
25 μM DOX solution to obtain carrier : DOX molar ratio at 100 : 1, 50 : 1, 25 : 1, 10 : 1, 
5 : 1 and 2.5 : 1, to keep the concentration of DOX constant at 12.5 / 25 μM. DOX 
solution of 12.5 / 25 μM with native γ-CD (100 : 1 of γ-CD : DOX molar ratio) was also 
experimented to compare the encapsulation affinity of γ-CD to DOX with the modified 
γ-CD.  
 
Figure 4.4 Cytotoxicity test by exposure KB / HCT116 cells to gradient 
concentrations of carrier in the presence of constant concentration of DOX (12.5 / 
25 µM, respectively). 
 
Cells were then exposed to the pre-heated (20 min at 37 °C water bath) test 
solutions by incubation with 100 µL of each solution/well for 30 min in triplicates 
according to Figure 4.4. At the end of incubation, test solutions and CM in control wells 
were removed and cells were washed by pre-heated CM twice and replaced with 100 
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µL/well fresh CM. Cells were then observed under the microscope to assess cell loss. 
Cells in the plate with refilled 100 µL/well fresh CM were further incubated for 48 hr.  
Cell viability was evaluated with MTT colorimetric assay 48 hr post exposure, as 
described in section 4.3.2.1. 
4.3.2.4 Cellular drug uptake evaluation assays 
KB / HCT116 cells were harvested and seeded at the density of 1.3×10
5
 per well in 
a 24-well plate and allowed to grow over 3 days prior to the assay. A solution of 12.5 / 
25 μM DOX (corresponding to the test for KB / HCT116 cells, respectively) was 
prepared by dilution of the DOX stock solution (100 mM) in DMSO by CM. The final 
concentration of DMSO in the diluted solution is 0.0125 / 0.025%, respectively. To the 
final 12.5 / 25 μM DOX solution, 0.1875 / 0.375 mg/mL of carrier was added to obtain a 
concentration of 125 / 250 μM (10 : 1 of carrier : DOX molar ratio). This solution was 
then filtered by 0.45 µm filter and was diluted by means of 12.5 / 25 μM DOX solution 
to obtain carrier : DOX molar ratio at 100 : 1, 50 : 1, 25 : 1, 10 : 1, 5 : 1 and 2.5 : 1, to 
keep the concentration of DOX is constant at 12.5 / 25 μM. Cells were exposed to DOX 
solution of 12.5 / 25 μM with native γ-CD (100 : 1 of γ-CD : DOX molar ratio) to 
compare the encapsulation affinity of unmodified γ-CD’s to DOX with that of modified 
γ-CD to DOX.   
For physiological temperature test, cells were exposed to the pre-heated (20 min at 
37 °C water bath) test solutions by incubation with 300 µL/well of each solution for 30 
min in triplicates / duplicates (see Figure 4.5). For thermal-responsivity test, cells were 
exposed to preheated (30 min at 42 °C and 50 °C oven) test solutions by incubation with 
300 µL/well of each solution in triplicates / duplicates (Figure 4.5). 
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Figure 4.5 Cellular DOX uptake by exposure KB / HCT116 cells to 
carrier-protected DOX (12.5 / 25 µM). The arrangement was the same for all 
experimental conditions: physiological (37 °C) and hyper-thermal temperatures 
(42 °C and 50 °C). 
 
At the end of the incubation time, test solutions were removed and the wells were 
washed twice with preheated (at 37 °C water bath) PBS. PBS was removed and 250 µL 
0.5% SDS were added to each well. Following observation under the microscope to 
ensure complete cell disruption by SDS, 200 µL total cell lysates from each well were 
transferred into wells of a black 96-well plate with µ-clear bottom for the measurement 
of the fluorescence intensity of intracellular DOX. Meanwhile, 25 µL of cell lysates 
from the same samples were transferred to wells of a normal transparent 96-well cell 
culture plate for protein determination by the BCA assay.  
BCA reagent was prepared by mixing 50 parts of bicinchoninic acid (reagent A) and 
1 part of 4% (w / v) copper sulphate solution (reagent B). Standard bovine serum 
albumin (BSA) solutions from 25 µg/mL to 500 µg/mL were prepared by diluting the 
standard BSA solution (1000 µg/mL) in the BCA kit by using the same cell lysis buffer 
(0.5% SDS). BCA assay was then carried out by adding 200 µL BCA reagent into 25 µL 
of cell lysates samples or BSA standard solutions to obtain the ratio of reagent and 
protein sample at 8 : 1. The plate was shaken for 30 sec and incubated for 30 min at 37 
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°C. After incubation, the plate was cooled down to room temperature and the absorbance 
was recorded. 
Both fluorescence intensity and absorbance were read by Infinite M200 multi-mode 
plate reader. Fluorescence intensity was measured at excitation and emission 
wavelengths at 485 nm and 592 nm, respectively. Absorbance of BCA assay was 
measured at a wavelength at 562 nm. 
The cellular uptake of DOX (% of free DOX) can be calculated according to 
Equation 4.3: 
 
 𝑝𝑡  𝑒% =
𝐼𝑥 𝑂𝐷𝑥⁄
𝐼𝐷𝑂𝑋 𝑂𝐷𝐷𝑂𝑋⁄
× 1   
Equation 4.3 Cellular uptake of DOX (% of DOX alone). 
 
Where, 𝐼𝑥  (IDOX) is the fluorescence intensity of cells exposed to DOX in the 
presence (or absence) of x concentration of carrier while 𝑂𝐷𝑥  (ODDOX) is the 
absorbance of BCA test for corresponding samples. DOX calibration curve can be 
adopted further to calculate the amount of cellular DOX uptake in the unit of µmol/µg 
total protein. 
4.4 Results and Discussion  
4.4.1 Cytotoxicity Test 
4.4.1.1 IC50 determination of DOX for KB and HCT116 cell lines 
KB and HCT116 cells were exposed to gradient concentrations of DOX to 
determine the IC50 for both cell lines. IC50 is an important criterion for choosing proper 




Figure 4.6 IC50 determination for DOX to KB cells expressed by the cell viability 
curve and the correlation between Inhibition% and Log10 [DOX, M] (Inset). 
 
Figure 4.6 demonstrates the viability of KB cells against gradient concentrations 
of DOX (30 min exposure at 37 °C), and the correlation curve and equation obtained 
by DOX inhibition rate for KB cells vs. the value of Log10 [DOX, M]. The viability of 
KB cells sharply decreased with increasing concentrations of DOX. When DOX 
concentrations went up to around 23.73 µM and higher, the viability of KB cells 
reached to a plateau where cell viable rate was only 2%, which gave the maximum 
inhibition rate at 98% (𝐼𝑛ℎ𝑖 𝑖𝑡𝑖𝑜𝑛𝑚𝑎𝑥). Accordingly, the maximum KB cell viability 
in the presence of DOX was 94.24%, thus, the minimum cell inhibition rate was 5.76% 
(𝐼𝑛ℎ𝑖 𝑖𝑡𝑖𝑜𝑛𝑚𝑖𝑛). Therefore, 𝐼𝑛ℎ𝑖 𝑖𝑡𝑖𝑜𝑛𝐼𝐶50% was obtained as 51.95% according to 
Equation 4.2. Together with the correlation equation generated between inhibition rates 
and Log10 [DOX, M], the value of Log10 [DOX, M] is equal to −5.52 at InhibitionIC50%, 
hence, DOX IC50 to KB human epidermal carcinoma cells was finally determined by 
Log10 [DOX, M] = −5.52 as IC50 (DOX to KB) = 5.01 µM.  
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Figure 4.7 IC50 determination for DOX to HCT116 cells expressed by the cell 
viability curve and the correlation between Inhibition% and Log10 [DOX, M] 
(Inset). 
 
Similar to KB cell line, Figure 4.7 depicts the viability of HCT116 cells exposed to 
DOX solutions (30 min exposure at 37 °C) and the relationship between DOX 
inhibition rates to HCT116 cells and Log10 [DOX, M]. In comparison to KB cells, 
HCT116 human colorectal cell line showed more resistance to DOX, as the minimum 
cell viability of HCT116 to DOX was at 20% whereas KB cells showed only 2%. The 
maximum viability of HCT116 to DOX was similar to KB cells, which was at 94.80%. 
Hence, the maximum inhibition rate of DOX to HCT116 cells was 80% while the 
minimum inhibition rate was 5.2%. According to Equation 4.2 again, 𝐼𝑛ℎ𝑖 𝑖𝑡𝑖𝑜𝑛𝐼𝐶50% 
was calculated as 42.6%, and Log10 [DOX, M] = −5.014 was obtained. Finally, IC50 of 
DOX to HCT116 human colorectal carcinoma cells was determined as IC50 (DOX to 
HCT116) = 9.68 µM. 
For easy calculation in future experiments, IC50 = 5 µM for KB cell line and IC50 = 
10 µM for HCT116 cell line were adopted, respectively. Consequently, concentrations 
of 2.5 × IC50 (O'Neill, Ormerod et al. 1996; Keenan, Liang et al. 2004; Vandyke, White 
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et al. 2007) of DOX for the treatment of KB and HCT116, 12.5 µM and 25 µM 
respectively, were employed for the viability and drug uptake assays by exposure KB 
and HCT116 cells to DOX in the presence of carriers. 
4.4.1.2 Cytotoxicity of encapsulated DOX by unmodified γ-CD and modified γ-CD 
carrier  
To validate the encapsulation capability of the carrier, in vitro cytotoxicity 
experiments were performed at 37 °C for 30 min. Both KB and HCT116 cells were 
exposed to gradient ratios (100 : 1, 50 : 1, 25 : 1, 10 : 1, 5 : 1 and 2.5 : 1) of 
carrier-DOX complex and were compared with DOX alone and γ-CD associated DOX, 
while keeping constant concentration of DOX.   
 
Table 4.1 Effect of carrier encapsulation on the viability of KB and HCT116 cells 
by DOX 







Carrier : DOX 
100:1 95.5±3.4 92.7±3.4 
50:1 84.6±3.9 91.8±3.3 
25:1 84.1±6.8 78.7±2.0 
10:1 85.4±4.5 65.9±4.1 
5:1 66.5±2.4 59.2±4.8 
2.5:1 39.4±2.9 54.2±1.7 
DOX alone 12.5 / 25 µM 
(KB / HCT116) 
12.9±1.2 37.2±1.5 
Carrier alone 1250 / 2500 µM 




(125+12.5 µM)/(250+25 µM) 
(KB / HCT116) 
24.7±3.5 37.9±0.8 
*The data were compiled from five separate experiments performed in triplicates and were expressed as means±SD. 
The MTT results (Table 4.1) show that this modified γ-CD derivative itself has no 
obvious cytotoxic effect on cancer cells, in which, 100.7 ± 2.6% viable KB cells and 
97.8 ± 2.0% viable HCT116 cells were observed after exposure to 1250 µM and 2500 
µM carrier, respectively. For both KB and HCT116 cell line, cell viability increased by 
increasing the concentration of carriers. Specifically, KB cells showed 85.4 ± 4.5% 
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viability when the ratio between carrier and DOX was 10 : 1, when the carrier to DOX 
ratio was increased to 25 : 1 and 50 : 1, The rates of viable KB cells (84.1± 6.8% and 
84.6 ± 3.9%) were similar to that at 10 : 1, and at highest ratio of 100 : 1 of carrier to 
DOX, viability of KB cells increased to 95.5 ± 3.4%. In comparison to KB cells, 
HCT116 cells exhibited relatively lower cell viability when the same ratio of carrier 
and DOX was employed, 65.9 ± 4.1% at 10 : 1, 78.7 ± 2.0% at 25 : 1, and 92.7 ± 3.4% 
at 100 : 1.  
In comparison to the exposure of DOX alone and DOX in the presence of 
unmodified γ-CD, inclusion of DOX by the modified carrier significantly reduced the 
toxicity of DOX in both KB and HCT116 cells: 12.9 ± 1.2 / 37.2 ± 1.5% of the cells 
were viable at the dose of 12.5 / 25 µM of DOX alone for KB / HCT116 cells; 24.7 ± 
3.4 / 37.9 ± 0.8% of the KB/HCT116 cells were viable when exposed to DOX in the 
presence of unmodified γ-CD. In addition, 39.4 ± 2.9% of KB cells and 54.2 ± 1.7% of 
HCT116 cells were found viable in the presence of lowest concentration of modified 
γ-CD derivative when exposed to DOX, all higher than that of cells exposed to DOX 
alone or DOX associated by native γ-CD.  
The above results indicate that the inclusion of DOX by the modified γ-CD 
derivative prevented DOX from eliciting cytotoxic effect on cultured human cancer 
cells. These results also validate that the encapsulation mechanism of CDs to drug 
molecules is in equilibrium: CDs+DOXCDs-DOX; when the concentration of CDs 
is increasing, the equilibrium moves to the right side to form more CDs-DOX complex 
inclusion which causes higher encapsulation efficiency. Moreover, HCT116 cells 
showed again higher resistance (higher cell viability) to DOX than KB cells, which is 
consistent with the IC50 evaluation of DOX in both cell lines in section 4.4.1.1. These 
results suggest that the optimal application ratio between the carrier and DOX is 10 : 1 
especially for KB cell line, which further supported this conclusion obtained in section 
3.4.4 in Chapter 3. Thus, ratio of 10 : 1 of carrier: DOX was adopted for a range of 
cellular drug uptake assays conducted in Chapter 5. 
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4.4.2 Cellular Drug Uptake   
4.4.2.1 Cellular drug uptake under physiological conditions 
Cellular DOX uptake investigation was performed to further confirm the 
encapsulation capability of the carrier. Similar to the above cytotoxicity assays, KB 
and HCT116 cells were exposure to gradient ratios (100 : 1, 50 : 1, 25 : 1, 10 : 1, 5 : 1 
and 2.5 : 1) of carrier-DOX complex and were compared with DOX alone and γ-CD 
associated DOX, while keeping DOX’s concentration constant. Drug exposure 
condition was 30 min at 37 °C. 
 
Table 4.2 Effect of carrier encapsulation on the uptake of DOX by KB cells and 
HCT116 cells 
  KB cells 
(Uptake % of 
DOX alone) 
HCT116 cells 
(Uptake % of 
DOX alone) 
Ratio of 
Carrier : DOX 
100:1 2.4±1.1 2.1±0.5 
50:1 4.6±0.6 3.6±0.2 
25:1 8.0±0.3 5.9±0.4 
10:1 13.3±2.4 11.5±0.5 
5:1 34.2±3.7 19.9±1.2 






*The results were compiled from five separate experiments performed in triplicates and were expressed as means±SD. 
Table 4.2 presents the prevention effect of carrier on DOX from being up-taken by 
both KB and HCT116 cells. Cellular DOX uptake percentage gradually increased 
along with decreasing concentrations of carrier. In the presence of the carrier, DOX 
cellular uptake had minimum 46.9 ± 4.5% reduction to KB cells and 64.3 ± 2.9% 
reduction to HCT116 cells at carrier-DOX ratio of 2.5 : 1. In consistence with above 
DOX IC50 and cytotoxicity results, HCT116 cells behaved more resistant to DOX 
exposure as their DOX uptake was lower than those by KB cells in both absence and 
presence of carriers. Unmodified γ-CD demonstrated some encapsulation capacity 
towards DOX as cellular DOX uptake by KB and HCT116 cells was 61.7 ± 5.3% and 
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58.9 ± 3.6%, much lower than DOX alone exposure.  
Overall, the cellular DOX uptake results confirmed the encapsulation capability of 
the carrier to DOX as well as validated that at carrier-DOX ratio of 10 : 1, the 
reduction of DOX uptake was as potent as 86.7 ± 2.4% and 88.5 ± 0.5% for KB and 
HCT116 cells. These results further suggested that the ratio of carrier and DOX at 10 : 
1 may be suitable for future cell culture studies and in vivo trials. 
To further quantify DOX uptake by cells in the unit of µmol/µg total protein, 
DOX calibration curves and BSA standard curve were obtained in each cellular uptake 
experiment. Figure 4.8 is an example of a DOX calibration curve up to DOX 
concentration of 1 µM (A), and a BSA standard curve (B).  
 
Figure 4.8 DOX calibration curve up to 1 µM at λexcitation = 485 nm, λemission = 592 
nm and optimal gain at 127 (A); BSA standard protein curve (B). 
 
Taking the above Figure 4.8 as an example, if fluorescence intensity of tested 
sample is 30000, by substituting it into equation 30000 = 45247x1, then x1 = 30000 / 
45247 = 0.66 (µM of DOX). If the same sample’s BCA absorbance is 0.75, then 0.75 = 
0.0013x2, in which x2 is equal to 0.75 / 0.0013 which is 576.92 (µg/mL). DOX cellular 
uptake per unit of total protein is then calculated as x1 / x2 = 0.66 / 576.92 = 1.14×10
-6 
µM/µg protein. This method will be applied in experiments wherever discussion of 
absolute amount of drug uptake is necessary. 
y = 45247x 































A: DOX Calibration Curve 1µM(max) 
y = 0.0013x 




















B: BSA standard curve 
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4.4.2.2 Cellular drug uptake under hyperthermia 
As described in Chapter 3, the modified γ-CD derivative was found to be 
thermo-sensitive. More cellular DOX uptake assays were performed by exposure of 
cancer cells to carrier-DOX under hyperthermia conditions (42 °C and 50 °C) to 
validate carrier’s thermo-responsivity in cell culture application. KB and HCT116 cells 
were exposed to various ratios (100 : 1, 50 : 1, 25 : 1, 10 : 1, 5 : 1 and 2.5 : 1) of 
carrier-DOX complex and the drug uptake was compared with DOX in the absence of 
carrier at 37 °C, 42 °C and 50 °C for 5 min, respectively. 
 
 
Figure 4.9 Effect of carrier encapsulation on the uptake of DOX by KB cells (A) 
and HCT116 cells (B) under hyperthermia conditions. 
 
Figure 4.9 depicts DOX cellular uptake by exposure of human cancer cells to 
carrier-DOX complex under hyperthermia conditions, 42 °C and 50 °C in comparison 
to physiological temperature (37 °C). DOX uptake by KB cells exhibited clear trend 
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that the uptake was increased by increasing exposure temperatures. For HCT116 cells, 
there was a slight increase of uptake when temperature was risen from 37 °C to 42 °C. 
At higher temperatures (50 °C) DOX cellular uptake was significantly increased 
compared to lower temperatures exposure.  
 
Figure 4.10 DOX release correlation with temperature changes. 
 
Figure 4.10 shows the correlation between temperature rise and DOX release rate 
from the carrier through carrier-DOX binding investigation. The drug release was 3.34% 
when temperature increased from 37 °C (73.50 ± 4.25% encapsulation) to 42 °C (70.16 
± 4.23% encapsulation) (see the table within Figure 4.10). And the increase of DOX 
cellular uptake in KB cells was 4.76% according to Figure 4.9 A (red circled), higher 
than DOX release rate of 3.34%. It should be noticed that the binding test between 
carrier and DOX conducted in Chapter 3 went through 30 min hyperthermia incubation 
without cells; while in the hyperthermia uptake assay reported here, cells were only 
treated by 5 min ‘heat shock’ and nonetheless showed higher uptake rate.  
Therefore, these results suggest that hyperthermia may have two effects on cellular 
drug uptake. The first effect is hyperthermia triggered DOX release from the 
encapsulated carrier-DOX inclusion which has been confirmed in Chapter 3 by the 


































temperatures increased; the second effect is that hyperthermia may enable the 
enlargement of pore size of cell membranes to allow more DOX enter the tumour cells, 
as thermal treatment has been shown to enhance permeability of cells (Ponce, 
Vujaskovic et al. 2006; Cabuy 2011).  
4.4.3 Statistical Analysis 
All cytotoxicity and drug uptake data were expressed as mean ± SD (standard 
deviations). P values for expressing differences between DOX alone / carrier+DOX 
treated samples and controls were calculated by unpaired two-tailed equal variance 
Student's t-test. Statistical significance was set at p < 0.05. 
4.5 Conclusions 
To summarise, the encapsulation potency of modified γ-CD derivative for DOX has 
been validated and confirmed by a range of cytotoxicity and cellular drug uptake 
evaluations in comparison to the exposure of drug alone and drug plus unmodified γ-CD. 
The encapsulation efficiency was potent enough at 10 part of carrier with 1 part of DOX; 
the ratio of 10 : 1 was further employed in sonoporation experiments in Chapter 5. The 
cell culture studies further confirmed the thermo-sensitive property of the novel 
modified γ-CD carrier, suggesting that this delivery system may have the potential to be 
used in chemotherapy in combination with heat treatments, such as RFA, microwave 
hyperthermia and HIFU.    
110 
Chapter 5  
In vitro FUS Sonication Investigation by A 
Standardised High Throughput Ultrasound 
Device 
5.1 Introduction 
As discussed in Chapter 2, US may play an increasing role in medical applications 
because of its thermal and mechanical effects on tissue, cells and bio-molecules, 
expanding its traditional applications from imaging and diagnostics to therapeutics. 
While hyperthermia and ablation with HIFU (ter Haar 2001) are better established 
therapeutic methods, there is very significant research interest in ultrasound-mediated 
delivery of therapeutic agents to cells and solid tumours (Lavon and Kost 2004; ter Haar 
2007; Deckers and Moonen 2010) including chemotherapeutics, genetic material 
(Hernot and Klibanov 2008), proteins and small molecules (Pitt, Husseini et al. 2004). 
US in focused form is thus expected to play an important role in future medical 
technologies (Jolesz and McDannold 2008) with potential major benefits including 
significantly reduced side effects via efficacious and targeted delivery of drugs. To 
translate the benefits of FUS into drug delivery for medical therapies, there is a need for 
an increase in experiments in vitro to form the basis of preclinical and in vivo studies.  
Referring to the experimental methodology reported in pioneers’ work on cell 
sonoporation, several common features of setups are:  
1) Most of the in vitro ultrasound exposure was conducted for cell suspensions 
(Ashush, Rozenszajn et al. 2000; Sundaram, Mellein et al. 2003; Karshafian, Bevan 
et al. 2009);  
2) Sonications were performed in dedicated chambers (Guzman, Nguyen et al. 2001; 
Feril, Kondo et al. 2002; Deng, Sieling et al. 2004), in Opti-cell environments 
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(Eisenbrey, Huang et al. 2009; Feril, Tachibana et al. 2010) or in wide petri-dishes 
(Hundt, Steinbach et al. 2009; Conti, Grimaldi et al. 2010);  
3) Most of the acoustic sources were bespoke transducers (Wang, Xu et al. 2010; 
Yudina, Lepetit-Coiffe et al. 2011).  
However, in vitro studies concerning the action of FUS by using piezoceramic bowl 
transducers with cells cultured in monolayers in a 96-well plate presently lack a 
standardised way to deliver the FUS and the comparative evaluation is difficult. 
In this chapter, a new high-throughput in vitro sonicator device is described, which 
was designed in the Nanoporation project based on the results obtained by Gerold et 
al.(Gerold, Gourevich et al. 2012). Sonoporation procedures in combination with USCA 
SonoVue
®
 MBs were applied to monolayers of human cancer cells cultured in 96-well 
plates and, through testing of cells’ viability, the drug release and cellular uptake of 
DOX from the modified γ-CD carrier-DOX inclusion discussed in the previous two 
chapters was determined.  
This chapter puts forward results obtained by application of FUS in the absence / 
presence of MBs with low mechanical indexes, under which negligible thermal effects 
were observed. AFM was employed for preliminary analysis of membrane morphology 
of cancer cells upon exposure to FUS. A thermal camera and thermocouples were 
employed to monitor temperature changes during the application of FUS. 
5.2 In vitro Micro-scale Sonicator 
5.2.1 FUS: Principles and FUS Device for TDD 
Similar, in principle, to using magnifying glass to focus multiple beams of light to a 
single point, ultrasound can be focused: 1) geometrically via a lens such as a 
polystyrene lens or a spherically curved transducer; 2) electronically via a phased array 
(the relative phases of electrical signals to an array of elements that comprise a 
transducer ); and 3) effectively by resonant electrical excitation of thin plates of a 
suitable piezoceramic, in the required frequency region (Hill and ter Haar 1995).  
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In general, the interaction between FUS waves and biological tissue can be divided 
into thermal and non-thermal (mechanical) effects (Jenne, Preusser et al. 2012), have 
been discussed in Chapter 2. However, thermal and mechanical effects of FUS 
propagation through tissue or cells can be described, and thus controlled, through a 
number of parameters that depend on the source characteristics and medium properties.  
When ultrasound travels through a medium, the intensity decreases as the energy of 
the wave is absorbed by the medium and as a result, local heating can occur. The 
intensity (I, W/m
2
) of a FUS beam (Hoskins, Martin et al. 2010) produced by a FUS 
source (transducer) is defined as the acoustic power (Pac, W), or the rate at which the 
energy of the FUS is produced by the source, flowing through the cross sectional area of 
the beam (S, m
2






Equation 5.1 Calculation of FUS beam intensity according to acoustic power. 
 
The intensity is also proportional to the acoustic pressure, P (MPa), as shown by the 






Equation 5.2 Calculation of FUS beam intensity according to acoustic pressure. 
 
Where, 𝑍  Pa ∙ s/m or N ∙ s/m3 = 𝜌 × 𝑐, is the acoustic impedance of the medium, 
ρ (kg/m3) is the density of the medium and c (m/s) is the speed of sound in that medium. 
Mechanical effects of ultrasound propagating through a medium can be estimated from 
P, which is a function of the acoustic power, calculated using both Equations 5.1 and 
5.2 to obtain Equation 5.3: 
 
𝑃 = √
𝑃𝑎𝑐 × 𝜌 × 𝑐
𝑆
 
Equation 5.3 Correlation between acoustic power and pressure. 
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If the medium contains gas MBs (ultrasound contrast agent), the FUS pressure 
waves can induce oscillations (volume changes) in the MBs at lower values, and 
generate violent collapse (inertial cavitation) at higher pressures. A useful parameter 
which can give a qualitative indication of the likelihood of cavitation is the mechanical 






Equation 5.4 Calculation of mechanical index (MI). 
 
Where, PNP is the peak negative pressure normalised to 1 MPa and f (MHz) is the 
centre frequency of the FUS field normalised to 1 MHz. As MI gives an estimation of 
the risk of the non-thermal effects including cavitation and streaming, thus, MI is most 
applicable with the use of ultrasound contrast agents. It is well documented that when 
MI < 0.3, it is preserving the contrast agents; while MI > 0.7 means cavitation risk is 
existing (De Jong 2002).  
A large number of experimental and acoustic parameters are used in the relevant 
literature including frequency of acoustic field, intensity, power, pressure, mechanical 
index, exposure duration, total energy delivered and others, in relation to FUS field 
interacting with the biological material or gas MBs. When the large volume of studies in 
TDD is taken into account, this makes determining the optimum drug delivery system 
for a specific type of cancer virtually impossible. Moreover, the issue of repeatability in 
FUS-mediated TDD in vitro experiments has been highlighted in recent reports (Hensel, 
Mienkina et al. 2011; Leskinen and Hynynen 2012), which specifically note that the 
methods of FUS exposure and the experimental conditions vary greatly between 
investigators, making it difficult to compare results. It has also been highlighted that 
there is an increased need for standardisation of experimental conditions and the 
reporting of FUS exposure levels (ter Haar, Shaw et al. 2011). 
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5.2.2 Standardisation of in vitro FUS Device for TDD 
It is common in FUS-mediated TDD experiments, to use a simple setup containing 
a transducer as an ultrasound source and a chamber containing a cell suspension as the 
target. However, a standard 96-well plate is best accommodated by most biological 
sample characterisation equipment. Transfer of biological samples for characterisation, 
after FUS exposure, from a suspension chamber to a 96-well plate, is likely to generate 
less accurate results. Therefore it was decided to carry out the experiments directly in 
the 96-well plates. 
To address this fundamental issue, a high-throughput sonication device was 
designed (section 1 in Appendices) to be small, robust and portable, and capable of 
generating customised and highly reproducible FUS conditions for a wide range of 
experiments in vitro, allowing sonication of the contents in selected wells or sequences 
of wells within standard 96-well cell culture plates (or other plates) in a short period of 
time. The rationale behind using the 96-well cell culture plate is to allow a large number 
of repetitions and also accurate and identical sonication of various sample groups on the 
same plate, including control groups used as references for drug uptake, sonoporation or 
MBs effects, creating a lab-on-a-bioplate approach. One of the advantages of this 
device is that it allows a large number of experiments under similar US exposures, as 
well as significant flexibility in experiment design on the same 96-well plate and is, 
uniquely, reported in sufficient detail here for the work to be reproduced fully and 
accurately.  
The high-throughput experiments were initially approached through a clinical 
MRgFUS system, ExAblate 2000/2100 for in vitro TDD experiments (Gourevich, 
Dogadkin et al. 2013). Although this approach could be useful for translation of in vitro 
results to in vivo experiments, due to limitations such as the multifocal sonication (16 
foci) on the clinical multi-element transducer (ExAblate 2100 Conformal Bone System) 
only 16 wells per plate could be used. Moreover, a rapid sequence of sonications on the 
clinical machine is difficult to obtain since this would require the repetition of treatment 
planning procedures, which are time consuming. The very high costs associated with 
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such a clinical FUS device in combination with a bulky MR system, also render the 
approach impractical for in vitro testing in a laboratory.  
5.3 Materials and Methods 
5.3.1 Materials 
5.3.1.1 In vitro cell culture, medium and supplementation 
Medium, supplementation 
and reagents 
Manufacturer and place 
of origin 
Specification 
KB cell line American Tissue Culture 
Collection, USA 
CCL-17 
HCT116 cell line American Tissue Culture 
Collection, USA 
CCL-247 
Fetal Bovine Serum (FBS) Gibco Invitrogen, UK Origin: South America 
Roswell Park Memorial 
Institute (RPMI)1640 
complete medium 
Gibco® Invitrogen, UK [+] 10% Fetal bovine 
serum (FBS) 
[+] 1% L-Glutamine 
[+] 1% Penicillin and 
Streptomycin (Pen-Strep) 
[+] 1% Sodium Pyruvate 
[+] 1% Non-essential 
Amino Acids 
[+] 0.5% HEPES buffer 
Dulbecco’s Modified 
Eagle’s Medium (DMEM) 
complete medium 
Gibco® Invitrogen, UK [+] 10% Fetal bovine 
serum (FBS) 
[+] 4.5g/L D-Glucose 
[+] 1% L-Glutamine 
[+] Pyruvate 
[+] Penicillin and 
Streptomycin (Pen-Strep) 
Phenol Red Free 
Dulbecco’s Modified 
Eagle’s Medium (DMEM) 
Gibco® Invitrogen, UK [+] 4.5g/L D-Glucose 
[+] L-Glutamine 
[+] 25Mm HEPES 
[−] Sodium Pyruvate 
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5.3.1.2 Other reagents 
Medium, supplementation and 
reagents 
Manufacturer and 




Gibco® Invitrogen, UK 0.05% 








Sigma-Aldrich, UK 5 mg/mL in PBS 
Bicinchoninic Acid (BCA) Protein 
Assay Kit 
Sigma-Aldrich, UK Solution A: 
bicinchoninic acid, 
sodium carbonate, 
sodium tartrate, sodium 
bicarbonate in 0.1 N 
NaOH (final pH 11.25). 
Solution B: 4% (w/v) 
copper(II) sulfate 
pentahydrate 
Protein Standard (Bovine Serum 
Albumin –BSA) 
 
Sigma-Aldrich, UK 1.0 mg/mL bovine 
serum albumin in 0.15 
M NaCl with 0.05% 
sodium azide 
Doxorubicin (DOX) Mesochem Technology 
Co.,Ltd, Beijing, China 
Purity ≥ 98% 
Sonovue® Bracco, Italy  
Terephthalic Acid (TA) Sigma-Aldrich, UK  
Hydroxyterephthalic Acid (HTA) Sigma-Aldrich, UK  
PBS tablets Oxoid, UK Typical Formual (g/L): 







pH 7.3±0.2 at 25°C 
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5.3.1.3 Other consumables  
Other consumables Manufacturer and place 
of origin 
Specification 
Distilled/deionised water Millipore, UK  





96-well plates Greiner, Austria Polystyrene cell culture 
black microplates with 
µClear® bottom 
Titer Tops™ sealing film ESM, USA  
Multi-mode plate reader Tecan, Austria Tecan infinite M200 
Atomic Force Microscopy 
(AFM) 





Omega, UK Type T, PTFE-insulated 
Cu-Constantan, 0.076 mm 
wire diameters 
Thermocouple data logger Omega, UK TC-08 
Infrared (IR) thermo 
camera 
FLIR, UK JADE 




LabVIEW National Instruments, UK  
5.3.2 Methods 
5.3.2.1 KB cell line viability screening 
To demonstrate accuracy and repeatability combined with high-throughput, that all 
facilitate a standardised experimental system (sonicator, section 1 in Appendices) for 
TDD in vitro, a wide range of cell viability tests were performed under various 
sonication sequences with different set of FUS parameters (frequencies, MI, power, 
duration, mode: continuous or pulsed) for human nasopharyngeal epidermal carcinoma 
KB cell line.  
In KB cells viability screening assays, FUS was applied at available frequencies: 
f = 0.4868, 1.142, 1.467 and 2.022 MHz, in continuous / pulsed FUS exposures with 
various acoustic intensities and sonication durations. Plate arrangement for sonications 
can be seen from Figure 5.1. 
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Figure 5.1 Protocols of KB cells viability screening by each transducer in a 96-well 
plate. Colour filled wells were treated by various sets of FUS parameters and 
selected control wells (purple) without FUS treatment. 
 
KB cell viabilities were screened by sonications within the parameter range shows 
in Table 5.1 by four transducers.  
 
      Table 5.1 Sonication parameters range for KB cell viability screening 


















0.4868 14.04 – 61.7 60 – 300 14.04 – 61.7 180 – 300 20 
1.142 17.72 – 277.87 40 – 600 116.25 – 195.65 60 – 180 10, 15, 20 
1.467 63.36 – 1339.51 40 – 300 575.12 – 1011.33 60 – 180 10, 15, 20 
2.022 58.08 – 1665.94 40 – 300 623.3 – 1127.73 60 – 300 10, 15, 20 
 
KB cell viability was calculated according to Equation 5.5: 
 
𝑉𝑖  𝑖𝑙𝑖𝑡𝑦% =
𝑂𝐷𝑐𝑒𝑙𝑙+𝐹𝑈𝑆 − 𝑂𝐷𝑏𝑙𝑎𝑛𝑘
𝑂𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑂𝐷𝑏𝑙𝑎𝑛𝑘
× 1  % 
Equation 5.5 Cell viability calculation after sonication treatment. 
 
Where, 𝑂𝐷𝑐𝑒𝑙𝑙+𝐹𝑈𝑆 is the absorbance of cells sonicated by FUS, 𝑂𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙 is the 
absorbance of control cells without FUS treatment, 𝑂𝐷𝑏𝑙𝑎𝑛𝑘 is the MTT reading of 
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CM without cultured cells.  
5.3.2.2 Temperature evaluation in the 96 wells by thermal camera and 
thermo-couples  
The thermal effect generated by the sonicator transducer at f = 0.4868 MHz was 
evaluated by FLIR thermal camera and Omega type T, PTFE-insulated 
Copper-Constantan thermocouples respectively to investigate temperature rising within 
selected sonication parameters in the absence / presence of SonoVue
®
 MBs.  
Thermal camera 
Infrared (IR) camera is a device that forms an image by using IR radiation rather 
than visible light used by normal camera. Instead of the 450 – 750 nm range of the 
visible light camera, IR cameras operate in wavelengths as long as 14 µm. These IR 
rays were mainly devoted to thermal measurement (Herschel 1800; Corsi 2014).  
Thermal camera was employed to monitor temperature changes of medium filled 
in wells of 96-well plate during sonication treatment. By using the IR thermal camera 
(Figure 5.2 A), which was placed above a partially submerged 96-well plate placed 
inverted inside the sonicator, focusing vertically against the transducer which is 
underneath of the focused single well of a 96-well plate (Figure 5.2 A). Temperatures 
within captured region can be selected and analysed according to points of interest, 
such as marked positions 4 (the well is being sonicated), 5 (the well will be sonicated 
next) and 6 (the well has just been sonicated) in Figure 5.2 B. 
 
Figure 5.2 IR thermal camera vertically setting up on top of the plate placed 
inside the sonicator (A); Thermal camera imaging region of a 96-well plate, where, 
the transducer is focused at marked position 4 underneath the plate (B). 
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Thermocouples 
Type T PTFE-insulated Copper-Constantan precision fine wire thermocouples 
(diameter 0.07 mm) were used to do the same temperature evaluation, aimed to 
confirm the results obtained from IR thermal camera experiments. Type T 
thermocouples were selected due to their wide range of temperature measurement 
(from –200 °C to 350 °C) and relatively low error (1 °C or 0.75% above 0 °C and 1 °C 
or 1.5% below 0 °C) (Omega-Thermocouple Reference Tables Type T ).  
In the current study, Type T thermocouples were placed inside of each well by 
drilling a small hole in the center of each well from the bottom of plate, and 
thermocouples were fixed and sealed by clear glue (Figure 5.3).  
 
Figure 5.3 Thermocouples fixed inside wells from bottom of the µclear 96-well 
plate and sealed by glue. 
 
Thermocouples were then connected to a Pico TC-08 thermocouple data logger 




Figure 5.4 Thermocouples connected to a Pico TC-08 thermocouple data logger. 
 
For both thermal camera and thermocouples temperature evaluations, test solution 
was prepared by using serum free PRMI1640 / DMEM medium in the absence / 
presence (0.1%, 1%, 2.5% and 5%) of SonoVue
® 
MBs. Sonication parameters were 
applied at: MI = 0.24, 0.31 and 0.53; sonication duration = 10 sec at continuous FUS 
wave. 
5.3.2.3 Stable / inertial cavitation detection 
Although the mechanism of US-mediated TDD has not been fully understood (Pitt, 
Husseini et al. 2004; Myhr and Moan 2006), its function is normally divided into 
thermal effects and non-thermal effects (Afadzi, Davies Cde et al. 2012). Among all 
the non-thermal effects, as introduced in section 2.3.3 in Chapter 2, FUS induced 
acoustic cavitation is the most important non-thermal mechanism and it has been 
shown to play a critical role in a wide range of novel therapeutic ultrasound 
applications during last two decades (Coussios, Farny et al. 2007).  
Cavitation can be classified into two types: stable cavitation and inertial cavitation 
(Naji Meidani and Hasan 2004). Stable cavitation generally refers to lower intensity 
insonations, whereby bubbles undergo stable, low amplitude oscillations. In contrast, 
inertial cavitation is associated with high intensity insonation, with bubbles undergoing 
significant volume fluctuations, and strong, violent collapses (Leighton 1994; Young 
1999; Leighton, Cox et al. 2000). Such bubble collapses can produce intense local 
(core) heating (5000 K) and high pressure (~ 1000 atmospheres) (Leighton, Cox et al. 
122 
2000).  
Inertial cavitation can also generate free radicals from the breakdown of water and 
other molecules to form radical-containing chemical species (McLean and Mortimer 
1988; Mason, Lorimer et al. 1994; Fang, Mark et al. 1996). The specific mechanism is 
the acoustic energy level achieved which can lead to the homolytic cleavage of 
covalent bonds between the oxygen and hydrogen atoms comprising water molecules. 
Water sonolysis then leads to the formation of reactive oxygen species such as 
hydroxyl radicals (OH･) and hydrogen peroxide (H2O2) according to the following 
chemical reactions (Villeneuve, Alberti et al. 2009): 
H2O → H･+ OH･ 
H･+O2 → HO2･ 
HO2･+ HO2･→ H2O2 + O2 
OH･+ OH･→H2O2 
H + H2O → H2OH･ 
In order to investigate whether inertial cavitation induced by FUS, the 
measurement of the OH radicals dissolved in sonication treated liquid was conducted 
by using chemical dosimetry method based on terephthalic acid (TA). TA is a 
well-known OH scavenger which has no chemical reactions with other radicals such as 
HO2 and H2O2 (Kanazawa, Furuki et al.), TA is also a non-fluorescent compound. 
When inertial cavitation happens, the generated OH radical can convert TA to a 







TA (Non-fluorescent) HTA (Fluorescent 425nm)
UV 310nm
C6H4(COOH)2 + OH → C6H4(COOH)2 OH  
Reaction 1 Terephthalic acid (TA) is converted by free OH radical to 
2-hydroxyterephthalic acid (HTA). 
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Where, the fluorescence intensity of HTA can be detected by fluorescence 
spectroscopy with excitation and emission wavelengths at 310 nm and 425 nm 
respectively.  
Initial TA solution was prepared by dissolving 16 mg TA powder by 0.5 ml NaOH 
(5 mM), as TA cannot be dissolved in acidic or neutral solutions (Mason, Lorimer et al. 
1994). The solution of dissolved TA in NaOH was then diluted to 50 mL by ddH2O to 
achieve the concentration of TA at 2 mM. Sonications were then performed by using 
transducer f = 0.4868 MHz, with 0.24 ≤ MI ≤ 0.91 and sonication duration of 10 sec 
in the absence / presence of 2.5 / 5% SonoVue
®
 MBs according to protocols in Figure 
5.5. Fluorescence intensities of sonicated TA were recorded at λexcitation = 310 nm and 
λemission = 425 nm before and after sonication.  
 
Figure 5.5 Protocols of TA solution sonication. 
5.3.2.4 Carrier-DOX binding investigation by exposure to FUS 
Certain groups of FUS parameters were employed to the carrier-DOX inclusion 
complex introduced in Chapter 3 by the in vitro sonicator, to investigate the 
responsivity of the carrier-drug system to FUS mechanical effects. Serum free 
RPMI1640 / DMEM medium was prepared as test solution in the absence / presence 
(0.1%, 1%, 2.5% and 5%) of SonoVue
®
 MBs. Sonication parameters were: MI = 0.24, 
0.31 and 0.53; sonication duration = 10 sec at continuous FUS wave. 
Similar as the Kbinding investigation performed in section 3.3.2.2b in Chapter 3, test 
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solutions’ fluorescence intensities were recorded before and after FUS treatment, and 
the drug release rate after sonication was calculated according to Equation 5.6: 
 
𝐸𝑛𝑐 𝑝𝑠𝑢𝑙 𝑡𝑖𝑜𝑛% =
𝐼 𝑐𝑎𝑟𝑟𝑖𝑒𝑟+𝐷𝑂𝑋 
𝐼𝐷𝑂𝑋
× 1  %  (1) 
 𝑒𝑙𝑒 𝑠𝑒𝐷𝑂𝑋% = 𝐸𝑛𝑐 𝑝𝑠𝑢𝑙 𝑡𝑖𝑜𝑛%𝑏𝑒 𝑜𝑟𝑒 𝑈𝑆 − 𝐸𝑛𝑐 𝑝𝑠𝑢𝑙 𝑡𝑖𝑜𝑛%𝑎 𝑡𝑒𝑟 𝑈𝑆 (2) 
Equation 5.6 Encapsulation and release rate of DOX after FUS sonication 
treatment in the absence/presence of MBs. 
 
In Equation 5.6 (1), 𝐼 𝑐𝑎𝑟𝑟𝑖𝑒𝑟+𝐷𝑂𝑋  is the fluorescence intensity of encapsulated 
DOX with / without FUS sonication treatment in the absence / presence of MBs, while 
𝐼𝐷𝑂𝑋 is fluorescence intensity of DOX alone solutions with / without FUS sonication 
treatment in the absence / presence of MBs. In Equation 5.6 (2), 
𝐸𝑛𝑐 𝑝𝑠𝑢𝑙 𝑡𝑖𝑜𝑛%𝑏𝑒 𝑜𝑟𝑒 𝑈𝑆 and 𝐸𝑛𝑐 𝑝𝑠𝑢𝑙 𝑡𝑖𝑜𝑛%𝑎 𝑡𝑒𝑟 𝑈𝑆 were both obtained from 
Equation 5.6 (1) for each test samples before and after FUS treatment. 
5.3.2.5 Cell viability test 
After KB cells viability screening assays, more cell viability tests were focused on 
the application of f = 0.4868 MHz transducer in the presence (0.1%, 1%, 2.5% and 5%) 
of SonoVue
® 
MBs. Two human cancer cell lines KB and HCT116 were selected. 
Various solutions were added to each well according to the defined protocols in 5 
replicates (Figure 5.6). Sonication parameters were: MI = 0.24, 0.31 and 0.53; 
sonication duration = 10 sec at continuous wave. 
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Figure 5.6 Protocols of cell viability sonication. 
 
Cell viability in this section was calculated by Equation 5.7: 
 
𝑉𝑖  𝑖𝑙𝑖𝑡𝑦% =
𝑂𝐷𝑈𝑆/ 𝑈𝑆+𝑀𝐵𝑠 − 𝑂𝐷𝑏𝑙𝑎𝑛𝑘
𝑂𝐷𝑐𝑒𝑙𝑙 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑂𝐷𝑏𝑙𝑎𝑛𝑘
× 1  % 
Equation 5.7 Cell viability calculation after FUS sonication treatment. 
 
Where, 𝑂𝐷𝑈𝑆/ 𝑈𝑆+𝑀𝐵𝑠  is the MTT absorbance of cells treated by FUS in the 
absence / presence of MBs, 𝑂𝐷𝑐𝑒𝑙𝑙 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 is the MTT absorbance of cells without any 
treatment and 𝑂𝐷𝑏𝑙𝑎𝑛𝑘 is the MTT absorbance of medium without cultured cells.  
5.3.2.6 Cellular drug uptake test 
Cellular drug uptake assay was performed to further investigate carrier-DOX 
inclusion’s responsivity to FUS sonication, as well as the response of human cancer 
cells to FUS treatment. Sonication experiments were focused on the application of f = 
0.4868 MHz transducer at FUS parameters without thermal effects but in the presence 
(0.1%, 1%, 2.5% and 5%) of SonoVue
® 
MBs. DOX concentration was applied at 12.5 
µM for KB cell line and at 25 µM for HCT116 cell line, the ratio of carrier-DOX was 
10 : 1. Various solutions were added to each well according to the defined treatment 
groups in 5 replicates (Figure 5.7). Sonication parameters were: MI = 0.24, 0.31 and 
0.53; sonication duration 10 sec at continuous wave. 
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Figure 5.7 Protocols of cellular drug uptake sonication assays. 
 
DOX cellular uptake calculation is according to Equation 5.8: 
 
 𝑝𝑡  𝑒% =
𝐼 𝑈𝑆 𝑀𝐵𝑠 𝐷𝑂𝑋/ 𝑐𝑎𝑟𝑟𝑖𝑒𝑟+𝐷𝑂𝑋 𝑂𝐷 𝑈𝑆 𝑀𝐵𝑠 𝐷𝑂𝑋/ 𝑐𝑎𝑟𝑟𝑖𝑒𝑟+𝐷𝑂𝑋 ⁄
𝐼𝐷𝑂𝑋 𝑂 𝑈𝑆 𝑂𝐷𝐷𝑂𝑋 𝑂 𝑈𝑆⁄
× 1  % 
Equation 5.8 Cellular drug uptake calculation after FUS sonication treatment. 
 
Where, 𝐼 𝑈𝑆 𝑀𝐵𝑠 𝐷𝑂𝑋/ 𝐷𝑂𝑋+𝑐𝑎𝑟𝑟𝑖𝑒𝑟  is the fluorescence intensity of the cell sample 
exposure to DOX alone / carrier+DOX with FUS treatment in the absence / presence of 
MBs, 𝑂𝐷 𝑈𝑆 𝑀𝐵𝑠 𝐷𝑂𝑋/ 𝑐𝑎𝑟𝑟𝑖𝑒𝑟+𝐷𝑂𝑋  is the BCA absorbance reading of those samples 
correspondingly. 𝐼𝐷𝑂𝑋 𝑂 𝑈𝑆 is the fluorescence intensity of the cell sample exposed to 
DOX alone solution without FUS treatment, 𝑂𝐷𝐷𝑂𝑋 𝑂 𝑈𝑆 is the BCA absorbance of 
this cell sample. 
5.3.2.7 Atomic Force Microscopy (AFM) cell membrane topography 
measurement 
AFM is a high-resolution type of scanning probe microscopy (SPM). It utilises a 
fine tip to measure surface morphology and properties through an interaction between 
the tip and sample surface. In an AFM, a constant force is maintained between the 
probe and sample while the probe is raster scanned (parallel lines) across the surface. 
127 
By monitoring the motion of the probe as it is scanned across the surface, a three 
dimensional image of the surface is constructed (Quate and Gerber 1986). AFM thus 
becomes one of the foremost tools for imaging, measuring, and manipulating matter at 
the nanoscale.  
In terms of biological applications, AFM is a well-established technique used to 
both image the topography of rigid / fixed samples (Langer and Koitschev 2002) and 
measure the mechanical properties of living material such as tissue and cells 
(Radmacher 1997). In this thesis report, Peak Force Quantitative Nano Mechanics 
(QNM), an extension of Peak Force Tapping mode in AFM was employed to 
investigate human cancer cell morphological and physico-mechanical behaviour 
changes in response to exposure to FUS.  
AFM was employed to measure the short time membrane morphology changes of 
KB cells, which were exposed to different frequencies transducers for various 
sonication durations (sec), in the absence / presence of SonoVue
®
 MBs. KB cells were 
seeded at a density of 8000 cells/well on sterilised glass cover slips (6 mm in diameter) 
placed in 96-well plates and incubated for 24 hr before FUS exposure. To be noticed 
that the glass cover slip did not influence the cells during sonication, as the cell culture 
plate was placed inverted and the monolayer of cells were facing to the transducer 
directly. Immediately after each FUS treatment, the medium was removed and cells 
were exposed directly to 200 µL/well of 2.5% (v/v) Glutaraldehyde fixed solution 
(freshly prepared on the day of the experiment), plates were placed in 4 °C fridge for 1 
hr. After fixation, fixed solution was aspirated carefully; cells were then washed by 
PBS three times to remove residual fixed solution, and washed by distilled water for 
five times. After all washing procedure, the glass cover slips with fixed cells were 
taken out carefully from 96-well plates and fixed on the surface of glass slides, cells 
were allowed to dry at room temperature for another 2 hr.  
Fixed and dried samples were then scanned in air at room temperature by 
BioScope Catalyst AFM in ScanAsyst imaging mode, using ScanAsyst in Air probe 
(tip radius: 2 nm), at scan frequency of 0.25 Hz with 384 scan lines per image. 
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5.3.2.8 General methods of cell seeding and solution preparation 
Cell handling 
KB and HCT116 were selected for FUS sonication experiments based on 
fundamental in vitro cell culture studies performed in Chapter 4. KB and HCT116 cells 
were cultured in complete RPMI1640 medium (section 4.3.1.2, Chapter 4) and 
complete DMEM medium (section 4.3.1.2, Chapter 4), respectively. 
For cell viability investigations, KB / HCT116 cells were harvested from the flask 
and seeded in 96-well plates with µclear base at cell density 4000 cells/well in 100 µL 
complete medium (CM) 1 day prior to sonication. Cells were not plated in columns 1 
and 12, rows A and H, but filled with CM as these are used as a blank for the plate 
reader to allow for the absorbance of the residual medium and MTT in the wells. 
Before sonication, up to 420 µL/well of CM was added in each well and the plate was 
sealed with Titer-Tops
®
 (plate-sized US-transparent films, Figure 5.8 A), carefully 
avoiding air-bubble formation. After sealing, the plate was inverted and placed in the 
sonicator using the plate holder located above the FUS sources (Figure 5.8 B), so that 
the cells adherents to the µclear base were uppermost. 
 
Figure 5.8 96-well plate fully filled with medium and sealed with Titer-Tops
®
 
sealing without air-bubble formation (A); Inverted plate with µclear bottom fixed 
in sonicator by plate holder and further fixed by rubber bands in both sides (B). 
 
After sonication treatment, the wells were emptied of their entire volume of CM 
carefully and refilled with 100 µL/well fresh CM, cells were observed by microscope 
for cells detach inspection. Cells were then followed by incubation for a further 48 hr. 
Cell viability was evaluated by MTT colorimetric assay (section 4.3.2.1, Chapter 4). 
For cellular drug uptake investigations, KB / HCT116 cells were harvested from 
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flask and seeded in 96-well plate with µclear base at cell density 12000 cells/well in 
100 µL CM and allowed to expand over 2 days prior to sonication. Before exposure to 
FUS, 420 µL of various solutions were added to each well according to the defined 
treatment groups in 5 replicates. After adding solutions, the plates were sealed with 
Titer-Tops
®
 sealing film to maintain cell culture sterility. After sealing, the plate was 
inverted, so that the cells adherent to the µclear base were uppermost, and placed in the 
sonicator using the plate holder located above the FUS transducer sources and fixed.  
At the end of FUS treatments, test solutions and CM in control wells were 
removed and the wells were washed by preheated PBS twice. Cells were observed 
under the microscope for cells lost inspection. PBS was then removed and 200 µL 0.5% 
SDS in ddH2O were added to each well. Following observation under the microscope to 
ensure total cell disruption by SDS, quantification of the fluorescence intensity of 
intracellular DOX was recorded. The fluorescence readings were normalised by total 
protein amount by transferring 25 µL of cell lysates from the same samples to wells of 
a normal transparent 96-well cell culture plate for protein determination by using the 
BCA method (section 4.3.2.4, Chapter 4).  






 MBs stock solution (100%) were prepared according to its manufacture 
protocol (Figure 5.9) and kept in ice box after preparation.  
 





In cell viability / AFM inspection assays, 1 µL/mL, 10 µL/mL, 25 µL/mL and 50  
µL/mL MBs stock solution were added into CM to obtain SonoVue
® 
MBs 
concentration at 0.1%, 1%, 2.5% and 5%, respectively. Similarly, in carrier-DOX 
binding investigation or cellular drug uptake assays, 1 µL/mL, 10 µL/mL, 25 µL/mL 
and 50 µL/mL MBs stock solution were added into DOX alone / carrier+DOX 
solutions to obtain SonoVue
® 
MBs concentration at 0.1%, 1%, 2.5% and 5%, 
respectively. 
DOX and carrier+DOX solutions 
A solution of 100 mM DOX stock was prepared by dissolving 58 mg DOX 
powder in 1 mL DMSO and kept frozen. A solution of 12.5 / 25 µM DOX was 
prepared by dilution of the DOX stock solution (100 mM) by CM for KB and HCT116 
cells accordingly. The final concentration of DMSO in the diluted solution is 0.0125 / 
0.025%. To 50 mL of the final 12.5 / 25 µM DOX solution, 0.1875 / 0.375 mg/ml of 
carrier was added to obtain a concentration of 125 / 250 µM (10 : 1 carrier : DOX 
molar ratio). Preheated (20 min at 37 °C) test solutions before exposure to cells. 
SonoVue
®
 MBs stock solution (100%) were prepared according to its manufacture 
protocol and placed in ice box. 1 µL/mL, 10 µL/mL, 25 µL/mL and 50 µL/mL MBs 
stock solution were added into DOX / carrier+DOX and to obtain SonoVue
® 
MBs 
concentration at 0.1%, 1%, 2.5% and 5% prior to sonication respectively. 
SDS reagent 
0.5% (w/v) SDS was prepared by dissolving 0.5 g SDS powder in 100 mL ddH2O, 
the solution was then stirred by magnetic plate stirrer until SDS salt dissolved 
completely.  
MTT reagent 
5 mg/ml MTT reagent was prepared by dissolving 250 mg of the MTT salt by 50 
ml PBS. The solution was stirred by magnetic plate stirrer until all solid was dissolved. 
The solution was filtered using a 0.45 µm filter, then aliquoted 10 ml/tube and kept 
frozen (–20 °C) until use. 
BCA reagent 
BCA reagent was freshly prepared on the day of the experiment, by mixing 50 
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parts of Bicinchoninic acid (reagent A) and 1 part of 4% (w/v) Copper sulphate 
solution (reagent B). Standard bovine serum albumin (BSA) solutions from 25 µg/mL 
to 500 µg/mL were prepared by diluting the standard BSA solution (1000 µg/mL) in 
the BCA kit by using the same cell lysis buffer (0.5% SDS).  
5.4 Results and Discussion 
5.4.1 Cell Viability Screening Results 
An initial cell culture application by all frequencies (2.022, 1.467, 1.142 and 
0.4868 MHz) of transducers has been employed through cell viability investigation by 
exposure KB cells to FUS source. Various combinations of US parameters (frequency, 
power, duration and US mode (continuous / pulsed), Table 5.1) have been applied in 
order to identify the optimal set of parameters in terms of safe mechanical response of 
equipment especially the power amplifier, FUS focused beam diameters, beam length 
(according to Table A.1 in Appendices) and temperature rising at different levels.  
Transducer f = 2.022 MHz 
For the transducer frequency of 2.022 MHz, KB cells were exposed to continuous 
FUS wave at power from 0.6 W to 17 W, and sonication duration from 40 sec to 300 
sec; while in pulsed FUS wave mode, FUS power was applied from 6.5 W up to 12 W, 
sonication duration was from 60 sec to 300 sec, selected duty cycles were 10%, 15% 
and 20%.  
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Figure 5.10 KB cells viability (% of control) 48 hr post transducer f = 2.022 MHz 
sonications. Continuous FUS wave mode (A); Pulsed FUS wave mode (B). 
 
As can be seen from Figure 5.10 A, KB cell viabilities were all over 82.36% when 
continuous FUS was applied under or equal to 5.3 W (at sonication duration of 40 sec, 
viable KB cells of 52.72% was obtained; it is suggested that this is an error in 
comparison to other higher / longer treatments). When 6W  ≤ Pac  ≤ 12 W and 
sonication duration was under 120 sec, cell viabilities showed higher than 73.24%; 
while, within this power range but when longer durations (120 sec and over) were 
applied, cell viability had sharp decreases (all under 50.55%). Moreover, higher power 
of 14 W and 17 W induced lower cell viabilities when sonication duration was 60 sec.  
In pulsed FUS sonications (Figure 5.10 B) mode, three FUS powers of 6.5 W, 10 
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W and 12 W were applied respectively, where, viable cells were over 95.21% when the 
power was lower than 10 W and sonication time was fewer than 180 sec. At FUS 
power of 12 W, cell viabilities decreased upon increased sonication durations at duty 
cycle of 20% (bars within the red square in Figure 5.10 B).  
Transducer f = 1.467 MHz 
In frequency of 1.467 MHz transducer’s sonication, results obtained by employing 
continuous FUS wave (Figure 5.11 A) were similar in comparison to frequency of 
2.022 MHz transducer. FUS power was applied from 0.78 W up to 17 W, sonication 
duration was from 40 sec to 300 sec. When FUS power was lower than 5.5 W, all 
treatment groups of cells responsed with high cell viabilities (over 74.39%); when FUS 
power was applied over 6 W (bars within the red square), KB cell death rate increased 
upon ever-increased both FUS power and sonication duration.  
 
 
Figure 5.11 KB cells viability (% of control) 48 hr post transducer f = 1.467 MHz 
sonications. Continuous FUS wave mode (A); Pulsed FUS wave mode (B). 
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In 1.467 MHz pulsed FUS wave sonications, three powers of 7.1 W, 10 W and 12 
W were employed. It is easy to conclude from Figure 5.11 B that at lowest power of 
7.1 W, cell viabilities were not affected much by all sonication treatments as the lowest 
cell viable rate was 91.77%. At higher power of 10 W and 12 W applications, cell 
viabilities again decreased by increased sonication duration when keeping the duty 
cycle constantly at 20%. 
Transducer f = 1.142 MHz 
In the third transducer at frequency of 1.142 MHz sonication treatments, KB cell 
viabilities (Figure 5.12 A and B) exhibited not much affected by all sonication 
parameters combinations in both continuous and pulsed wave mode. Where, two 
extreme low cell viability values (red circled bars) obtained under continuous wave 
mode at 0.8 W for 300 sec duration (34.64%) and under pulsed wave mode at 3 W for 
60 sec, 20% duty cycle induced viable cells were only 5.35% which was suggested to 




Figure 5.12 KB cells viability (% of control) 48 hr post transducer f = 1.142 MHz 
sonications continuous FUS wave mode (A); Pulsed FUS wave mode (B). 
 
Transducer f = 0.4868 MHz 
The lowest frequency (0.4868 MHz) of transducer, again, did not severely affect 
KB cell monolayer post sonications, except after longest duration of 300 sec with 
highest continuous power of 4.8 W applied, cell viable rate expressed at only 3.19%. 
For all the other parameters applied, cell viable rate were all over 81.22% (Figure 5.13 




Figure 5.13 KB cells viability (% of control) 48 hr post transducer f = 0.4868 MHz 
sonications. Continuous FUS wave mode (A); Pulsed FUS wave mode (B). 
 
Summary 
To summarise, cell viability values were high (over 80%), for FUS exposures at 
f = 1.142 and 0.4868 MHz and power in the range of 0.3 – 5 W. This suggests that cell 
viability and proliferation is not much affected, as expected, or sometimes even 
enhanced / triggered by FUS at low acoustic intensity (Pitt and Ross 2003; Yu, Wang et 
al. 2004). Cell viabilities after 48 hr incubation post sonication at f = 2.022 and 1.467 
MHz with continuous power under 6 W were still over 80%; with pulsed power under 
10 W and duration under 180 sec were over 73%. Cell viabilities also observed drop 
dramatically below 50% for various combinations of higher acoustic intensity, 
frequency and exposure time. However it is desirable for TDD experiments to maintain 
high cell viability values (over 80%) for accurate control and repeatability.  
Cell viable rate upon sonication is a crucial aspect in the following in vitro cellular 
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drug uptake assay and in vivo MRgFUS application to animals. As targeted drug 
release is an active process, and the energetic cavitational phenomena discussed in this 
chapter that may be detrimental to tissues are requisite in promoting the physical or 
chemical release of drugs from the nanocarriers, or the transport of drugs into cells. 
However, low acoustic intensity may not be adequate to effectively active TDD. Thus a 
proper level of cavitational activity must be compensated to achieve the medicinal 
purpose of FUS-mediated TDD. Somewhere between these harsh and mild extremes 
lies the desired realm of ultrasonic TDD – a cavitational level that produces cavitation 
activity sufficient to sonoporate cell membranes temporary without killing the cells, an 
energy level that creates a sufficient number of micro-jets to allow extravasation from 
capillary walls without killing the endothelial cells or causing thrombosis, or a level 
that generates sufficient microstreaming to break open desired γ-CD based 
nanocarriers or other vesicles without lysing red cells or other host cells (Pitt, Husseini 
et al. 2004). 
5.4.2 Evaluation of MBs Related Temperature Effects 
If the thermal effects of US are exploited, then a small focal zone, diameter 1 – 3 
mm, and increased US durations may provide the energy necessary for the desired 
effects through heat transfer. However, the size of the focal zone is highly relevant for 
US-mediated TDD experiments, if carrier-drug insensitive to temperature or sensitive 
to mechanical effects are used, then those mechanical effects of FUS in conjunction 
with gas MBs as possible “tools” to open the carriers and release the drug in the 
vicinity of the cell membrane will benefit from a wider focal zone, and the coverage of 
US-exposed cell layers will improve.  
According to mechanical characterisations of acoustic field and focused zone 
(section 2 in Appendices), efficiency (section 3 in Appendices) and temperature rising 
with various combinations of US parameters for each transducer (section 4 in 
Appendices), combined with the target carrier-drug system were found to be 
thermo-sensitive (Chapter 3 and Chapter 4), it is necessary to have rational 
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experiments design to figure out responsivity of the carrier-drug system under US 
mechanical effects only, in which, thermal effects need to be avoid.  
Therefore, transducer f = 0.4868 MHz was selected for the following experiments, 
as 1) it shows lowest energy efficiency to delivery as low acoustic power as desired; 2) 
it has lowest temperature rising; and 3) its focused zone is the largest of 5.3 mm 
(obtained from experimental scan) to cover the most cells monolayer on a 6.9 mm well, 
among others. Together with SonoVue
®
 MBs half-life time is 41.05 ± 1.83 sec when 
exposure to 1 MHz transducer at intensity of 4 W/cm
2
 (Tinkov, Bekeredjian et al. 
2009), desired plate sonication arrangement and total drug exposure time in drug 
cellular uptake investigation, sonication duration for the following experiments was 
determined for 10 sec per single well constantly. To assess the impact of FUS 
application on cells in the presence of MBs, selected MI between 0.2 to 0.6 was 
applied, as stable cavitation happen with MBs when 0.1 < MI < 0.6 (Hernot and 
Klibanov 2008) and MBs destruction (oblique implosion) reported to occur when MI is 
over 0.7 (Lindner 2002).  
Moreover, it is well known that bubble collapsing is a microscopic implosion that 
generates high local turbulence and the release of heat energy. The consequence is a 
significant increase of temperature and pressure (Leong, Ashokkumar et al. 2011). 
Furthermore, it is reported that at 20 kHz ultrasound frequency, the bubbles generated 
in the acoustic field are relatively large and their collapse results in strong shockwaves 
(Leong, Wooster et al. 2009). However, acoustic frequency between 100 to 1000 kHz, 
their collapse induces a higher increase in temperature (Suslick and Crum 1998). Thus, 
the aim of experiments in this section is to evaluate whether MBs’ concentration would 
affect temperature changes upon sonication. IR thermal camera and thermocouples 
have been adopted to investigate thermal effect within selected US parameters in the 






5.4.2.1 Temperature measurement by thermal camera 
MI = 0.24 
 
 
Figure 5.14 Temperature changes by US exposure of MI = 0.24, duration 10 sec, in 
the absence/presence (0.1%, 1%, 2.5% and 5%) of SonoVue
®
 MBs. Temperature 
mapping from thermal camera (A); Calculated temperature changes of before 
and after US treatment (40 msec time record frame) (B) 
 
As can be seen from the thermal camera temperature mapping shows in Figure 
5.14 A, temperatures in three wells (position 4, 5 and 6) have been selected to analyse 
the results. Temperature in position 4 (light blue curve) was the well being sonicated, 
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position 5 and 6 are the two adjacent wells, 5 would be sonicated next, 6 was the well 
just been treated (pictures can be found in Figure 5.2 B within this chapter). The 
temperature mapping indicated not much temperature changes in three interested 
positions before and after US exposure. In Figure 5.14 B, very little temperature 
increase (maximum 0.34 ± 0.32 °C) was observed according to data calculation in all 
treatment groups.  
MI = 0.31 
 
 
Figure 5.15 Temperature changes by US exposure of MI = 0.31, duration 10 sec, in 
the absence/presence (0.1%, 1%, 2.5% and 5%) of SonoVue
®
 MBs. Temperature 
mapping from thermal camera (A); Calculated temperature changes of before 
and after US treatment (40 msec time record frame) (B). 
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Different temperature mapping displays in Figure 5.15 A and it illustrates that 
when MI = 0.31, sonicated well (position 4) had a sharp temperature increase within 10 
sec (increasing segment on light blue curve) from around 34 °C up to roughly 35.5 °C. 
While, temperatures in adjacent position 5 (light brown curve, non-sonicated wells) 
were not influenced much which stated insignificant heating (< 0.2 °C) spread to 
adjacent wells within desired US parameters. Figure 5.15 B further demonstrates 
calculated temperature changes within this set of US parameters, where, the maximum 
temperature increase was 1.30 ± 0.46 °C. Furthermore, the presence of MBs showed 























MI = 0.53 
 
 
Figure 5.16 Temperature changes by US exposure of MI = 0.53, duration 10 sec, in 
the absence/presence (0.1%, 1%, 2.5% and 5%) of SonoVue
®
 MBs. Temperature 
mapping from thermal camera (A); Calculated temperature changes of before 
and after US treatment (40 msec time record frame) (B). 
 
Results in Figure 5.16 are similar to Figure 5.15, when MI = 0.53 applied, higher 
temperature increase was observed (maximum 1.97 ± 0.43 °C), but again, little heating 
(< 0.5 °C) spread to adjacent wells and MBs did not affect thermal effects of US 
treatment. 
All temperatures presented here are average temperatures compiled from three 
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separate experiments performed in triplicates and were expressed as means ± SD.  
5.4.2.2 Temperature measurement by thermocouples 
Thermocouples are complementary experiments to confirm results obtained by 
thermal camera. Temperatures by exposure MI = 0.24, 0.31 and 0.53 in the absence of 











Figure 5.17 Temperature mapping by thermocouples. MI = 0.24, no MBs (A); MI 
= 0.31, no MBs (B); MI = 0.53, no MBs (C); and MI = 0.53 with 5% MBs (D). 
 
From Figure 5.17 A and B, very little temperature increase (< 0.5 °C) was received 
when MI = 0.24 and 0.31. To be noticed in both A and B, channel 1 exhibits a sharp 
temperature increase segment where channel 1 thermocouples was placed in the first 
sonicated well, this phenomenon suggested the very first sonication might be subjected 
to a split-second higher US power then desired, at the moment of switching on the 
power amplifier.  
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In Figure 5.17 C and D, obvious temperature rise (marked ascendant part of curve 
by black dotted line) happened to all thermocouples channels when US MI = 0.53 was 
employed; the maximum temperature increase was around 2 °C, which was consistent 
with data received by thermal camera.  
Temperature evaluation within selected US parameters is critical reference for the 
next carrier-drug binding test and drug cellular uptake assays, which helps to 
distinguish what is the main effects (thermal or mechanical) to cause drug release or 
increased cellular drug uptake.  
5.4.3 Cavitation 
By exposure FUS to TA solutions to test fluorescence intensity changes by 
selected low acoustic parameters; no obvious increasing of fluorescent signals was 
received after 10 sec sonication.  
 
Figure 5.18 Fluorescence intensity changes of TA solutions post US exposure in 
the presence of 5% MBs. The embedded table lists fluorescence intensities of two 
control samples: TA with no MBs no US and TA with 5% MBs no US. 
In Figure 5.18, a slight increase of fluorescence intensity was detected, however, 
in comparison to two control groups of data displays in the table embedded in Figure 
5.18, TA solution without MBs with no US treatment also has an increasing of 
fluorescence intensity from 62.33 ± 6.00 to 66.00 ± 2.64, and TA solution with 5% of 
MBs but no US treatment was also observed fluorescence intensity increased from 



























 Fluorescence Intensity  
 No US, No MBs 5% MBs alone 
before US 62.33±6.00 61.00±1.53 
After US 66.00±2.64 68.33±4.81 
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similar results gained as above. 
Thus, observation of increased fluorescent signal was believed not due to inertial 
cavitations occurring, it is suggested to be physical influences such as temperature, 
exposure time in air and etc. Therefore, it is difficult to say inertial cavitations were 
induced by desired low acoustic parameters. However, it is also hard to conclude that 
only stable cavitations existed. Better analysis methods are needed to clarify this point. 
All data presented here is average fluorescence intensity compiled from three 
separate experiments performed in triplicates and were expressed as means ± SD. 
5.4.4 Carrier-drug Binding Results 
Carrier-DOX inclusion solution was exposed to FUS and their encapsulation 
changes were obtained. 
 
Table 5.2 Encapsulation percentage of DOX by the carrier before and post 10 sec 
US sonication treatment at MI = 0.24, 0.31 and 0.53 in the presence of MBs (0.1%, 
1%, 2.5% and 5%) 
 Encapsulation 
(% of control) 
Before US 
Encapsulation (% of control) 
After US 
No US, No 
MBs 
81.06±1.19 MI=0.24 MI=0.31 MI=0.53 
No MBs+US 81.21±0.29 77.69±0.37 77.60±0.08 77.88±0.12 
0.1% MBs+US 81.28±0.39 77.96±0.22 77.20±0.15 78.56±0.14 
1% MBs+US 80.19±0.48 77.37±0.14 76.89±0.04 77.12±0.19 
2.5% MBs+US 80.84±0.22 77.11±0.20 76.61±0.27 76.48±0.08 
5% MBs+US 85.32±0.21 78.20±0.30 78.57±0.30 78.68±0.56 
*The results are presented from three separate experiments carried out in triplicates and were expressed as means±SD. 
As can be seen from Table 5.2, encapsulation efficacy of DOX by the carrier is 
over 80% before US treatment. Three groups of US treatment showed slightly DOX 
release after sonication, minimum encapsulation rate was 76.48 ± 0.08%. However, 
this ~ 4% ‘drug release’ was believed not attributed to US mechanical effects and it is 
suggested to be triggered by US thermal effect mainly.  
The explanation, first of all, is the procedure of transferring little volume of 420 
µL/well pre-heated carrier-DOX solution into 96-well plate has been implemented at 
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room temperature, in which, such a small volume of test solution is difficult to be 
maintained at pre-heated temperature of 37 °C. Nonetheless, DOX’s encapsulation 
efficiency was measured at room temperature before US exposure, whereas the 
sonicator water bath was maintained at 34 °C that warmed up test solution when the 
plate was in. Furthermore, sonication also generated minor heating. Therefore, lower 
encapsulation observed of carrier-DOX system after sonication was suggested to be 
carrier’s responsivity to thermal effect, according to ‘thermal-sensitive’ conclusion 
stated in Chapter 3. Moreover, no additional changes of encapsulation rate were 
observed in Table 5.3 when different MI were applied, either in the presence of 
different concentrations of MBs, which is the second explanation of this 
non-mechanical-sensitive carrier-drug system. Nonetheless, because very low US 
powers were employed and only 10 sec duration were applied for each single cell 
culture well, that are insufficient to induce drug release from the complex inclusion. 
5.4.5 Cell Viability in The Presence of MBs 
After temperature and carrier-responsivity investigation of selected sets of acoustic 
parameters, more in-vitro cell culture studies were performed to optimise applicable 
parameters in TDD drug delivery. Cell viability test in the presence of MBs was 















Figure 5.19 KB cells viability (% of control) 48 hr post sonication in the 
absence/presence of MBs. KB cells viability as a function of MBs’ concentration 
(A); KB cells viability as a function of US mechanical index (B). 
 
From Figure 5.19 A, KB cells expressed high viable rate (over 85%) when lowest 
MI of 0.24 was applied except in the presence of the highest MBs of 5% (62.61%). In 
parallel, under the same MI, viabilities of KB cells were high when MBs concentration 
≤ 0.1%. Along with either increased MI or concentrations of MBs, the viable KB cells 
decreased correspondingly.  
Figure 5.19 B presents cell viability in another way by different MIs, in which, 
clear observation of decreasing trend of viable cells with increasing MI and 







Figure 5.20 HCT116 cells viability (% of control) 48 hr post sonication in the 
absence/presence of MBs. HCT116 cells viability as a function of MBs’ 
concentration (A); HCT116 cells viability as a function of US mechanical index 
(B). 
 
As can be seen from Figure 5.20, HCT116 cells behaved more sensitive to US 
exposure in the presence of MBs, viable HCT116 cells were lower than that of KB 
cells. The results were consistent with observation of HCT116 cells which exhibited 
less-stable adhesion property in Chapter 4, therefore, HCT116 cells were more 
vulnerable to US exposure. This is why the highest 5% of MBs was not applied for 
HCT116 cells. Again, except MI = 0.24, cell viability decreased when increased either 






































5.4.6 Cellular Drug Uptake 
To evaluate the efficiency of FUS as a drug uptake stimulant for encapsulated 
carrier-drug inclusion, drug cellular uptake experiments were performed on the basis of 
above results of temperature investigation, cavitations detection, carrier’s responsivity 
measurements and cell viability evaluation.  
KB cells 
 
Figure 5.21 DOX cellular update in KB cells after US exposure in the presence of 
drug carrier and MBs. 
 
Figure 5.21 shows drug cellular uptake (% of control) of KB cells post sonication 
in the presence of drug carrier without / with MBs. Bars highlighted by squares are 
data of cells exposed to no carriers containing DOX solutions, where, cellular drug 
uptake increased sharply (from ~ 100% up to ~ 280%) along with both increased MI 
and MBs concentrations. This suggested cell sonoporation occurred and the pore size 
of cell membrane was enlarged to induce more drug molecule intercalation.  
By looking at bars highlighted by circles in Figure 5.21, drug uptake of cell 
samples exposed to protected drug solutions are presented. In which, successful 
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protection of DOX by the carrier can be seen as very low drug uptake was obtained (~ 
15%), which supported those results achieved in Chapter 4. Besides, no significant 
increase of cellular uptake was recorded in cell samples exposed to carrier-drug 
solutions without MBs but with US treatment (bars in red circle) only. However, 
cellular DOX uptake increased when concentrations of MBs rose up. Detailed analysis 
of increased drug uptake shows in Table 5.3. 
 
Table 5.3 Increased fold of KB cells DOX cellular uptake of (DOX+C*+MBs+US) 
treatment compared to (DOX+C*+US) treatment at different MI 
 
Increased fold of DOX uptake 
[MBs] MI=0.24 MI=0.31 MI=0.53 
0.1% MBs 3.03 2.56 2.25 
1% MBs 3.17 3.89 3.78 
2.5% MBs 1.61 1.38 4.51 
5% MBs 1.34 1.69 5.49 
*C stands for carrier. 
Table 5.3 aims to express significant factors of increased drug uptake between cell 
samples subjected to protected drug solutions with MBs and without MBs. From this 
table, minimum 1.34-fold of DOX uptake was achieved by employing MI of 0.24 with 
5% MBs. While maximum of 5.49-fold drug uptake was obtained by using MI of 0.53 
with 5% MBs. However, when concentration of MBs was 1%, minimum 3.17-fold and 
maximum 3.78-fold were received. As well as sonication with 0.1% of MBs by MI of 
0.24, 3.03-fold drug uptake was get. The results suggested again sonoporation 
happened in the presence of MBs and MBs’ oscillation / collapse stimulated more drug 
uptake by KB cells, and, another possibility was drug released from the carrier by 
minor thermal effect, or by mechanical effect.  
HCT116 cells 
Similar experiments were performed for HCT116 cells. According to experience 
from its viability test, as significant cell loss was obtained with 5% of MBs, and less 
effective of 0.1% MBs, only two intermediate concentrations of 1% and 2.5% of MBs 
were employed to HCT116 cells. 
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Figure 5.22 DOX cellular update in HCT116 cells after US exposure in the 
presence of drug carrier and MBs. 
 
Table 5.4 Increased fold of HCT116 cells DOX cellular uptake of 
(DOX+C*+MB+US) treatment compared to (DOX+C*+US) treatment at 
different MI 
 
Increased fold of DOX uptake 
[MBs] MI=0.24 MI=0.31 MI=0.53 
1% MBs 1.40 2.38 2.33 
2.5% MBs 1.62 2.42 2.89 
*C stands for carrier. 
As expected, similar results were delivered and show in Figure 5.22 for drug 
uptake situation by HCT116 cells. No significant cellular drug uptake increased in US 
treatment without MBs for protected DOX (red circle area). Apparently, enhanced 
DOX uptake was observed in cell samples subjected to both DOX alone and protected 
DOX in the presence of MBs, and treated by sonications. Table 5.4 shows significant 
increased factors of DOX uptake between sonication with MBs and without MBs for 
cells were exposed to protected DOX solutions. Minimum of 1.4-fold was achieved of 
MI = 0.24 with 1% of MBs, while maximum of 2.89-fold was obtained when MI = 
0.53 with 2.5% of MBs.  
To summarise, mechanical insensitivity of the carrier-drug inclusion was 
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suggested in section 5.4.4 in this chapter. However, significant increased DOX cellular 
drug uptake by both KB and HCT116 cells occurred in the presence of MBs with US 
treatment illustrates important cell response to MBs-induced mechanical effects such 
as cavitations.  
5.4.7 AFM Measurement of Cell Sonoporation 
Short time membrane morphology and topography changes of KB cells were 
inspected by AFM post sonication with and without SonoVue
®
 MBs by various 
frequencies of FUS transducers.  
Transducer f = 1.467 MHz 
AFM images of KB cells sonicated 60 sec by f = 1.467 MHz in continuous FUS 
wave without MBs show in Figure 5.23. 
 
Figure 5.23 AFM cell surface morphology and topography of KB cells before and 
after f = 1.467 MHz sonication. Surface of cells before US treatment (A); 3D 
image of cells before US treatment (B); surface of cells after sonication (C); and 
3D image of cells after sonication (D). 
 
As can be seen from Figure 5.23, smoother cell membrane (Figure 5.23 A) and 
normal 3D sharp of cells (Figure 5.23 B) were observed before US treatment, while 
uneven cell membrane (Figure 5.23 C) and more protrusion shape of cells (Figure 5.23 
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D) can be seen after sonication treatment. The results indicate stress/strain response of 
cells to pressures came from acoustic wave.  
Transducer f = 1.142 MHz 
KB cells were sonicated 60 sec by f = 1.142 MHz in continuous FUS wave, where, 
5% MBs was added. 
 
Figure 5.24 AFM cell surface morphology and topography of KB cells before and 
after f = 1.142 MHz sonication. Surface of cells before US treatment (A); 3D 
image of cells before US treatment (B); surface of cells after sonication without 
MBs (C); 3D image of cells after sonication without MBs (D); surface of cells after 




Figure 5.25 AFM cell surface morphology and sonoporation observation of KB 
cells after f = 1.142 MHz sonication with 5% MBs. Surface of KB cells after 
sonication with 5% MBs (A); and selected sonoporation plot depth and width of a 
defect (B). 
 
Transducer f = 0.4868 MHz 
KB cells were sonicated 10sec by f = 0.4868 MHz in continuous FUS wave in the 
absence/presence (2.5%) MBs. 
 
Figure 5.26 AFM cell surface morphology comparison of KB cells before (A) and 




Figure 5.27 AFM cell surface morphology of KB cells after f=0.4868MHz 
sonication with and without 2.5% MBs. Surface image of cells after sonication 
without MBs (A); selected sonoporation plot depth and width of defects in picture 
A (B); surface image of cells after sonication with MBs (C); and selected 
sonoporation plot depth and width of defects in picture C (D). 
 
From Figure 5.24 A and B, Figure 5.26 A, all non-treated cells possessed normal 
shape and size, with highly rich surface profiles observed, in terms of cell cytoskeleton 
structures (fibre structures), etc. After the US treatments, flatter cell membranes were 
documented by the AFM (with much less fibre structures observed). Small pits were 
found on the cell membranes with depth of 100 – 200 nm (Figure 5.25 and Figure 5.27 
A and B). These observations were speculated to be caused by US, which induced 
non-uniform pressure (or stress & strain) on the cells, resulting in the changes of cell 
topography (Figure 5.24 C and D). 
By adding the MBs to the US treatments, a significant difference in membrane 
structural topography was seen immediately when compared to the previous 
experimental groups. Cell membranes were covered with different kind of pore 
structures with very sharp edges (Figure 5.24 E and F, Figure 5.25 and Figure 5.27 C 
and D), which it is thought are the disrupted membranes, sonoporated by FUS+MBs 
treatment (Prentice, Cuschieri et al. 2005). It should be noted that these pore structures 
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were not observed on all the treated cells (Figure 26 B). 
AFM study was a complementary method in this thesis research for cell 
morphology and topography observation to further investigate cell membrane 
sonoporation situation in FUS-triggered TDD. The above AFM images illustrate potent 
sonoporation occurred in the presence of additional MBs, which is an explanation to 
increased drug uptake observed in section 5.4.6.  
5.5 Conclusions 
In this chapter, it was expected that the use of a standardised in vitro sonication 
device and experimental method would reduce instrument-related variability in reported 
results, reduce the time associated with the US exposure of a large number of wells of a 
96-well plate and thus increase the accuracy of exposure durations of cells to both 
encapsulated and non-encapsulated drugs.  
The carrier-DOX drug delivery system was validated to be mechanically (low 
acoustic power induced) stable, and, by adding additional ultrasound contrast agent of 
SonoVue
®
 MBs into the system, cell membrane sonoporation with exposure to FUS was 
confirmed through both cellular drug uptake and AFM studies.  
In spite of that, answers to some questions are still unclear, including the form of 
cavitation (stable / inertial), DOX release / uptake mechanism (such as whether the 
carrier-DOX complex penetrates the cell membrane intact before the DOX is released) 
and biochemistry response of cells (cell signalling pathway) to US exposure. Possible 
methodologies to clarify these will be discussed in Chapter 7.  
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Chapter 6  
Animal House Design and Experimental 
Planning for Clinical MR-guided FUS 
System  
6.1 Introduction 
An extensive cell culture study had been carried out to investigate 
thermal-responsivity and mechanical-responsivity of the carrier-DOX complex 
inclusion by thermo oven and FUS, respectively. The logical continuation of this work 
is the initiation of in vivo study to confirm the ability of ultrasound to locally release 
cytotoxic drug and increase cellular drug uptake by tumour tissues employing the 
combination of thermal and mechanical effects of FUS under MRI guidance. However, 
before starting experiments with live animal, setup configuration, MR and ultrasound 
parameters should be evaluated in a series of experiments that will simulate as close as 
possible real in vivo experiments conditions, but without complexity involved in 
treating anaesthetised live animals. The perfect model for this purpose is mice cadavers, 
since they provide same positioning challenges as live mice, same anatomical details 
and similar acoustic properties.  
Thus, this chapter aims to introduce the establishment and verification of 1) animal 
model: small rodents with and without tumours; 2) imaging and positioning of mice 
cadavers (with and without tumours); 3) sonication trials for optimisation of FUS 
sonication mode and acoustic parameters; 4) best MR imaging coils, and 5) procedure 
time frame. All experiments were carried out using clinical MR-guided FUS system - 
ExAblate 2000.  
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6.2 Animal Model and Clinical MR-guided FUS System 
6.2.1 Animal Model 
Small animal resource unit (RU) 
A standard RU for handling immune-compromised live mice with or without 
tumours during daily experiments was setup. It comprises an internally ventilated 
cages (IVC) rack with an air handling unit and a high-efficiency particulate absorption 
(HEPA) filter. For transfer of mice from IVC to other housing boxes and for other 
procedures a Class II Bio-safety cabinet is available.  
 
Figure 6.1 Mice housing system for internally ventilated cages (IVC) rack with a 
high-efficiency particulate absorption (HEPA) filter (A); Class II Bio-safety 
cabinet (B); MRI compatible anaesthetic device (C). 
 
Nude mice (Fogh and Giovanella 1978; Fogh and Giovanella 1982)  
Nude mouse is a laboratory mouse strain with genetic mutant (disruption of the 
FOXN1 gene) that has a deteriorated or removed thymus, resulting in an inhibited 
immune system due to a greatly reduced number of T cells. The main characteristic of 
nude mouse is lack of body hair, which gives this mutant strain the name of ‘nude’. 
Nude mice are valuable to oncology research because these are well-established as 
tumour xenografts recipients due to no rejection response. Such xenografts are often 
established in research to test new diagnostic and therapeutic methods. Hence, nude 
mice model is ideal for the current research reported here. Figure 6.2 shows a 
laboratory nude mouse model.  
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Figure 6.2 A nude mouse (From http://en.wikipedia.org/wiki/Nude_mouse, 
created by Armin Kübelbeck). 
6.2.2 Clinical MR-guided FUS System-ExAblate 2000 for 
Animal 
1.5 Tesla MRI system 
MRI is a medical imaging technique used in radiology to investigate the anatomy 
and function of the body in both health and disease. MRI is potent at finding and 
pinpointing some cancers. Main application in cancer diagnosis contains: 1) an MRI 
with contrast agent is the best combination to see such as brain tumours; 2) by MRI, 
doctors can sometimes distinguish whether a tumour is benign or malignant; 3) MRI 
can also be used to look for signs that cancer may have metastasised from where it 
started to another part of the body; 4) MRI images can help to be as an efficient 
guidance in treatment such as surgery, radiation therapy or chemotherapy. MRI is the 
investigation of choice in the preoperative staging of cancers, and has a role in the 
diagnosis, staging, and follow-up of other tumours (Husband and Padhani 2006). 
Wider interest in solid tumour microenvironment has come from more and more 
exquisite data available by employing MRI (Gillies, Raghunand et al. 2002).  
In the thesis reports here, a 1.5 Tesla MR scanner was used for the guidance of 
treatment with FUS. The MR imaging was performed using either a single-channel 
surface coil or two versions of the 8-channel DUOFLEX interventional coil: a 10 
cm × 10 cm surface coil and 24 cm × 24 cm surface coil.  
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ExAblate 2000 
ExAblate 2000 system deliveries FUS energy into human body in a 
minimal-invasive manner. In a matter of seconds, the tissue at the focal spot of the 
ultrasound beam is heated to the point of irreversible thermal coagulation, while 
nearby tissue remains unaffected.  
ExAblate 2000 (Figure 6.3) is a clinical approved FUS surgery system which 
consists of a bowl shaped transducer (Figure 6.3 D) with 208 transmitting ultrasonic 
elements. The system controls each element and has the ability for continuous power 
and phase modulation individually. Additional bowl shaped element (Figure 6.3 D, red 
circle) is acting as a receiver and it is located in the middle of the transducer. The 
element is used for the spectrum measurements.  
 
Figure 6.3 ExAblate 2000. Cradle (A); Operator console (B); Table components in 
degased water (C); Bowl shaped transducer (removed) (D). 
 
ExAblate 2000’s FUS system operates inside a MRI scanner that used to provide 
images of the patient’s anatomy, and prepare an appropriate treatment plan. The MRI 
also measures temperature changes inside the body during FUS treatment. The system 
acquires MR images and runs dedicated sequences to display temperature maps. The 
temperature maps are used to calculate the extent of thermal ablation and to help 
ensure safety and efficacy. In terms of operating site, ExAblate operator has full 
control of all acoustic parameters, so system performance can be adjusted to do 
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hyperthermia instead of ablation and ‘irreversible tissue damage’. ExAblate 2000 was 
used as the sonication platform for the ex vivo study within this thesis report.  








Mycoplasma Detection Kit 
Lonza, Rockland, ME USA  
High concentration 
Matrigel 
BD Biosciences, Two Oak 
Park, Bedford, MA USA 
 
McCoy's 5A (Modified) 
Medium 
Gibco® Invitrogen, UK [+] High Glucose 
[+] L-Glutamine 
[+] Bacto-peptone 
[+] Phenol Red 
[−] Sodium Pyruvate 
[−] HEPES 
Fetal Bovine Serum (FBS) Gibco Invitrogen, UK Origin: South America 
Gentamycin Gibco® Invitrogen, UK 10 mg/mL 
Nu/nu mice Clare Hall Laboratories, 
London, UK 
4 females 
1.5 Tesla MRI system General Electric, USA Signa HDX 
ExAblate 2000 InSightec LTD, Israel UF 
Single channel surface coil InSightec LTD, Israel 5GP breast 
8-channel DUOFLEX 
interventional coil 
MR Instruments ltd. 
Minneapolis, USA 
10 cm×10 cm 
24 cm×24 cm 
6.3.2 Methods  
6.3.2.1 Ex vivo MR imaging and FUS sonication 
Preliminary set up testing was done on nude mice cadavers (obtained from Animal 
Resource Unit of university) were used in this ex vivo study as a simulation for in vivo 
experiment. Lack of fur in these animals presents additional benefit for FUS 
experiments, since it is possible to create good acoustic coupling without shaving.  
MRgFUS procedures were performed on the hind leg muscle of 5 nude mice 
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cadavers, from same day culling. ExAblate 2000 (uterine fibroid, UF) system was used 
in the experiments. The system’s targeting accuracy was verified with tissue 
mimicking phantom on the day prior to beginning of experiment. 
During the procedure, the mouse was positioned above the ExAblate 2000 system 
therapy table, on its right side, on top of coupling gel-pad, so that right leg of the 
animal was entirely immersed in a small cut-out of the gel filled with degassed water 
(Figure 6.4 C). In the experiments the gel-pad with mouse cadaver was placed inside a 
rodent chamber (Figure 6.4 A and 6.4 B), especially designed for in vivo experiments 
to provide sterile and controlled environment for the anaesthetised animal during the 
experiment and to prevent animal’s escape in case anaesthesia level drops.. The 
chamber consists of Plexiglas box with Mylar surface on the bottom to allow access for 
the focused ultrasound.  
Two gloves filled with water were arranged around the mouse cadaver, so that its 
head was kept above water level and right and left legs were fully separated to avoid 
passage of ultrasound to non-targeted leg (in in vivo experiment it is proposed to use 
mice with tumours grown on both sides, but only one will be sonicated, leaving the 
second one for control). Another purpose of gloves was to simulate conditions for in 
vivo experiments in which a glove with warm water is planned be used as heating 
source to maintain animals’ body temperature during MR scanning and FUS 
sonication.    
 
Figure 6.4 Animal positioning on ExAblate 2000 table inside rodent chamber (A); 
mouse was protected by gloves filled with water (B); on top of coupling gel-pad 
with a small cut-out (C). 
 
Several imaging coils were evaluated in different experiments for best image 
quality including DUOFLEX Interventional 8-channel phased array coil 24 × 24 cm 
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and 10 × 10 cm, DUOFLEX interventional single channel coil and InSightec 5GP 
breast coil, respectively (Figure 6.5).  
 
Figure 6.5 DUOFLEX interventional 8-channel phased array coil 24 × 24 cm (A) 
and 10 × 10 cm (B); DUOFLEX interventional single channel coil (C); and 
InSightec 5GP breast coil (D). 
 
A short 3-plane localiser scan was performed to verify proper positioning, 
followed by Coronal and Sagittal T2-weighted FSE MR imaging sequences with the 
following parameters: TE = 84 msec, TR = 200 msec, flip angle 80 °, field of view 
16 × 16 cm, receiver bandwidth 10 kHz and 384 × 384 matrix. The treatment region 
was outlined using those MR images, see Figure 6.6. 
 
Figure 6.6 Planning of sonication. Coronal T2-weighted image, showing targeted 
treatment location (A); Sagittal T2-weighted image showing one of the performed 
sonication spots, blue area designates passage of ultrasound beam (B) and Axial 
T2-weighted image showing glove position around the animal (C). 
 
Following verification, several (6 – 8) sonications were performed, with a 
‘hyperthermia’ sonication mode, using acoustic power of 4 – 5W. Hyperthermia 
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sonication mode consisted in the first part of 20 sec long continuous sonication and in 
the second part of 54 sec long pulsed sonication with 1 sec power ON and 2.5 sec 
power OFF cycle. These parameters were evaluated in phantom session prior to the 
experiment. Highest available acoustic frequency (1.35 MHz) was selected to avoid 
deep penetration of US into tissue. Focal point of sonications was placed at the distal 
edge of the targeted muscle to increase distance to skin, which even with this measure 
was still smaller than ExAblate software recommends, but since sonications planned to 
be of very low power as compared to ablation levels, skin to focal distance was 
considered within safety limits. 
During the sonications, real time MR thermometry was used to monitor and 
control spot position and tissue temperature. Reference temperature for thermometry 
calculation was updated in ExAblate software to be 20 °C, as was room temperature on 
the day of experiment. ExAblate thermal imaging protocol was adjusted for imaging of 
small sample, providing good spatial resolution and reasonable Signal-to-Noise Ratio 
(SNR) on the same time. Resulting scan time, 10sec per thermal image, was longer 
than in clinical system, but since performed sonications were rather long (74 sec), 
temporal resolution did not suffer much.  
Immediately following the procedure, a set of high quality images was acquired to 
find any potential changes in tissue due to MRgFUS procedure; however since 
cadavers lack perfusion and the energies used were very low, no radiological findings 
were anticipated. After the imaging, the mice cadavers were examined for any 
evidence of skin damage or any other noticeable treatment effect. 
6.3.2.2 Ex vivo and in vivo MR imaging 
Followed the above nude mice cadavers’ MR imaging and ExAblate FUS 
sonication simulations, a human colorectal xenograft (HCT116) was implanted in live 
nude mice and tumour growth has been monitored regularly until tumours reached to 
certain sizes which were suitable (large enough) for in vivo MR imaging.  
Tumour injection, growth and monitoring 
HCT116 cell line has been introduced and employed in Chapter 4 for in vitro cell 
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culture study and they are tumourigenic in nude mice. For mice implantation, HCT116 
cells were grown in McCoys 5A (modified) growth medium containing 10% FBS and 
0.5% Gentamycin at 37 °C with 5% CO2. Cultured HCT116 cells were tested for 
mycoplasma prior to harvesting. Mycoplasma-free cells were trypsinised, harvested, 
rinsed, and then suspended at ratio of 1 : 1 (50 μl : 50 μl) McCoys 5A medium 
(modified) and high concentration matrigel. The suspension was kept below 4 °C at all 
times. Xenograft studies with HCT116 were carried out under project licence PPL 
60/4462 and personal licence PIL 60/14010 in accordance with the guidelines of the 
United Kingdom Coordinating Committee on Cancer Research (UKCCCR).  
Four female nude mice were obtained at age of 4 weeks and breed in cage No.27 
(C27), and they were weighed around 20 g and identified as C27.4, C27.6, C27.40 and 
C27. NM (No Mark) by ear mark positioning prior to tumour implantation. Mice were 
then injected subcutaneously in the right flank (Figure 6.7 D) with 100 μl of McCoys 
5A medium (modified) and matrigel (50 μl : 50 μl) suspension, containing 1×108 
HCT116 cells. The mice were housed under aseptic conditions, in individually 
ventilated cages with full records in a temperature (24 °C) and light-controlled (12 
hr/day) environment (Kang, Oh et al. 2011).  
After injection, mice were checked daily and weighed weekly. Tumour 
measurements were carried out for monitoring. Tumour dimensions were measured 
twice a week using calliper. Tumour sizes were calculated according to spherical 
tumour volume (V) Equation 6.1(Tomayko and Reynolds 1989): 
 
V = 4/3[(d1 + d2)/4)]
3 
Equation 6.1 Tumour volume calculation 
 
Where, d1 and d2 are tumour’s horizontal and vertical diameters (mm), 
respectively.  
MR imaging procedure 
MR imaging procedures for mice cadaver with tumours and live mouse with 
tumour were the same as ex vivo MR imaging described in section 6.3.2.1. Several 
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MRI experiments were carried out to acquire magnetic resonance images of mice with 
tumours. Different rodent chambers and MR coils (Figure 6.7 B and D) were used to 
find the optimal set.  
 
Figure 6.7 Comparison between different rodent chambers and different MR 
imaging coils. Big Perspex chamber with DUOFLEX interventional phased array 
24 cm × 24 cm coil (A and B); small bucket chamber with InSightec 5GP breast 
coil (C and D). 
6.4 Results and Discussion  
6.4.1 Ex vivo Mice Cadaver MR Imaging and Sonications 
6.4.1.1 MR imaging parameters 
MR imaging parameters were optimised to provide the best image quality for the 
spatial resolution required to image such as small samples. The following imaging 








Table 6.1 Selected MR imaging parameters 
 Planning images  Thermometry 
Field of View (FOV, cm) 16×16 16×16 
Matrix 256×256 256×128 
Slice thickness (mm) 3 3 
Bandwidth (kHz) 15.6 5.7 
TE (msec) 85 15 
TR (msec) 3600 28 
Number of averages 
(NEX) 
2 3 
Echo train length 15 N/A 
 
For the comparison among different MR imaging coils, the coil which provided 
the best image quality was the single-channel surface coil (InSightec’s Breast coil 5GP) 
(Figure 6.8 C and c), it provided best image quality both in treatment planning and in 
thermometry. The 8-channel DUOFLEX interventional coil also produced images of 
reasonable quality (Figure 6.8 B and b), although lower when compared to the 
single-channel surface coil. However, this coil currently cannot be used with rodent 
chamber, since its cable is too short and there is currently no opening in the rodent 
chamber to provide access for the coil. When DUOFLEX interventional phased array 
(24 × 24 cm and 10 × 10 cm) coil was used, no reliable thermometry could be 
measured, since the distance to the receiver element of the coil for such a small sample 
is too great to collect reliable data. Figure 6.8 illustrates difference in image quality of 




Figure 6.8 Comparison of MR scans with different imaging coils, Coronal 
T2-weighted planning images on the upper row (A, B and C) and Sagittal 
T2-weighted planning images on the lower row (a, b and c) acquired with 
DUOFLEX interventional phased array 10 cm × 10 cm coil (A and a); DUOFLEX 
interventional single channel coil (B and b); and InSightec’s Breast coil (5GP) (C 
and c). 
6.4.1.2 Sonication mode and acoustic parameters 
One of the goals of these experiments was to select sonication mode that will 
create sufficient temperature rise (8 – 10 °C) to cause hyperthermia (typically 40 – 
47 °C), but will still be below the level of ablation (higher than 57 °C). 
After thorough phantom tests the following sonication regime was selected: 20 sec 
continuous sonication, followed by pulsed sonication with 1 sec ON, 2.5 sec OFF cycle. 
This mode consistently created required heating pattern in phantom: rapid temperature 
rise of 8 – 10 °C in the beginning of sonication followed by temperature plateau till 
energy delivery stops. Continuous part of sonication is responsible for the initial 
temperature rise, while pulses maintain temperature at the same level. Power of 4 W 
was used for both parts of sonication.  
Hyperthermia sonications were then performed in 5 ex vivo mice treatments, 
targeting right leg of the animal, 6 – 8 sonications per treatment. Temperature pattern 
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observed in dead mice tissue was similar to one seen in phantom tests: temperature rise 
of 7 – 10 °C in the beginning of sonication followed by constant temperature till 
sonication is over. Temperature graph of the typical sonication is shown in Figure 6.9. 
Some sonications resulted in higher temperature rise of 10 – 12 °C (which is still 
below ablation level), probably due to the presence of bony structures in the acoustic 
pass zone. 
 
Figure 6.9 Thermal monitoring during the sonication. Coronal T2-weighted image 
showing planned spot location (A); Sagittal thermal image showing area of 
temperature rise (bright) around focal point (B); and Temperature graph showing 
temperature during the sonication (red line designates maximum temperature at 
the selected point and green line designates the average temperature over the 3 ×
 3 pixel area around the selected point) (C). 
 
Sonications with power of 5 W produced considerably higher thermal rise (12 – 
15 °C) than required and it was noticed that heating was less uniform (Figure 6.10). 
 
Figure 6.10 An example of sonications with power of 5 W and less uniformity of 
temperature rising. 
 
In most sonications, the heating occurred just below focal point, with a constant 
shift of 5 – 6 mm towards the transducer. After noticing this shift, focal point was 
moved up, increasing skin-to-focal distance, and thus the treatment safety. Each time, 
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the heated spot covered roughly a circular area with diameter of ~ 10 mm. Assuming 
maximal tumour diameter of 15 mm, a treatment of 6 to 8 sonications should cover the 
required volume (tumour + margins) with sufficient overlap.  
Post treatment mice cadavers were closely examined to find any skin damage or 
any other treatment effect. There were no signs on skin in any of the treated animals. 
No radiological findings were observed on post-treatment MR images.  
6.4.1.3 Evaluation of rodent chamber and experimental time frame 
Although the rodent chamber served its function well in above ex vivo experiments, 
several weak points were noted as MR images did not have the desired quality. Some 
modifications were required prior to initiation of live animals study.  
The weak points and necessary improvements include: 1) the box is too deep as it 
was designed to be suitable for rats and guinea pigs as well as mice, so working inside 
the chamber with both hands during the positioning for example, is very uncomfortable, 
which will be even more so in in vivo experiment when injections will have to be 
performed inside the chamber (for administration of contrast agent or MBs) and the 
environment must stay sterile during the entire procedure; 2) two openings for gloved 
hands from the opposite sides of the box would increase the level of comfort 
significantly; 3) another opening in the box should be created for the imaging coil, 
which should be placed around the animal; 4) alternatively, a smaller round box can be 
constructed especially for mice experiments, preferably with size that will fit inside the 
Breast coil. 
In terms of experiments time frame, the average treatment time (sonications time) 
was 30 min for 8 sonications, while imaging before and after treatment took additional 
20 min in average. Since in vivo experiments are planned to be performed using gas 
anaesthesia, the experiment time of up to 1 hr is considered acceptable. 
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6.4.2 Tumour Growth and Monitoring for ex vivo and in vivo 
Experiments 
Mice C27.4, C27.6 and C27.40 were subjected to HCT116 human colorectal 
cancer cells subcutaneous injection in the same day at the beginning as these three 
mice were proposed to be scanned by MR under terminal anaesthesia. Mouse C27.NM 
was injected HCT116 cells a week after, which was for conducting MR scanning under 
normal anaesthesia with full recovery.  
After subcutaneous injection of HCT116 colon cancer cells, tumour volumes were 
monitored and mice weights measurements were conducted regularly. Tumour 
monitoring progress is shown in Figures 6.13 – 6.16 for each mouse. The values for the 
volume of the tumours are shown in Table 6.2 and tumour growth evolution in time in 











Figure 6.11 Mouse C27.4 tumour growth and monitoring until sacrifice (33 days 






Figure 6.12 Mouse C27.6 tumour growth and monitoring until sacrifice (33 days 









Figure 6.13 Mouse C27.NM tumour growth and monitoring until sacrifice (24 
days after injection HCT116 cells, ulcerated). 
 
Tumour monitoring revealed that tumour implanted for mouse C27.NM (Figure 
6.13) was ulcerated after 24 days post injection, and it was suggested to euthanise the 
animal as soon as possible to minimise its suffering. Therefore, mouse C27.NM 
(exchanged with mouse C27.40) together with mouse C27.4 (Figure 6.11) and C27.6 
(Figure 6.12), whose tumours grew faster in comparison to mouse C27.40 (Figure 6.14), 
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were terminated by CO2 euthanasia after 24 days (mouse C27.NM) and 33 days (mouse 
C27.4 and C27.6) post injection of HCT116 cells. Right before termination, tumour 
volume of three mice was 332.98 mm
3
 (mouse C27.NM), 572.04 mm
3
 (mouse C27.4) 
and 1059.71 mm
3
 (mouse C27.6), respectively. Moreover, tumours of mouse C27.4 and 
C27.6 appeared as a multi-tumours shape.  
 
Figure 6.14 Mouse C27.40 tumour growth and monitoring until after injection 33 
days. 
 
On the contrary, mouse C27.40, which was supposed to be sacrificed and to 
undergo MR imaging as a cadaver, replaced mouse C27.NM and was scanned as live 
due to its relatively slower tumour growth rate and smaller tumour volume (Figure 
6.14).  
Table 6.2 lists detailed information of tumours’ monitoring process and their sizes 
in different stages. Figure 6.15 shows by curves the overall trend of tumour growth of 
four mice.  
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# Mouse Dates 29-04-13 02-05-13 06-05-13 12-05-13 13-05-13 16-05-13 20-05-13 23-05-13 28-05-13 
C27.4 





14.56 32.26 23.22 69.44 80.16 113.08 253.24 332.98 572.04 
C27.6 





16.91 11.49 22.93 61.59 104.81 212.13 338.82 893.35 1059.71 
C27.NM 





  9.47 13.44 27.61 75.75 124.76 220.85 332.98 
C27.40 
d1/d2 (mm) 3.31/3.39 4.0/3.3 3.3/3.82 3.5/3.8 4.4/4.0 4.6/4.7 5.5/6.0 6.3/6.2 5.5/5.4 
Tumour 
Volume(mm3) 






In parallel, all mice weights were measured once a week. Table 6.3 presents weights 
of four mice after tumour implantation. For mouse C27.4 and C27.NM, their weights 
were increasing every week due to tumours growth. In contrast, weights of mouse 
C27.6 and mouse C27.40 were decreasing after 3 weeks of tumour implantation; it 
might be because their body had relevant pathological response to the tumour 
xenografts such as loosing weights.  
Table 6.3 Mice weights monitoring 















C27.4 18.5 20.1 22.1 22.9 22.5 23.2 
C27.6 19.7 22.0 24.4 24.1 23.3 22.7 
C27.NM 21.5 22.4 25.2 25.3 25.5 26.1 
C27.40 20.5 22.3 24.4 23.9 23.0 22.6 
6.4.3 Ex vivo Mice Cadaver Bearing Tumours MR Imaging 
The following tables (Table 6.4 – 6.6) list selected MR parameters for scanning 
three mice (C27.4, C27.6 and C27.NM) cadavers bearing tumours. 
Mouse C27.4 
Table 6.4 Mouse C27.4 MR imaging parameters 






Sequence FRFSE-XL FRFSE-XL FSE-XL FRFSE-XL 
TR (ms) 5880 6480 580 3260 
TE (ms) 84.5 84.5 8.2 85 
Bandwidth (kHz) 10 10 31.2 10 
FOV (cm) 14×14 14×14 14×14 13×13 
Slice thickness 
(mm) 
2 2 2 2 
Number of averages 
(NEX) 
2 3 2 2 
 
Three groups of MR scans were conducted for the first mouse C27.4 by using MR 
parameters list in Table 6.4 and three different coils (DUOFLEX interventional phased 
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array 10 × 10 cm, 24 × 24 cm coil, and InSightec 5GP breast coil) were used under 
different set of MR parameters according to different coils’ property.  
 
Figure 6.16 MR images of mouse C27.4 placed inside big Perspex rodent chamber 
and scanned by DUOFLEX interventional phased array 10 × 10 cm coil. Axial (A); 
coronal (B); and sagittal (C) T2-weighted scans of the animal lying on a gel pad 
were taken to visualise the tumour. 
 
 
Figure 6.17 MR images of mouse C27.4 placed inside big Perspex rodent chamber 
and scanned by DUOFLEX interventional phased array 24 × 24 cm coil. Axial (A), 
coronal (B) and sagittal (C) T2-weighted scans of the mouse lying on a gel pad, 
were taken to visualise the tumour. 
 
 
Figure 6.18 MR images of mouse C27.4 placed inside small Bucket rodent 
chamber and scanned by InSightec 5GP breast coil. An axial T1-weighted MR 
image was first taken to plan the scan (A); axial T2-weighted; (B) and sagittal 
T2-weighted (C) images of the animal were taken to visualise the tumour. 
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Figure 6.16 shows MR images of mouse C27.4 scanned by DUOFLEX 
interventional phased array 10 × 10 cm coil. The image quality was not good enough 
to observe the exact location of tumour especially when the image orientations were 
coronal and sagittal. The reason was that the small mouse cadaver inside the big 
Perspex rodent chamber was located too far from the receiving elements of the coil. 
Similarly, images obtained by using DUOFLEX interventional phased array 24 × 24 
cm coil were not satisfactory either because big rodent chamber was still keeping the 
mouse cadaver too far from the coil. However, when using DUOFLEX 24 × 24 cm 
coil higher image quality was achieved (Figure 6.17 A) than DUOFLEX 10 10cm coil 
as can be seen from the clear tumour position in the axial image.  
In comparison to Figure 6.16 and 6.17, much clear MR anatomy images of the 
mouse were obtained by using InSightec 5GP breast coil which was set up around a 
small round Bucket chamber. As can be seen from Figure 6.18, both mouse anatomy 
and location of the tumour were clearly seen in both axial and sagittal orientations as 
opposed to Figure 6.16 and 6.17. This was because the scanned object (mouse) was 
nearer to the imaging coil.  
Mouse C27.6 
Based on scanning parameters for the above mouse C27.4, for the second mouse 
C27.6, only two coils (DUOFLEX interventional phased array 24 × 24 cm coil and 
InSightec 5GP breast coil) were used. Two sets of scans were conducted according to 
the parameters list in Table 6.5, respectively.  
Table 6.5 Mouse C27.6 MR imaging parameters 
 Mouse C27.6 
Coil DUOFLEX 24×24 5GP breast 
Sequence FRFSE-XL FSE-XL FRFSE-XL 
TR (ms) 3260 740 3600 
TE (ms) 85 8.2 85.2 
Bandwidth (kHz) 10 31.2 10 
FOV (cm) 13×13 14×14 14×14 
Slice thickness (mm) 3 2 2 
Number of averages 
(NEX) 
3 3 3 
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Figure 6.19 MR images of mouse C27.4 placed inside big Perspex rodent chamber 
and scanned by DUOFLEX interventional phased array 24 × 24 cm coil. Sagittal 
(A) and axial (B) T2-weighted scans of the mouse lying on a gel pad were taken to 
visualise the tumour. 
 
 
Figure 6.20 MR images of mouse C27.4 placed inside small Bucket rodent 
chamber and scanned by InSightec 5GP breast coil. A sagittal T1-weighted MR 
image was first taken to plan the scan (A); axial (B) and sagittal (C) images of the 
animal were taken to visualise the tumour. 
 
The MRI images obtained for mouse C27.6 were similar to the ones for C27.4. 
Images obtained by using DUOFLEX interventional phased array 24 × 24 cm coil 
were less clear (Figure 6.19). This was due to the mouse placing inside the big Perspex 
animal chamber which kept the mouse far away from the coil. 5GP breast coil gave 
better image quality (Figure 6.20) by fixed around the small bucket animal chamber 
where the coil was located nearer to the mouse cadaver. 
Mouse C27.NM 
For the last mouse cadaver C27.NM, only 5GP breast coil was used for MR 
scanning. Table 6.6 lists MR scanning parameters used for C27.NM. 
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Table 6.6 Mouse C27.NM MR imaging parameters 
 Mouse C27.NM 
Coil 5GP breast 
Sequence FSE-XL FRFSE-XL 
TR (ms) 580 2940 
TE (ms) 8.2 84.5 
Bandwidth (kHz) 31.2 10 
FOV (cm) 14×14 14×14 
Slice thickness (mm) 2 2 





Figure 6.21 MR images of mouse C27.NM placed inside small Bucket rodent 
chamber and scanned by InSightec 5GP breast coil. An axial T1-weighted MR 
image was first taken to plan the scan (A); sagittal (B), coronal (C) and axial (D) 
images of the animal were taken to visualise the tumour. 
 
InSightec 5GP breast coil gave the best image quality among all the other coils, 
this coil and set up were further adopted for the next step: in vivo MR imaging. 
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For anaesthesia procedure, it was administered 0.23 ml of the ketamine/xylazine 
mixture to mouse C27.40 according to its weight was 23 g by intra-peritoneal injection. 
The full surgical anaesthesia was achieved approximately 3 min later. The mouse was 
inspected according to MR imaging protocol shows in Table 6.6 in section 6.4.3, by 
employing InSightec 5GP breast coil. Coronal, axial and sagittal MR images were 
obtained for mouse C27.40 can be seen in Figure 6.22. 
 
Figure 6.22 MR images of live mouse C27.40 placed inside small Bucket rodent 
chamber and scanned by InSightec 5GP breast coil. An axial T1-weighted MR 
image was first taken to plan the scan (A); sagittal (B), axial (C) and coronal (D) 
images of the mouse were taken to visualise the tumour. 
 
From Figure 6.22, high resolution live mouse anatomy images were obtained by 
MR with clear localisation of the implanted tumour. During MR scanning, the mouse 
was surrounded by gloves filled with warm water (~ 50 °C) (Figure 6.22 D) for 
maintaining mouse’s normal body temperature. After 35 min MR scanning, it was 
Glove filled with warm water 
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noticed that the mouse was coming out of deep anaesthesia and was responding to 
painful stimuli, which confirmed the proper anaesthesia administration of ketamine / 
xylazine mixture for desired mouse recovery time frame at around 30 min. Warm water 
filled gloves successfully maintained mouse’s normal body temperature during the 
entire imaging procedure in the cold environment of MRI room.  
As the procedure was proposed to be conducted continually under terminal 
anaesthesia without recovery, a further dose of 0.1 ml of ketamine / xylazine mixture 
was given, which achieved full surgical anaesthesia again in approximately 1min. The 
warm water filled glove was then replaced with one filled with freshly heated water and 
it was resumed the imaging procedure for a last scan. This procedure lasted 
approximately 12 min and the mouse was found to be dead at the end.  
6.5 Conclusions 
In this study, the optimal experimental set-up and the MR imaging protocol that 
gives the best images for the tumour visualisation were found. The optimal set up for the 
MR imaging included the receive-only InSightec 5GP Breast coil and the small 
cylindrical mouse house. It was found during procedure that for optimal imaging 
results the mouse house and coil were best sited on some pads to raise them to (or as 
near to) the isocentre of the magnet. For ease of localisation and prescribing 
subsequent scans the animal should be placed either head or feet first into the scanner.  
The experimental arrangement was tested firstly in ex-vivo experiments in which 
mice cadavers were used prior to conducting the first experiments with live animals. 
These ex vivo experiments were successfully conducted and the parameters (sonication 
parameters as well as MR imaging parameters and imaging coil) for the future in-vivo 
experiments have been optimised, and such a protocol was considered as a general 
hands-on rehearsal for the research team before the first live animal experiments was 
carried out. 
HCT116 tumour xenografts were successfully implanted and grew well in the 
rodent mode of female nude mice. Tumour growth monitoring and tumour volume 
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measurement were conducted according to standard routines. The high resolution MR 
images of dead/live mice bearing tumour xenografts ensured the future in vivo 
sonication experiments will be conducted under precise imaging guidance. Together 
with the FUS parameters, these parameters form a set that will allow application of 



















Chapter 7  
Discussions and Conclusions 
7.1 Discussions and Prospects  
This thesis has presented comprehensive research on a TDD vehicle for potential 
joint chemotherapy for cancer from the chemical design and synthesis of nanocarriers 
through in vitro work to in vivo trials. Many achievements were made but these are also 
accompanied with many future prospects.  
CDs’ deviation as TDD nanocarriers 
First of all, CDs are multi-functional agents that have attracted much attention and 
use in the pharmaceutical field. Research in both humans and animals has illustrated 
that CDs can be utilised to improve drug delivery for almost any type of drug 
formulation. The properties of bio-adaptability and multi-functionality make CDs 
capable of alleviating those undesirable characteristics of drug molecules in various 
routes of administration through the formation of CD-drug inclusion complexes.  
Knowledge of different impact factors which can influence complex formation to 
obtain clinically applicable CD-drug complexes with potently desirable properties is 
essential. However, adding CDs to existing drug molecules without further optimisation 
will seldom result in an acceptable outcome. Thus, the work for this thesis sought to 
explore chemical modification based on native CDs in the design of an innovative TDD 
system with existing anticancer drugs.  
Since CDs are capable of extending the function of pharmaceutical additives, the 
combination of molecular encapsulation with other possible materials will become 
effective and a valuable tool for the improvement of drug formulation in the manner of 
stability and circulation time in vivo. Moreover, the most desirable attribute for a drug 
carrier is the ability to deliver enough potency of a drug to a targeted site. For the novel 
synthesised carrier 3b discussed in this study, a hypothesised model of possible 
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conjugation with polymers or peptides to further improve its drug delivery properties, 
and rational tagging with a delivery ligand is presented in Figure 7.1. 
 
Figure 7.1 γ-CD based drug delivery vehicle. 
 
Here, the yellow part is γ-CD derivative monomers; several of them will capture a 
drug molecule (blue balls); the green chain could be a polymer or peptide to carry the 
monomer CD carriers and the red arrow molecule represents a targeting ligand that will 
recognise certain receptors of tumours. The targeting ligand could be a folate receptor 
(FR) acceptor which can recognise high FR-expressing tumour cells such as the KB 
cells discussed in this thesis. 
The conjugation of a drug with CD can be a versatile means to construct a new 
class of novel drug delivery systems like liposomes, microspheres, peptides, 
nanoparticles and site specific prodrugs. Thus, there is scope for a vibrant future in the 
research and development of CD based drug delivery systems (Arun, Ashok et al. 
2008).  
Establishment of in vitro human cancer cell models for FUS-mediated TDD 
Chemical modification, characterisation and analysis are very early stage 
investigations relating to the inclusion of CD-drug complexation; whether the same 
strong encapsulation affinity between modified CD and the drug will be observed in 
vivo or in further clinical studies, in vitro experiments are indispensable. A typical and 
reliable in vitro study for a novel exploited TDD system is performed by using cultured 
human cancer cells which usually express a unique surface marker specifically entrusted 
with the task of testing the targeted delivery strategy (Bae and Park 2011). Cytotoxicity 
and cellular drug uptake are commonly examined by exposure of drug delivery systems 
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directly to those cells grown as monolayers or in suspension under various 
environmental conditions.  
Two human cancer cell lines: KB and HCT116, were successfully tested in vitro, 
leading to the achievement of the objective of fast screening of the carriers’ 
encapsulation potency to different drug molecules, investigation of drug release factors 
and confirmation of sonoporation. A particularly interesting contribution was the 
establishment of a precise sonoporation protocol for cell monolayers in a 96-well plate.  
In terms of in vitro cell sonoporation reported in the current literatures, they are mostly 
carried out with cell suspensions (Ashush, Rozenszajn et al. 2000; Guzman, Nguyen et 
al. 2001; Sundaram, Mellein et al. 2003; Karshafian, Bevan et al. 2009) rather than 
adhesion cell monolayers, despite the fact that cell suspensions are believed to be far 
away from the real cell conditions in vivo. Secondly, sonications were commonly 
performed in physical environments such as an Opti-cell chamber (Yudina, de Smet et 
al. 2011) or a petri-dish (Liu, Cho et al. 2001), in which, cells are cultured in a unitary 
environment without the possibility of isolated control samples undergoing the same 
sonication conditions.  
Taking the above aspects into account, the sonicator device for cell monolayer 
sonication in a 96-well plate was established as a unique but standardised and precisely 
repeatable US applicator. A sonication protocol with cell monolayers in a single well 
achieved experimental conditions with the following features: 
1) the cell monolayer more closely resembles the conditions of cells in tissue;  
2) single wells are isolated from each other and can be treated and examined 
separately;  
3) sonication groups with various US parameters together with control groups can 
be easily arranged within a single 96-well plate.  
MBs-involved FUS-mediated TDD under non-thermal effects 
Through the application of the in vitro sonicator, another contribution was to 
prevent FUS induced thermal effects and thus to investigate cells’ response only to 
mechanical effects by employing very low acoustic power. It has been shown in the in 
vitro sonication results that MB-stimulated oscillation (e.g. microstreaming) or 
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cavitation involved in cell sonoporation occurred with negligible thermal effects 
detected and that sonoporation in human cancer cells is directly related to MB 
concentration (Ward, Wu et al. 2000). This indicated FUS-mediated drug delivery in 
the presence of MBs is effective; however, much more work needs to be carried out to 
demonstrate the precise mechanisms of this action.  
Although the acoustic pressure threshold of oscillation or cavitation from MBs is 
not fully understood, several parameters, including the abundance of cavitation nuclei 
in the exposed medium, affect the process (Han, Ikegami et al. 2007). Other factors 
affecting sonoporation include MI, acoustic pressure amplitude, exposure time, duty 
cycle and pulse repetition frequency (PRF). Sonoporation efficiency improved (as 
shown by enhanced cell permeability and cellular drug uptake) with increased values 
of MI, acoustic pressure amplitude and FUS exposure time in the present study. 
The conclusion that follows is that the method of in vitro cell cultivation and 
sonoporation is a very useful tool in FUS-mediated TDD, recognizing that certain 
methods cannot be examined with in vivo models directly before validation of their 
safety. However, it is generally believed that the most trustworthy preclinical 
experiments are animal studies. Nevertheless, methods to eliminate any pain or distress 
in trials involving live animals are continuously advocated. Hence there is a steady and 
increasing demand to replace animal studies by in vitro experiments in research, 
leading to the need for better understanding of the replacement of in vivo by in vitro 
methods. Many questions certainly can be answered by in vitro experiments, but these 
cannot cover the whole area of scientific research. Working with live animals means 
the examination of questions in their full complexity; whereas in vitro experiments 
may be able to answer only one special aspect of a question (Varga 2011). 
MRgFUS-ExAblate 2000: ex vivo and in vivo pre-clinical studies 
Although the in vitro cell sonicator has the potential to become a potent instrument 
for prolonged application and investigation in FUS-involved TDD, in practice, 
efficient monitoring tools for sonication parameters, cavitation detection and thermal 
isolation are still under development. The sonicator cannot be used in in vivo studies in 
its current state and it is not MR compatible; hence results could not be translated 
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directly into clinical use. Therefore, a clinically approved MRgFUS system–ExAblate 
2000 was adopted to perform in vivo trials by utilising a small rodent model to further 
evaluate the FUS-induced TDD systems developed in this study.  
Before exposure of any animals to either FUS or encapsulated drugs, post mortem 
and in vivo MRI scans and ExAblate sonications were performed and optimised MRI 
and FUS parameters were determined. In vivo carrier-drug distribution was also 
investigated by intravenous administration of encapsulated DOX and DOX alone to 
healthy mice. In the later studies, mice were sacrificed immediately and 0.5 min, 2 min, 
2 hr, 4 hr and 10 hr after drug / encapsulated drug administration, respectively. 
Necessary organs were extracted and homogenised.  
Following the results achieved with optimised MRI and FUS parameters, validated 
potency of drug protection in vivo and the significant drug release in the presence of 
hyperthermia and FUS with MBs, the in vivo release of encapsulated DOX from the 
carriers by application of MRgFUS on a targeted region was considered. The purpose 
of the experiment described next was to evaluate encapsulation and drug release by the 
use of MRgFUS in the quadriceps muscles of living healthy mice. A total of five mice 
were involved; four of these were treated with MRgFUS and one remained as a 
non-sonicated control.  
The applied acoustic power (4 W) and sonication duration (14 min) failed to 
produce the desired temperature increase of 6 – 8 °C, as was initially planned and seen 
ex vivo. Chemical analyses showed that although there was a fluorescent signal of 
DOX in the collected organs (blood, liver and kidney), there were no detectable signals 
in the quadriceps muscles samples. This indicated that there might be a problem with 
the length of exposure time to DOX. Previous in vivo experiments showed that the 
optimal time for encapsulated DOX absorption in the quadriceps muscles is about 
10 hr following injection, strongly suggesting that the short exposure time of 14 min 
would not be enough to produce a clear DOX signal from this tissue.  
Future experiments should consider the application of higher powers as well as the 
examination of different time points of DOX exposure both before and after MRgFUS 
application. The sonoporation stimulus of MB USCA should also be considered for 
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injection with encapsulated DOX. Still more specifically, the proof of efficacy of the 
drug delivery system developed in the work reported here requires in vivo experiments 
with xenografts of human cancer in mice, rabbits or rats in the near future. The 
experiments should be conducted following percutaneous or image guided orthotopic 
implantation of human tumour cell lines such as ultrasound monitored prostate 
orthotopic tumour reported by Saar et al. (Saar, Körbel et al. 2012) and orthotopic U87 
gliomas assessed by MRI present by Weidensteriner et al. (Weidensteiner, Reichardt et 
al. 2013). When the tumour size reaches 5 – 10 mm, the cytotoxic drug bound to the 
nano-carrier and/or MBs suspension should be injected intravenously. MRI guided 
insonation of the tumour should then be carried out using protocols established by 
previous in vitro and in vivo studies. 
7.2 Conclusions 
Overall, this thesis study concludes feasibiltiy of a MRgFUS mediated TDD vehicle 
from: 
1) rational design and synthesis of natural γ-CD as an encapsulation and transport 
nanocarrier for DOX;  
2) full chemical characterisation of desired carrier 3b;  
3) comprehensive inclusion affinity and drug release analysis of the carrier-DOX 
complex;  
4) successful establishment of in vitro human cancer cell models;  
5) validation of the encapsulation efficiency both in vitro and in vivo, as well as 
thermo-sensitivity of carrier-DOX inclusion in monolayers of cells; 
6) successful in vitro sonoporation application of a unique sonicator in combination 
with MBs; 
7) successful optimisation of clinical MRI and FUS parameters ex vivo and in vivo.  
The results from this study confirm the possibility of translation of the constructed 
γ-CD derived carrier into clinical use as a delivery vehicle of DOX for release with 
combined thermal and mechanical mechanisms by clinically applicable 
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MRgFUS-triggered TDD for cancer therapy. 
The Thesis provides better understanding of the mechanism of and potential for this 
novel delivery approach: MRI-guided, ultrasound-mediated, site-specific drug delivery 
assisted by MB contrast agents. It is likely that this novel technology will enter the 
clinical arena in the near future, based on the ever-increasing scientific contributions 
from researchers. The chemical modifications and in vitro, ex vivo and in vivo 
preclinical studies discussed here represent only a glimpse into the future of clinical 
application. 
Finally, to master MRgFUS-mediated therapeutic applications of the kind presented 
here and to translated them into the clinic still requires interdisciplinary collaborations. 
Much effort is being dedicated to technological advancement in all aspects of the drug 
delivery platform: hardware, software, and wetware (protocols and molecular devices 
used in molecular biology and synthetic biology) (Castle, Butts et al. 2013). Expertise in 
the fields of physical chemistry, cellular physiology, genetics, ultrasound physics and 
imaging must come together with shared goals. Following relationships formed in the 
Nanoporation project, it is conceivable that new strategic partnerships will be developed 
among the partners, to involve pharmaceutical companies, and clinical reseach to 








1 Standardisation, Apparatus and Set-up of in vitro FUS 
Device for TDD 
In the current setup, the acoustic fields of four interchangeable custom transducers, 
built in-house, were simulated using a model created in MATLAB and the results were 
compared with output measurements from each transducer, taken with a needle 
hydrophone. Frequencies of desired transducers are 0.486 MHz, 1.142 MHz, 1.467 
MHz and 2.022 MHz, which can deliver maximum acoustic powers, 5 < Pac < 25 W, 
depending on the transducer and its efficiency. The range of frequencies was chosen to 
cover clinically available FUS system ExAblate in order to produce relevant guidance 
for pre-clinical studies (Chapter 6).  
The device (Figure A.1 A) consists of a Perspex box with several separate 
compartments including a larger one for the water bath in which the ultrasound sources 
and the 96-well plate are placed. Degassed water is circulated to prevent air bubble 
formation beneath the plate interfering with the FUS propagation and its temperature is 
kept close to physiological levels (37 °C) using an external heater. A smaller 
compartment inside the water bath (14 × 10.5 × 6 cm3) accommodates detachable 
nylon housing (Figure A.1 D) for the transducers. These are activated with a signal 
generator (Figure A.1 F) that can generate various wave-forms amplified with an A075 
RF power amplifier (Figure A.1 G). Alongside the water bath, a linear stage translates 
a Perspex transducer holder (Figure A.1 E) for a 96-well plate through the water above 
the transducers on two parallel aluminum tracks, using small linear bearing carriages.  
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Figure A.1 Photograph (A) and schematic drawing (B) of the sonicator; stepper 
motor (C) to move the plate holder; piezoceramic bowl transducers within nylon 
housing (D); Perspex transducer cases (E); signal generator (F); and RF power 
amplifier (G). 
 
The plate holder (Figure A.2 C) has two cutout adaptors (Figure A.2 A, B) for 
precise inverted (Figure A.2 D) or normal positioning (Figure A.2 E) of the 96-well 
plate and accurate horizontal location of the ultrasound focal point at the centre of each 
well (Figure A.2 F). Inverted plates allow FUS propagation within the wells, to 
minimise possible acoustic scattering or reflection from the bottom of the plate. The 
positions of the holes housing the transducers were chosen to allow sonication of all 
lines of a 96-well plate: lines A, B, D and F and then C, E, G and H after a manual 
rotation through 180° according to transducer positions 1, 2, 3 and 4 respectively, in 
the horizontal plane of the plate.  
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Figure A.2 Two cutout adaptors for plates (A, B); plate holder (C); inverted plate 
places in the adaptor (D); normal position plate places in the adaptor (E); and 
inverted plate in the adaptor fixed in the plate holder within the sonicator (F). 
 
The water in the bath is heated by an ETH200 heater (Figure A.3 A) using Positive 
Thermal Coefficient (PTC) of resistance technology and thus acting as its own 
thermostat. It is returned to the reservoir using a micro-pump. This system maintains 
the temperature (measured with a glass thermometer) at 34 °C (Figure A.3 B), a few 
degrees below human body temperature, to avoid critical overheating (> 43 °C) of the 
biological material on exposure to FUS. To avoid air bubble formation and to maintain 
the water temperature at a desired level, the pump drive voltage was reduced to 6 or 9 
V to lower the flow. 
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Figure A.3 The ETH200 heater system (A); water bath temperature maintain at ~ 
34 ºC constantly (B). 
 
An X-slide linear stage connected to a programmable VXM motor controller and a 
NEMA 17 stepper motor are the main components of the motion system. The 
LabVIEW software allows the user to choose between four starting positions 
corresponding to the lateral centers of the FUS sources and then sends commands to 
the VXM controller to activate the stepper motor. The motor advances the stage 0.5 ×
 10-2 mm/step for precise positioning of the focal regions at the centres of the wells. 
Once a sequence of sonications in the same line is completed, the plate can be 
re-positioned manually above different US sources. All 12 wells in a line on the 
96-well plate can be sonicated or only certain wells can be selected, as required. This is 
very useful to minimise the heat transfer from the site of sonication to adjacent wells, 
as discussed later.  
For FUS sources, four transducers were made with geometrically-focused 
piezoceramic bowls (Figure A.4) with dimensions and type of piezoceramic specified 
in Table A.1.  
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Figure A.4 Various frequencies geometrically-focused piezoceramic bowls. 
 
Table A.1 Dimensions of US focal zone at (-6 dB) for the four transducers, and 


















water at 24°C      
(Ω) 
Impedance in 
water at 34°C      
(Ω) 
0.4868 3.14 5.30 20.34 19 82.1 83.5 
1.142 1.34 3.04 9.70 28 46.4 46.7 
1.467 1.25 1.60 10.94 76 54.0 67.1 
2.022 1.16 1.60 12.81 50 20.2 20.7 
 
The outer diameters (ODs) of the piezoceramics were in the range 30 – 35 mm, the 
focal distances 30 – 50 mm, and the resonance frequencies are 0.4868 – 2.022 MHz. 
The transducers cases were made from Perspex tube (OD = 40 mm) with a bowl 
positioned at the top of each case. Adapted lengths were cut for the transducer cases, in 
the range 20 – 40 mm, to position the focus of the field exactly at the bottom of the 
96-well plate.  
The input commands for the linear stage as well as the sonication parameters 
defined by the waveform generator including exposure duration, duty cycle, voltage 
amplitude, frequency, and wave form type (sinusoidal, pulsed and other options) are 
provided through a user friendly interface (Figure A.5) implemented in LabVIEW.  
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Figure A.5 LabVIEW interface allows control of numerical values for acoustic 
parameters at the focal point through the amplitude of the applied voltage, wave 
form (pulsed, sinusoidal), frequency, US duty cycle and to a sequence of 
individually selected wells in the plate (out of 12 wells in each line) to be sonicated. 
 
Acoustic field characterisations (can be found in Appendices) of all transducers 
have been fully conducted and confirmed by needle hydrophone and MATLAB 
simulations to make an accurate assessment before performing sonoporation to cells.  
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2 The MATLAB Simulations and Real Acoustic Field Scan 
for 1W of Transducers 1.142MHz, 0.4868MHz, 1.467 MHz 
and 2.022MHz 




Figure A.6 Simulation (A) and Hydrophone (B) scan of acoustic field for 0.4868 
MHz FUS transducer. 
A: Simulation of acoustic field 
B: Hydrophone scan of real field 
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2.2 Transducer f = 1.142MHz: 
 
Figure A.7 Simulation (A) and Hydrophone (B) scan of acoustic field for 1.142 












Figure A.8 Simulation (A) and Hydrophone (B) scan of acoustic field for 1.467 





A: Simulation of acoustic field 
B: Hydrophone scan of real field 
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Figure A.9 Simulation (A) and Hydrophone (B) scan of acoustic field for 2.022 




A: Simulation of acoustic field 
B: Hydrophone scan of real field 
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3 Acoustic Intensity and Mechanical Index were Calculated 
for Various Acoustic Powers of Transducers 1.142MHz, 
0.4868MHz, 1.467 MHz and 2.022MHz  
3.1 Transducer f=0.4868MHz, Efficiency=19%: 
 





3.3 Transducer f=1.467MHz, Efficiency= 76.4%: 
 
3.4 Transducer f=2.022MHz, Efficiency= 50.3%: 
 








4.1 Maximum temperature achieved for four transducers (*T 







Maximum Temperature (°C) 
*T1 T2 T5 T3 T4 T6 T7 
0.4868 1 20 34.16 37.02 38.35 37.35 36.4 34.64 40.1 
40 34.19 37.83 39.06 38.64 38.03 35.02 41.01 
60 34.49 39.51 40.34 39.75 38.91 35.44 43.99 
2.5 20 34.28 39.31 43.69 41.56 41 35.22 45.14 
40 34.46 43.64 46.85 43.93 45.38 36.21 49.74 
60 34.68 46.09 50.78 45.21 46.38 36.98 51.66 
5 20 34.53 43.15 47.53 46.91 53.92 35.75 49.19 
40 35.08 49.4 64.02 53.29 65.49 38.86 55.29 
60 35.54 53.12 65.14 56.07 62.19 39.25 56.17 
1.142 1 20 33.84 35.46 35.21 36.06 34.62 34.26 36 
40 33.97 36.4 36.24 37.36 35.64 34.55 37.15 
60 33.94 36.51 36.71 37.89 36.15 34.87 37.73 
2.5 20 34.18 37.83 36.88 38.58 36.6 34.64 39.5 
40 34.35 40.02 38.71 41.59 48.8 35.41 42.5 
60 34.42 40.59 39.91 42.97 39.82 35.79 43.5 
5 20 34.34 41.32 38.96 42.32 39.59 35.42 46.11 
40 34.43 44.21 41.99 47.83 42.34 36.7 50.48 
60 34.67 45.2 44.17 49.5 44.27 37.55 52.47 
1.467 1 20 34.49 35.97 36.36 36.35 36.15 35.37 37.06 
40 34.07 36.55 36.55 36.96 36.48 35.33 37.74 
60 34.06 37.29 37.1 37.54 37.06 35.68 38.42 
2.5 20 34.06 36.53 36.23 36.56 36.22 35.12 38.37 
40 34.16 38.02 37.98 38.28 37.85 35.96 39.32 
60 34.27 39.37 38.78 39.49 38.54 36.68 39.85 
5 20 34.2 38.58 38.06 38.64 38.06 36.03 40.29 
40 34.27 41.69 40.96 41.55 40.3 37.63 41.95 
60 34.33 41.02 41.02 42.26 41.39 37.79 43.4 
2.022 1 20 33.97 35.77 39.08 35.8 36.26 34.17 37.82 
40 34.2 37.16 41.57 37.94 37.87 34.52 37.82 
60 34.29 37.86 42.71 38.81 38.62 34.42 40.07 
2.5 20 34.03 37.42 41.51 38.64 38.44 34.42 40.07 
40 33.93 37.67 37.81 37.89 37.43 35.98 39.4 
60 34.1 40.52 44.47 42.63 41.87 35.05 44.16 
5 20 33.98 40.15 44.54 42.79 40.87 34.73 43.47 
40 34.23 43.1 49.19 49.66 45.22 35.65 45.48 
60 34.29 44.94 49.62 52.39 46.93 36.25 50.02 
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4.2 Distribution of Thermocouples Inside the Wells of A 
96-well Plate: 
 
4.3 The Average Temperature of 1W, 2.5 W and 5W 
Power Time T1 T2 T5 T3 T4 T6 T7 
1W 20s 34.1 36.1 37.3 36.4 35.9 34.6 37.7 
40s 34.1 37.0 38.4 37.7 37.0 34.9 38.4 
60s 34.2 37.8 39.2 38.5 37.7 35.1 40.1 
2.5W 20s 34.1 37.8 39.6 38.8 38.1 34.9 40.8 
40s 34.2 39.8 40.3 40.4 42.4 35.9 42.7 
60s 34.4 41.6 43.5 42.6 41.7 36.1 44.8 
5W 20s 34.3 40.8 42.3 42.7 43.1 35.5 44.8 
40s 34.5 44.6 49.0 48.1 48.3 37.2 48.3 
60s 34.7 46.1 50.0 50.1 48.7 37.7 50.5 





Abedin, M. and N. King (2010). "Diverse evolutionary paths to cell adhesion." Trends Cell Biol 20(12): 
734-742. 
Adler, A. D., F. R. Longo, et al. (1967). "A simplified synthesis for meso-tetraphenylporphine." The 
Journal of Organic Chemistry 32(2): 476-476. 
Adler, A. D., F. R. Longo, et al. (1970). "On the preparation of metalloporphyrins." Journal of Inorganic 
and Nuclear Chemistry 32(7): 2443-2445. 
Afadzi, M., L. Davies Cde, et al. (2012). "Effect of ultrasound parameters on the release of liposomal 
calcein." Ultrasound Med Biol 38(3): 476-486. 
Agrawal, P., S. K. Barthwal, et al. (2009). "Studies on self-aggregation of anthracycline drugs by 
restrained molecular dynamics approach using nuclear magnetic resonance spectroscopy 
supported by absorption, fluorescence, diffusion ordered spectroscopy and mass spectrometry." 
European Journal of Medicinal Chemistry 44(4): 1437-1451. 
Agrawal, P., S. K. Barthwal, et al. (2009). "Studies on self-aggregation of anthracycline drugs by 
restrained molecular dynamics approach using nuclear magnetic resonance spectroscopy 
supported by absorption, fluorescence, diffusion ordered spectroscopy and mass spectrometry." 
Eur J Med Chem 44(4): 1437-1451. 
Ahmad, I. and T. M. Allen (1992). "Antibody-mediated specific binding and cytotoxicity of 
liposome-entrapped doxorubicin to lung cancer cells in vitro." Cancer Res 52(17): 4817-4820. 
Ahmad, I., M. Longenecker, et al. (1993). "Antibody-targeted delivery of doxorubicin entrapped in 
sterically stabilized liposomes can eradicate lung cancer in mice." Cancer Res 53(7): 
1484-1488. 
Ahmed, H. U., E. Zacharakis, et al. (2009). "High-intensity-focused ultrasound in the treatment of 
primary prostate cancer: the first UK series." Br J Cancer 101(1): 19-26. 
Akerman, M. E., W. C. Chan, et al. (2002). "Nanocrystal targeting in vivo." Proc Natl Acad Sci U S A 
99(20): 12617-12621. 
Al-Bataineh, O., J. Jenne, et al. (2012). "Clinical and future applications of high intensity focused 
ultrasound in cancer." Cancer Treat Rev 38(5): 346-353. 
Alexis, F., E. M. Pridgen, et al. (2010). "Nanoparticle technologies for cancer therapy." Handb Exp 
Pharmacol(197): 55-86. 
Alfarouk, K. O., A. K. Muddathir, et al. (2011). "Tumor Acidity as Evolutionary Spite." Cancers 3(1): 
408-414. 
Allegre, M. and A. Deratani (1994). "Cyclodextrin uses: From concept to industrial reality." Agro. Food 
Ind. Technol. 31: 9-17. 
Allen, C., D. Maysinger, et al. (1999). "Nano-engineering block copolymer aggregates for drug 
delivery." Colloids and Surfaces B: Biointerfaces 16(1–4): 3-27. 
Allen, T. M., A. K. Agrawal, et al. (1994). "Antibody-Mediated Targeting of Long-Circulating (StealthR) 
Liposomes." Journal of Liposome Research 4(1): 1-25. 
Allen, T. M., E. Brandeis, et al. (1995). "A new strategy for attachment of antibodies to sterically 
stabilized liposomes resulting in efficient targeting to cancer cells." Biochim Biophys Acta 
26(2): 99-108. 
Allen, T. M. and P. R. Cullis (2013). "Liposomal drug delivery systems: from concept to clinical 
A.xvi 
applications." Adv Drug Deliv Rev 65(1): 36-48. 
Allen, T. M., C. Hansen, et al. (1991). "Liposomes containing synthetic lipid derivatives of 
poly(ethylene glycol) show prolonged circulation half-lives in vivo." Biochimica et Biophysica 
Acta (BBA) - Biomembranes 1066(1): 29-36. 
Alley, M. C., D. A. Scudiero, et al. (1988). "Feasibility of drug screening with panels of human tumor 
cell lines using a microculture tetrazolium assay." Cancer Res 48(3): 589-601. 
Anand, R., S. Ottani, et al. (2012). "A close-up on doxorubicin binding to γ-cyclodextrin: an elucidating 
spectroscopic, photophysical and conformational study." RSC Advan. 2: 2346-2357. 
Anand, R., S. Ottani, et al. (2012). "A close-up on doxorubicin binding to γ-cyclodextrin: an elucidating 
spectroscopic, photophysical and conformational study." RSC Advances 2: 2346-2357. 
Antony, A. C., M. A. Kane, et al. (1989). "Folate (pteroylglutamate) uptake in human red blood cells, 
erythroid precursors and KB cells at high extracellular folate concentrations. Evidence against a 
role for specific folate-binding and transport proteins." Biochem J 260(2): 401-411. 
Anyarambhatla, G. R. and D. Needham (1999). "Enhancement of the Phase Transition Permeability of 
DPPC Liposomes by Incorporation of MPPC: A New Temperature-Sensitive Liposome for use 
with Mild Hyperthermia." J Liposome Res 9(4): 491-506. 
Arima, H., H. Adachi, et al. (1990). "Enhancement of the antiinflammatory effect of ethyl 4-biphenylyl 
acetate in ointment by beta-cyclodextrin derivatives: increased absorption and localized 
activation of the prodrug in rats." Pharm Res 7(11): 1152-1156. 
Armarego, W. L. F. and C. L. L. Chai (2003). Chapter 1 - Common Physical Techniques used in 
Purification. Purification of Laboratory Chemicals (Fifth Edition). W. L. F. Armarego and C. L. 
L. Chai. Burlington, Butterworth-Heinemann: 1-52. 
Arun, R., K. C. K. Ashok, et al. (2008). "Cyclodextrins as Drug Carrier Molecule: A Review." Scientia 
Pharmaceutica 76(4): 567-598. 
Ashush, H., L. A. Rozenszajn, et al. (2000). "Apoptosis induction of human myeloid leukemic cells by 
ultrasound exposure." Cancer Res 60(4): 1014-1020. 
Bader, H., H. Ringsdorf, et al. (1984). "Watersoluble polymers in medicine." Die Angewandte 
Makromolekulare Chemie 123(1): 457-485. 
Bae, Y. H. and K. Park (2011). "Targeted drug delivery to tumors: myths, reality and possibility." J 
Control Release 153(3): 198-205. 
Baguley, B. C., K. O. Hicks, et al. (2002). "Chapter15 tumor cell cultures in drug development." 
ANTICANCER DRUG DEVELOPMENT: 269-284. 
Bakker-Woudenberg, I. A., A. F. Lokerse, et al. (1992). "Enhanced localization of liposomes with 
prolonged blood circulation time in infected lung tissue." Biochim Biophys Acta 14(4): 
318-326. 
Balamuralidhara, V., T. M. Pramodkumar, et al. (2011). "pH Sensitive Drug Delivery Systems: A 
Review." Am. J. Drug Discovery Dev. 1: 24-48. 
Balci, M. (2005). Basic 1H-and 13C-NMR spectroscopy, Elsevier. 
Ballou, B., B. C. Lagerholm, et al. (2004). "Noninvasive imaging of quantum dots in mice." Bioconjug 
Chem 15(1): 79-86. 
Baptista, P., E. Pereira, et al. (2008). "Gold nanoparticles for the development of clinical diagnosis 
methods." Anal Bioanal Chem 391(3): 943-950. 
Barenholz, Y., S. Amselem, et al. (1993). "Stability of liposomal-doxorubicin formulation: problems and 
prospects." Med Res Rev 13: 449-491. 
A.xvii 
Barnett, S. B., G. R. ter Haar, et al. (1994). "Current status of research on biophysical effects of 
ultrasound." Ultrasound Med Biol 20(3): 205-218. 
Bawarski, W. E., E. Chidlowsky, et al. (2008). "Emerging nanopharmaceuticals." Nanomedicine 4(4): 
273-282. 
Bekers, O., J. H. Beijnen, et al. (1990). "Inclusion complexation of doxorubicin and daunorubicin with 
cyclodextrins." J Pharm Biomed Anal 8(8-12): 671-674. 
Bekers, O., J. H. Beijnen, et al. (1990). "Inclusion complexation of doxorubicin and daunorubicin with 
cyclodextrins." Journal of Pharmaceutical and Biomedical Analysis 8(8–12): 671-674. 
Bekers, O., J. H. Beijnen, et al. (1991). "Effect of cyclodextrin complexation on the chemical stability of 
doxorubicin and daunorubicin in aqueous solutions." International Journal of Pharmaceutics 
72(2): 123-130. 
Belotti, D. (1996). "The microtubule-affecting drug paclitaxel has antiangiogenic activity." Clinical 
Cancer Research 2(11): 1843. 
Bender, M. L. and M. Komiyama (1978). "Cyclodextrin Chemistry." Springer-Verlag, Berlin. 
Bergeron, R. J. (1984). "Cycloamylose-substrate binding. In: Attwood, J.L., Bavies, J.E.D., MacNicol, 
D.D. (Eds.)." Inclusion Compounds. Academic Press, London: 391-443. 
Berridge, M. and C. Rao (1993). "Characterization of the cellular reduction of 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, 
substrate dependence, and involvement of mitochondrial electron transport in MTT 
reduction. ." Archives Biochem Biophys 303: 474-482. 
Bhardwaj, R., R. T. Dorr, et al. (2000). "Approaches to reducing toxicity of parenteral anticancer drug 
formulations using cyclodextrins." PDA J Pharm Sci Technol 54(3): 233-239. 
Bianco, A. and M. Prato (2003). "Can Carbon Nanotubes be Considered Useful Tools for Biological 
Applications?" Advanced Materials 15(20): 1765-1768. 
Blanco, E., A. Hsiao, et al. (2011). "Nanomedicine in cancer therapy: innovative trends and prospects." 
Cancer Sci 102(7): 1247-1252. 
Blanco, E., C. W. Kessinger, et al. (2009). "Multifunctional micellar nanomedicine for cancer therapy." 
Exp Biol Med (Maywood) 234(2): 123-131. 
Blume, G. and G. Cevc (1990). "Liposomes for the sustained drug release in vivo." Biochim Biophys 
Acta 2(1): 91-97. 
Blume, G., G. Cevc, et al. (1993). "Specific targeting with poly(ethylene glycol)-modified liposomes: 
coupling of homing devices to the ends of the polymeric chains combines effective target 
binding with long circulation times." Biochim Biophys Acta 18(1): 180-184. 
Bohmer, M. R., C. H. Chlon, et al. (2010). "Focused ultrasound and microbubbles for enhanced 
extravasation." J Control Release 148(1): 18-24. 
Bontha, S., A. V. Kabanov, et al. (2006). "Polymer micelles with cross-linked ionic cores for delivery of 
anticancer drugs." Journal of Controlled Release 114(2): 163-174. 
Bosman, A. W., H. M. Janssen, et al. (1999). "About Dendrimers: Structure, Physical Properties, and 
Applications." Chem Rev 99(7): 1665-1688. 
Brewster, M. E. and T. Loftsson (2007). "Cyclodextrins as pharmaceutical solubilizers." Advanced Drug 
Delivery Reviews 59(7): 645-666. 
Burgess, A. and K. Hynynen (2013). "Noninvasive and targeted drug delivery to the brain using focused 
ultrasound." ACS Chem Neurosci 4(4): 519-526. 
Busbee, B. D., S. O. Obare, et al. (2003). "An Improved Synthesis of High-Aspect-Ratio Gold 
A.xviii 
Nanorods." Advanced Materials 15(5): 414-416. 
Busch, K. W., I. M. Swamidoss, et al. (2003). "Determination of the enantiomeric composition of guest 
molecules by chemometric analysis of the UV-visible spectra of cyclodextrin guest-host 
complexes." J Am Chem Soc 125(7): 1690-1691. 
Cabuy, E. (2011). "Hyperthermia in cancer treatment " Reliable Cancer Therapies. Energy based 
therapies 1(2): 1-48. 
Castle, J., M. Butts, et al. (2013). "Ultrasound-mediated targeted drug delivery: recent success and 
remaining challenges." Am J Physiol Heart Circ Physiol 304(3): 30. 
Chavez-Gutierrez, L., L. Bammens, et al. (2012). "The mechanism of gamma-Secretase dysfunction in 
familial Alzheimer disease." Embo J 31(10): 2261-2274. 
Chen, R. J., S. Bangsaruntip, et al. (2003). "Noncovalent functionalization of carbon nanotubes for 
highly specific electronic biosensors." Proceedings of the National Academy of Sciences 
100(9): 4984-4989. 
Chen, Y., T. Xu, et al. (2005). "Temperature dependence of the inclusion–dissociation behavior of the 
inclusion complexes between cationic substituted 3H-indoles and β-cyclodextrin: Design of a 
novel type of semi-rotaxane." Journal of Photochemistry and Photobiology A: Chemistry 
173(1): 42-50. 
Cheng, J. F.-K., Kay T., K. F.-D. Khin, Mark E., et al. (2004). "Antitumor activity of beta-cyclodextrin 
polymer-camptothecin conjugates." Mol Pharm 1(3): 183-193. 
Cheng, J. F.-K., Kay T., K. F.-J. Khin, Gregory S., et al. (2003). "Synthesis of linear, 
beta-cyclodextrin-based polymers and their camptothecin conjugates." Bioconjug Chem 14(5): 
1007-1017. 
Cheng, Y., C. S. A, et al. (2008). "Highly efficient drug delivery with gold nanoparticle vectors for in 
vivo photodynamic therapy of cancer." J Am Chem Soc 130(32): 10643-10647. 
Cheng, Y., J. Wang, et al. (2008). "Pharmaceutical applications of dendrimers: promising nanocarriers 
for drug delivery." Front Biosci 13: 1447-1471. 
Choi, Y., T. Thomas, et al. (2005). "Synthesis and functional evaluation of DNA-assembled 
polyamidoamine dendrimer clusters for cancer cell-specific targeting." Chem Biol 12(1): 35-43. 
Collins, P. G., K. Bradley, et al. (2000). "Extreme Oxygen Sensitivity of Electronic Properties of Carbon 
Nanotubes." Science 287(5459): 1801-1804. 
Connors, K. A. (1995). "Population characteristics of cyclodextrin complex stabilities in aqueous 
solution." J Pharm Sci 84(7): 843-848. 
Connors, K. A. (1997). "The Stability of Cyclodextrin Complexes in Solution." Chem Rev 97(5): 
1325-1358. 
Conti, L., P. Grimaldi, et al. (2010). "Effects induced in cells by ultrasound revealed by ATR-FTIR 
spectroscopy." Vibrational Spectroscopy 52(1): 79-84. 
Corsi, C. (2014). Infrared: A Key Technology for Security Systems. Sensors. F. Baldini, A. D’Amico, C. 
Di Nataleet al, Springer New York. 162: 37-42. 
Cory, A. H., T. C. Owen, et al. (1991). "Use of an aqueous soluble tetrazolium/formazan assay for cell 
growth assays in culture." Cancer Commun 3(7): 207-212. 
Coussios, C. C., C. H. Farny, et al. (2007). "Role of acoustic cavitation in the delivery and monitoring of 
cancer treatment by high-intensity focused ultrasound (HIFU)." Int J Hyperthermia 23(2): 
105-120. 
Cramer, F. (1954). "Einschlussverbindungen." Springer-Verlag, Berlin. 
A.xix 
Dai, X., Z. Yue, et al. (2008). "Fluorescence intensity and lifetime imaging of free and 
micellar-encapsulated doxorubicin in living cells." Nanomedicine 4(1): 49-56. 
Davis, M. (2009). "- Design and development of IT-101, a cyclodextrin-containing polymer conjugate of 
camptothecin." Adv Drug Deliv Rev 61(13): 1189-1192. 
Davis, M. E., Z. G. Chen, et al. (2008). "Nanoparticle therapeutics: an emerging treatment modality for 
cancer." Nat Rev Drug Discov 7(9): 771-782. 
Davis, M. E., H. Gonzalez, et al. (2004). "Cyclodextrin-based pharmaceutics: past, present and future." 
Nat Rev Drug Discov 3(12): 1023-1035. 
De Jong, N. (2002). "Mechanical index." European Journal of Echocardiography 3(1): 73-74. 
Deckers, R. and C. T. Moonen (2010). "Ultrasound triggered, image guided, local drug delivery." J 
Control Release 148(1): 25-33. 
Deckers, R. and C. T. W. Moonen (2010). "Ultrasound triggered, image guided, local drug delivery." 
Journal of Controlled Release 148(1): 25-33. 
Deckers, R., C. Rome, et al. (2008). "The role of ultrasound and magnetic resonance in local drug 
delivery." J Magn Reson Imaging 27(2): 400-409. 
Deng, C. X., F. Sieling, et al. (2004). "Ultrasound-induced cell membrane porosity." Ultrasound Med 
Biol 30(4): 519-526. 
Denkewalter, R. G., J. F. Kolc, et al. (1981). "Macromolecular highly branched homogeneous 
compound." Allied Corporation. 
Derfus, A. M., W. C. W. Chan, et al. (2004). "Probing the Cytotoxicity of Semiconductor Quantum 
Dots." Nano Letters 4(1): 11-18. 
Dewhirst, M. W., C. D. Landon, et al. (2013). "Novel approaches to treatment of hepatocellular 
carcinoma and hepatic metastases using thermal ablation and thermosensitive liposomes." 
Surgical oncology clinics of North America 22(3): 545-561. 
Dick, E. A. and W. M. Gedroyc (2010). "ExAblate magnetic resonance-guided focused ultrasound 
system in multiple body applications." Expert Rev Med Devices 7(5): 589-597. 
Djukovic, D., G. A. Nagana Gowda, et al. (2013). Chapter 18 - Mass Spectrometry and NMR 
Spectroscopy–Based Quantitative Metabolomics. Proteomic and Metabolomic Approaches to 
Biomarker Discovery. H. J. Issaq and T. D. Veenstra. Boston, Academic Press: 279-297. 
Donald, A. T. (2005). Dendrimeric Supramolecular and Supramacromolecular Assemblies. 
Supramolecular Polymers, Second Edition, CRC Press. 
Draper, D. O., J. C. Castel, et al. (1995). "Rate of temperature increase in human muscle during 1 MHz 
and 3 MHz continuous ultrasound." J Orthop Sports Phys Ther 22(4): 142-150. 
Dreher, M. R., D. Raucher, et al. (2003). "Evaluation of an elastin-like polypeptide-doxorubicin 
conjugate for cancer therapy." J Control Release 91(1-2): 31-43. 
Dromi, S., V. Frenkel, et al. (2007). "Pulsed-high intensity focused ultrasound and low 
temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect." 
Clin Cancer Res 13(9): 2722-2727. 
Drummond, D. C., C. O. Noble, et al. (2008). "Pharmacokinetics and in vivo drug release rates in 
liposomal nanocarrier development." J Pharm Sci 97(11): 4696-4740. 
Duck, F. A., A. C. Baker, et al. (1998). Ultrasound in Medicine, Taylor & Francis. 
Duncan, R. (2003). "The dawning era of polymer therapeutics." Nat Rev Drug Discov 2(5): 347-360. 
Dupont, J., C. S. Consorti, et al. (2003). Preparation of 1-Butyl-3-Methyl Imidazolium-Based Room 
Temperature Ionic Liquids. Organic Syntheses, John Wiley & Sons, Inc. 
A.xx 
E.Buhleier, W. W., F. Vögtle (1978). ""Cascade"- and "Nonskid-Chain-like" Syntheses of Molecular 
Cavity Topologies." Synthesis 2: 155-158. 
Eisenbrey, J. R., P. Huang, et al. (2009). "Ultrasound triggered cell death in vitro with doxorubicin 
loaded poly lactic-acid contrast agents." Ultrasonics 49(8): 628-633. 
El-Sayed, M. E., A. S. Hoffman, et al. (2005). "Rational design of composition and activity correlations 
for pH-sensitive and glutathione-reactive polymer therapeutics." J Control Release 101(1-3): 
47-58. 
El Fegoun, A. B., E. Barret, et al. (2011). "Focal therapy with high-intensity focused ultrasound for 
prostate cancer in the elderly. A feasibility study with 10 years follow-up." Int Braz J Urol 
37(2): 213-219. 
Elwood, P. C. (1989). "Molecular cloning and characterization of the human folate-binding protein 
cDNA from placenta and malignant tissue culture (KB) cells." J Biol Chem 264(25): 
14893-14901. 
Emara S, M. I., Tamura K, Razee S, Masujima T, Mohamed HA, El-Gizawy SM, El-Rabbat NA. (2000). 
"Effect of cyclodextrins on the stability of adriamycin, adriamycinol, adriamycinone and 
daunomycin." Talanta 51(2): 359-364. 
Esenaliev, R. O., I. V. Larina, et al. (2001). Cavitation-induced drug delivery in tumors for cancer 
chemotherapy: animal studies. 
Fang, X., G. Mark, et al. (1996). "OH radical formation by ultrasound in aqueous solutions Part I: the 
chemistry underlying the terephthalate dosimeter." Ultrasonics Sonochemistry 3(1): 57-63. 
Farlow, J., D. Seo, et al. (2013). "Formation of targeted monovalent quantum dots by steric exclusion." 
Nat Meth advance online publication. 
Farokhzad, O. C. and R. Langer (2009). "Impact of nanotechnology on drug delivery." ACS Nano 3(1): 
16-20. 
Feril, L., Jr., K. Tachibana, et al. (2010). "Hypotonia-induced cell swelling enhances ultrasound-induced 
mechanical damage to cancer cells." Journal of Medical Ultrasonics 37(1): 3-8. 
Feril, L. B., Jr., T. Kondo, et al. (2002). "Enhancement of hyperthermia-induced apoptosis by 
non-thermal effects of ultrasound." Cancer Lett 178(1): 63-70. 
Fernandez, A.-M., K. V. derpoorten, et al. (2001). 
"N-Succinyl-(β-alanyl-l-leucyl-l-alanyl-l-leucyl)doxorubicin:  An Extracellularly 
Tumor-Activated Prodrug Devoid of Intravenous Acute Toxicity." J. Med. Chem. 44: 
3750-3753. 
Ferrari, M. (2005). "Cancer nanotechnology: opportunities and challenges." Nat Rev Cancer 5(3): 
161-171. 
Finlay, G. J., W. R. Wilson, et al. (1986). "Comparison of in vitro activity of cytotoxic drugs towards 
human carcinoma and leukaemia cell lines." Eur J Cancer Clin Oncol 22(6): 655-662. 
Fogh, J. and B. C. Giovanella (1978). "The Nude Mouse in Experimental and Clinical Research 
(Vol.1)." (eds) Academic Press. 
Fogh, J. and B. C. Giovanella (1982). "The Nude Mouse in Experimental and Clinical Research(Vol.2)." 
(eds) Academic Press. 
Fréchet, J. M. J., Tomalia, D.A. (2001). "Dendrimers and Other Dendritic Polymers." Wiley, Chichester. 
French, D., Pulley, A.O., Effenberger, J.A., Rougvie, M.A., Abdullah, M. (1965). "Studies on the 
Schardinger dextrins. XII. The molecular size and structure of the δ-, ε-, ζ-, and η-dextrins. ." 
Arch. Biochem. Biophys. 111: 153-160. 
A.xxi 
Frenkel, V. (2008). "Ultrasound mediated delivery of drugs and genes to solid tumors." Adv Drug Deliv 
Rev 60(10): 1193-1208. 
Frenkel, V., A. Etherington, et al. (2006). "Delivery of liposomal doxorubicin (Doxil) in a breast cancer 
tumor model: investigation of potential enhancement by pulsed-high intensity focused 
ultrasound exposure." Acad Radiol 13(4): 469-479. 
Freudenberg, K. and F. Cramer (1948). "Die Konstitution der Schardinger-Dextrine α, β und γ. Z." 
Naturforsch 3b: 464. 
Freudenberg, K., Cramer, F., Plieninger, H. (1953). "Verfahren zur Herstellung von 
Einschlusverbindungen physiologisch wirksamer organischer Verbindungen." Knoll A.-G. 
Chemische Fabriken, Germany, Patent No. 895,769. 
Freudenberg, K. and R. Jacobi (1935). "U  ¨ber Schardinger Dextrine aus Sta r¨ke." Liebigs Ann. Chem. 
518: 102-108. 
Fridborg, H., P. Nygren, et al. (1995). "Relationship between pharmacokinetic parameters in patients 
and cytotoxicity in vitro of standard and investigational anticancer drugs." Anticancer Drugs 
6(1): 64-69. 
Fruehauf, J. H., W. Back, et al. (2008). "High-intensity focused ultrasound for the targeted destruction of 
uterine tissues: experiences from a pilot study using a mobile HIFU unit." Arch Gynecol Obstet 
277(2): 143-150. 
Fry, W. J. (1950). "Physical factors involved in ultrasonically Induced Changes in Living Systems: I. 
Identification of Non-Temperature Effects." J ACOUST SOC AMER 22(6): 867-876. 
Fujiwara, A., T. Hoshino, et al. (1985). "Anthracycline Antibiotics." Critical Reviews in Biotechnology 
3(2): 133-157. 
Furgeson, D. Y., M. R. Dreher, et al. (2006). "Structural optimization of a "smart" 
doxorubicin-polypeptide conjugate for thermally targeted delivery to solid tumors." J Control 
Release 110(2): 362-369. 
Furnari, B., N. Rhind, et al. (1997). "Cdc25 mitotic inducer targeted by chk1 DNA damage checkpoint 
kinase." Science 277(5331): 1495-1497. 
Furusawa, H., K. Namba, et al. (2007). "The evolving non-surgical ablation of breast cancer: MR guided 
focused ultrasound (MRgFUS)." Breast Cancer 14(1): 55-58. 
Gaber, M. H., N. Z. Wu, et al. (1996). "Thermosensitive liposomes: extravasation and release of 
contents in tumor microvascular networks." Int J Radiat Oncol Biol Phys 36(5): 1177-1187. 
Gabizon, A., R. Catane, et al. (1994). "Prolonged circulation time and enhanced accumulation in 
malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes." 
Cancer Res 54(4): 987-992. 
Gabizon, A., R. Chisin, et al. (1991). "Pharmacokinetic and imaging studies in patients receiving a 
formulation of liposome-associated adriamycin." Br. J. Cancer 64(6): 1125-1132. 
Gabizon, A., T. Peretz, et al. (1989). "Systemic administration of doxorubicin-containing liposomes in 
cancer patients: a phase I study." Eur J Cancer Clin Oncol 25(12): 1795-1803. 
Gao, X., Y. Cui, et al. (2004). "In vivo cancer targeting and imaging with semiconductor quantum dots." 
Nature Biotechnology 22(8): 969-976. 
Gao, X., L. Yang, et al. (2005). "In vivo molecular and cellular imaging with quantum dots." Current 
Opinion in Biotechnology 16(1): 63-72. 
Gatenby, R. A., E. T. Gawlinski, et al. (2006). "Acid-mediated tumor invasion: a multidisciplinary 
study." Cancer Res 66(10): 5216-5223. 
A.xxii 
Gatenby, R. A. and R. J. Gillies (2004). "Why do cancers have high aerobic glycolysis?" Nat Rev 
Cancer 4(11): 891-899. 
Gaucher, G., M. H. Dufresne, et al. (2005). "Block copolymer micelles: preparation, characterization 
and application in drug delivery." J Control Release 109(1-3): 169-188. 
Gaur, S., L. Chen, et al. (2012). "Preclinical study of the cyclodextrin-polymer conjugate of 
camptothecin CRLX101 for the treatment of gastric cancer." Nanomedicine: Nanotechnology, 
Biology and Medicine 8(5): 721-730. 
Gerlóczy, A., S. Antal, et al. (1988). Percutaneous Absorption of Heptakis-(2,6-Di-O-14C-Methyl)-β 
-Cyclodextrin in Rats. Proceedings of the Fourth International Symposium on Cyclodextrins. O. 
Huber and J. Szejtli, Springer Netherlands. 5: 415-420. 
Gerold, B., D. Gourevich, et al. (2012). Applicator for in-vitro ultrasound-activated targeted drug 
delivery. 11TH INTERNATIONAL SYMPOSIUM ON THERAPEUTIC ULTRASOUND, 
AIP Publishing. 
Gerweck, L. E. and K. Seetharaman (1996). "Cellular pH Gradient in Tumor versus Normal Tissue - 
Potential Exploitation for the treatment of cancer." CANCER RESEARCH 56: 1194-1198. 
Gianfelice, D., A. Khiat, et al. (2003). "MR imaging-guided focused US ablation of breast cancer: 
histopathologic assessment of effectiveness-- initial experience." Radiology 227(3): 849-855. 
Gilchrist, A., M. Bunemann, et al. (1999). "A dominant-negative strategy for studying roles of G 
proteins in vivo." J Biol Chem 274(10): 6610-6616. 
Gillies, E. R. and J. M. Frechet (2005). "Dendrimers and dendritic polymers in drug delivery." Drug 
Discov Today 10(1): 35-43. 
Gillies, R. J., N. Raghunand, et al. (2002). "MRI of the tumor microenvironment." J Magn Reson 
Imaging 16(4): 430-450. 
Giordano, F., C. Novak, et al. (2001). "Thermal analysis of cyclodextrins and their inclusion 
compounds." Thermochimica Acta 380: 123-151. 
Giraudeau, P., N. Guignard, et al. (2007). "Optimization of homonuclear 2D NMR for fast quantitative 
analysis: Application to tropine–nortropine mixtures." Journal of Pharmaceutical and 
Biomedical Analysis 43(4): 1243-1248. 
Gong, J., M. Chen, et al. (2012). "Polymeric micelles drug delivery system in oncology." J Control 
Release 159(3): 312-323. 
Gorin, B. I., R. J. Riopelle, et al. (1996). "Efficient perfacial derivatization of cyclodextrins at the 
primary face." Tetrahedron Letters 37(27): 4647-4650. 
Gourevich, D., O. Dogadkin, et al. (2013). "Ultrasound-mediated targeted drug delivery with a novel 
cyclodextrin-based drug carrier by mechanical and thermal mechanisms." J Control Release 
170(3): 316-324. 
Grazú, V., M. Moros, et al. (2012). "Chapter 14 – Nanocarriers as Nanomedicines: Design Concepts and 
Recent Advances." Frontiers of Nanoscience: 337-440. 
Greenleaf, W. J., M. E. Bolander, et al. (1998). "Artificial cavitation nuclei significantly enhance 
acoustically induced cell transfection." Ultrasound Med Biol 24(4): 587-595. 
Gregoriadis, G. (1995). "Engineering targeted liposomes: progress and problems." Trends in Biotechnol. 
13: 527-537. 
Gregoriadis, G. and J. Wiley (1988). "Liposomes as drug carriers: recent trends and progress." Chicester: 
52-61. 
Gros, L., H. Ringsdorf, et al. (1981). "Polymeric Antitumor Agents on a Molecular and on a Cellular 
A.xxiii 
Level?" Angewandte Chemie International Edition in English 20(4): 305-325. 
Grosse, P. Y., F. Bressolle, et al. (1999). "Methyl-β-cyclodextrin and doxorubicin pharmacokinetics and 
tissue concentrations following bolus injection of these drugs alone or together in the rabbit." 
International Journal of Pharmaceutics. 180(2): 215-223. 
Guzman, H. R., D. X. Nguyen, et al. (2001). "Ultrasound-mediated disruption of cell membranes. I. 
Quantification of molecular uptake and cell viability." J Acoust Soc Am 110(1): 588-596. 
Guzman, H. R., D. X. Nguyen, et al. (2002). "Equilibrium loading of cells with macromolecules by 
ultrasound: effects of molecular size and acoustic energy." J Pharm Sci 91(7): 1693-1701. 
Hainfeld, J., D. Slatkin, et al. (2004). "The use of gold nanoparticles to enhance radiotherapy in mice." 
Phys Med Biol 49(18): N309-315. 
Hamaguchi, T., T. Doi, et al. (2010). "Phase I study of NK012, a novel SN-38-incorporating micellar 
nanoparticle, in adult patients with solid tumors." Clin Cancer Res 16(20): 5058-5066. 
Hamaguchi, T., K. Kato, et al. (2007). "A phase I and pharmacokinetic study of NK105, a 
paclitaxel-incorporating micellar nanoparticle formulation." Br J Cancer 97(2): 170-176. 
Hamaguchi, T., Y. Matsumura, et al. (2005). "NK105, a paclitaxel-incorporating micellar nanoparticle 
formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel." 
Br J Cancer 92(7): 1240-1246. 
Han, G., P. Ghosh, et al. (2007). Multi-Functional Gold Nanoparticles for Drug Delivery. 
Bio-Applications of Nanoparticles. W. W. Chan, Springer New York. 620: 48-56. 
Han, Y. W., A. Ikegami, et al. (2007). "Sonoporation is an efficient tool for intracellular fluorescent 
dextran delivery and one-step double-crossover mutant construction in Fusobacterium 
nucleatum." Appl Environ Microbiol 73(11): 3677-3683. 
Hansen, C. B., G. Y. Kao, et al. (1995). "Attachment of antibodies to sterically stabilized liposomes: 
evaluation, comparison and optimization of coupling procedures." Biochimica et Biophysica 
Acta (BBA) - Biomembranes 1239(2): 133-144. 
Harwood, L. M. (1989). Experimental organic chemistry : principles and practice. C. Moody. Oxford 
[England] ;, Blackwell Scientific Publications: 127-132. 
Hattori, K., A. Kenmoku, et al. (2006). "Saccharide-branched Cyclodextrins as Targeting Drug 
Carriers." J. Incl. Phen. Macr. Chem. 56: 9-16. 
Hawker, C. J. and J. M. J. Frechet (1990). "Preparation of polymers with controlled molecular 
architecture. A new convergent approach to dendritic macromolecules." Journal of the 
American Chemical Society 112(21): 7638-7647. 
Heath, T. D., R. T. Fraley, et al. (1980). "Antibody targeting of liposomes: cell specificity obtained by 
conjugation of F(ab')2 to vesicle surface." Science 210(4469): 539-541. 
Heath, T. D., J. A. Montgomery, et al. (1983). "Antibody-targeted liposomes: increase in specific 
toxicity of methotrexate-gamma-aspartate." Proc Natl Acad Sci U S A 80(5): 1377-1381. 
Hensel, K., M. P. Mienkina, et al. (2011). "Analysis of ultrasound fields in cell culture wells for in vitro 
ultrasound therapy experiments." Ultrasound Med Biol 37(12): 2105-2115. 
Hernot, S. and A. L. Klibanov (2008). "Microbubbles in ultrasound-triggered drug and gene delivery." 
Adv Drug Deliv Rev 60(10): 1153-1166. 
Herschel, W. (1800). "Experiments on the refrangibility of the visible rays of the sun." Philosophical 
Transactions of the Royal Society of London 90: 284-292. 
Hill, C. R. and G. R. ter Haar (1995). "Review article: high intensity focused ultrasound--potential for 
cancer treatment." Br J Radiol 68(816): 1296-1303. 
A.xxiv 
Hillebrenner, H., F. Buyukserin, et al. (2006). "Template synthesized nanotubes for biomedical delivery 
applications." Nanomedicine 1(1): 39-50. 
Hirayama, F., M. Yamamoto, et al. (1992). "Acid‐catalyzed hydrolysis of maltosyl‐β‐cyclodextrin." 
Journal of Pharmaceutical Science 89(9): 913-916. 
Holister, P., C. R. Vas, et al. (2003). "Dendrimers." Cientifica Technology White Papers nr.6. 
Hoskins, P., K. Martin, et al. (2010). Diagnostic Ultrasound: Physics and Equipment, New York: 
Cambridge University Press. 
Howarth, M., W. Liu, et al. (2008). "Monovalent, reduced-size quantum dots for imaging receptors on 
living cells." Nat Methods 5(5): 397-399. 
Hrkach, J., D. Von Hoff, et al. (2012). "Preclinical development and clinical translation of a 
PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile." Sci 
Transl Med 4(128): 3003651. 
Hu, C. M. and L. Zhang (2012). "Nanoparticle-based combination therapy toward overcoming drug 
resistance in cancer." Biochem Pharmacol 83(8): 1104-1111. 
Huang, X., P. Jain, et al. (2007). "Gold nanoparticles: interesting optical properties and recent 
applications in cancer diagnostics and therapy." Nanomedicine 2(5): 681-693. 
Huber, P. E., J. W. Jenne, et al. (2001). "A new noninvasive approach in breast cancer therapy using 
magnetic resonance imaging-guided focused ultrasound surgery." Cancer Res 61(23): 
8441-8447. 
Hundt, W., S. Steinbach, et al. (2009). "The effect of high intensity focused ultrasound on luciferase 
activity on two tumor cell lines in vitro, under the control of a CMV promoter." Ultrasonics 
49(3): 312-318. 
Husain, N., T. T. Ndou, et al. (1992). "Complexation of doxorubicin with β- and γ-cyclodextrins." 
Applied Spectroscopy 46(4): 652-658. 
Husband, J. and A. Padhani (2006). "Recommendations for Cross-Sectional Imaging in Cancer 
Management:  
Computed Tomography - CT  
Magnetic Resonance Imaging - MRI  
Positron Emission Tomography - PET-CT." Royal College of Radiologists(2). 
Husseini, G. A. and W. G. Pitt (2008). "Micelles and Nanoparticles for Ultrasonic Drug and Gene 
Deliver." Adv Drug Deliv Rev. 60(10): 1137-1152. 
Husseini, G. A. and W. G. Pitt (2008). "Micelles and nanoparticles for ultrasonic drug and gene 
delivery." Adv Drug Deliv Rev 60(10): 1137-1152. 
Ibsen, S., M. Benchimol, et al. (2011). "A novel nested liposome drug delivery vehicle capable of 
ultrasound triggered release of its payload." J Control Release 155(3): 358-366. 
Illing, R. O., J. E. Kennedy, et al. (2005). "The safety and feasibility of extracorporeal high-intensity 
focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western 
population." Br J Cancer 93(8): 890-895. 
Irie, T. and K. Uekama (1997). "Pharmaceutical applications of cyclodextrins. III. Toxicological issues 
and safety evaluation." J Pharm Sci 86(2): 147-162. 
Jain, R. K. (1999). Transport of molecules, particles, and cells in solid tumors: 241-263. 
Jain, R. K. (2001). "Delivery of molecular medicine to solid tumors: Lessons from in vivo imaging of 
gene expression and function." Journal of Controlled Release 74(1-3): 7-25. 
James, N. D., R. J. Coker, et al. (1994). "Liposomal doxorubicin (Doxil): An effective new treatment for 
A.xxv 
Kaposi's sarcoma in AIDS." Clinical Oncology 6(5): 294-296. 
James R. Dewald, D. A. T. (1983). "Dense star polymers having core, core branches, terminal groups." 
The Dow Chemical Corporation. 
Jemal, A., R. Siegel, et al. (2010). "Cancer statistics, 2010." CA Cancer J Clin 60(5): 277-300. 
Jenne, J. W., T. Preusser, et al. (2012). "High-intensity focused ultrasound: Principles, therapy guidance, 
simulations and applications." Zeitschrift für Medizinische Physik 22(4): 311-322. 
Johannsen, M., U. Gneveckow, et al. (2007). "Thermotherapy of prostate cancer using magnetic 
nanoparticles: feasibility, imaging, and three-dimensional temperature distribution." Eur Urol 
52(6): 1653-1661. 
Jolesz, F. A. and N. McDannold (2008). "Current status and future potential of MRI-guided focused 
ultrasound surgery." J Magn Reson Imaging 27(2): 391-399. 
Jolesz, F. A. and N. J. McDannold (2014). "Magnetic resonance-guided focused ultrasound: a new 
technology for clinical neurosciences." Neurol Clin 32(1): 253-269. 
Jones, M.-C. and J.-C. Leroux (1999). "Polymeric micelles – a new generation of colloidal drug 
carriers." European Journal of Pharmaceutics and Biopharmaceutics 48(2): 101-111. 
Kamaly, N., T. Kalber, et al. (2009). "Folate Receptor Targeted Bimodal Liposomes for Tumor 
Magnetic Resonance Imaging." Bioconjugate Chemistry 20(4): 648-655. 
Kamimura, M., T. Furukawa, et al. (2013). "Enhanced intracellular drug delivery of pH-sensitive 
doxorubicin/poly(ethylene glycol)-block-poly(4-vinylbenzylphosphonate) nanoparticles in 
multi-drug resistant human epidermoid KB carcinoma cells." Biomaterials Science 1(4): 
361-367. 
Kanazawa, S., T. Furuki, et al. "Measurement of OH Radicals in Aqueous Solution Produced by 
Atmospheric-pressure LF Plasma Jet." 
Kang, K., S. H. Oh, et al. (2011). "A novel topoisomerase inhibitor, daurinol, suppresses growth of 
HCT116 cells with low hematological toxicity compared to etoposide." Neoplasia 13(11): 
1043-1057. 
Karino, T., S. Koga, et al. (1988). "Experimental studies of the effects of local hyperthermia on blood 
flow, oxygen pressure and pH in tumors." Jpn J Surg 18(3): 276-283. 
Karshafian, R., P. D. Bevan, et al. (2009). "Sonoporation by ultrasound-activated microbubble contrast 
agents: effect of acoustic exposure parameters on cell membrane permeability and cell 
viability." Ultrasound Med Biol 35(5): 847-860. 
Kasai, S., H. Nagasawa, et al. (2002). "Design and synthesis of antiangiogenic/heparin-binding arginine 
dendrimer mimicking the surface of endostatin." Bioorg Med Chem Lett 12(6): 951-954. 
Keenan, J., Y. Liang, et al. (2004). "Two-deoxyglucose as an anti-metabolite in human carcinoma cell 
line RPMI-2650 and drug-resistant variants." Anticancer Res 24(2A): 433-440. 
Kennedy, J. E., G. R. Ter Haar, et al. (2003). "High intensity focused ultrasound: surgery of the future?" 
Br J Radiol 76(909): 590-599. 
Kerry K. Karukstis, E. H. Z. T., Jennifer A. Whiles, and R. J. Rosenfeld (1998). "Deciphering the 
fluorescence signature of daunomycin and doxorubicin." Biophysical Chemistry 73: 249-263. 
Khan, M. K., S. S. Nigavekar, et al. (2005). "In vivo biodistribution of dendrimers and dendrimer 
nanocomposites -- implications for cancer imaging and therapy." Technol Cancer Res Treat 
4(6): 603-613. 
Kim, C. S., G. Y. Tonga, et al. (2013). "Inorganic nanosystems for therapeutic delivery: status and 
prospects." Adv Drug Deliv Rev 65(1): 93-99. 
A.xxvi 
Kim, J. W. and C. V. Dang (2006). "Cancer's molecular sweet tooth and the Warburg effect." Cancer 
Res 66(18): 8927-8930. 
Kim, S. Y., I. G. Shin, et al. (1998). "Preparation and characterization of biodegradable nanospheres 
composed of methoxy poly(ethylene glycol) and DL-lactide block copolymer as novel drug 
carriers." J Control Release 56(1-3): 197-208. 
Kim, T. Y., D. W. Kim, et al. (2004). "Phase I and pharmacokinetic study of Genexol-PM, a 
Cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced 
malignancies." Clinical Cancer Research 10(11): 3708-3716. 
Kleinstreuer, C., E. Childress, et al. (2013). Chapter 10 - Targeted Drug Delivery: Multifunctional 
Nanoparticles and Direct Micro-Drug Delivery to Tumors. Transport in Biological Media. S. M. 
Becker and A. V. Kuznetsov. Boston, Elsevier: 391-416. 
Klibanov, A. L. (2006). "Microbubble contrast agents: targeted ultrasound imaging and 
ultrasound-assisted drug-delivery applications." Invest Radiol 41(3): 354-362. 
Klibanov, A. L., K. Maruyama, et al. (1990). "Amphipathic polyethyleneglycols effectively prolong the 
circulation time of liposomes." FEBS Lett 268(1): 235-237. 
Klingler, H. C., M. Susani, et al. (2008). "A novel approach to energy ablative therapy of small renal 
tumours: laparoscopic high-intensity focused ultrasound." Eur Urol 53(4): 810-816. 
Kobayashi, T., S. Tsukagoshi, et al. (1975). "Enhancement of the cancer chemotherapeutic effect of 
cytosine arabinoside entrapped in liposomes on mouse leukemia L-1210." Gann 66(6): 
719-720. 
Kohori, F., K. Sakai, et al. (1998). "Preparation and characterization of thermally responsive block 
copolymer micelles comprising poly(N-isopropylacrylamide-b-dl-lactide)." Journal of 
Controlled Release 55(1): 87-98. 
Kong, G., R. D. Braun, et al. (2000). "Hyperthermia enables tumor-specific nanoparticle delivery: effect 
of particle size." Cancer Res 60(16): 4440-4445. 
Kong, G., R. D. Braun, et al. (2001). "Characterization of the effect of hyperthermia on nanoparticle 
extravasation from tumor vasculature." Cancer Res 61(7): 3027-3032. 
Kong, J., N. R. Franklin, et al. (2000). "Nanotube Molecular Wires as Chemical Sensors." Science 
287(5453): 622-625. 
Koning, G. A., A. M. Eggermont, et al. (2010). "Hyperthermia and thermosensitive liposomes for 
improved delivery of chemotherapeutic drugs to solid tumors." Pharm Res 27(8): 1750-1754. 
Kost, J., K. Leong, et al. (1989). "Ultrasound-enhanced polymer degradation and release of incorporated 
substances." Proc Natl Acad Sci U S A 86(20): 7663-7666. 
Kostarelos, K., L. Lacerda, et al. (2007). "Cellular uptake of functionalized carbon nanotubes is 
independent of functional group and cell type." Nat Nano 2(2): 108-113. 
Kralova, J., Z. Konak, et al. (2010). "Porphyrin-Cyclodextrin Conjugates as a Nanosystem for Versatile 
Drug Delivery and Multimodal 
Cancer Therapy." J. Med. Chem. 53: 128-138. 
Kudo, N., K. Okada, et al. (2009). "Sonoporation by single-shot pulsed ultrasound with microbubbles 
adjacent to cells." Biophys J 96(12): 4866-4876. 
Kukowska-Latallo, J. F., K. A. Candido, et al. (2005). "Nanoparticle targeting of anticancer drug 
improves therapeutic response in animal model of human epithelial cancer." Cancer Res 65(12): 
5317-5324. 
Kumar, S. (2006). "Spectroscopy of Organic Compounds." Cosmic rays 10: 4. 
A.xxvii 
Kurkov, S. V. and T. Loftsson (2012). "Cyclodextrins." International Journal of Pharmaceutics 453(1): 
167-180. 
Kwon, G., S. Suwa, et al. (1994). "Enhanced tumor accumulation and prolonged circulation times of 
micelle-forming poly (ethylene oxide-aspartate) block copolymer-adriamycin conjugates." 
Journal of Controlled Release 29(1–2): 17-23. 
Lacerda, L., A. Bianco, et al. (2006). "Carbon nanotubes as nanomedicines: from toxicology to 
pharmacology." Adv Drug Deliv Rev 58(14): 1460-1470. 
Lakshmanan, S., G. K. Gupta, et al. (2013). "Physical energy for drug delivery; poration, concentration 
and activation." Adv Drug Deliv Rev 7(13): 00148-00148. 
Lam, C. W., J. T. James, et al. (2004). "Pulmonary toxicity of single-wall carbon nanotubes in mice 7 
and 90 days after intratracheal instillation." Toxicol Sci 77(1): 126-134. 
Langdon, S. P. (2003). "Cancer Cell Culture: Methods and Protocols." 
Langer, M. G. and A. Koitschev (2002). Chapter 7 The biophysics of sensory cells of the inner ear 
examined by atomic force microscopy and patch clamp. Methods in Cell Biology. H. J. K. H. 
Bhanu P. Jena, Academic Press. Volume 68: 141-169. 
Larina, I. V., B. M. Evers, et al. (2005). "Optimal drug and gene delivery in cancer cells by 
ultrasound-induced cavitation." Anticancer Res 25(1A): 149-156. 
Lasic, D. D. (1998). "Novel applications of liposomes." TIBTECH 16: 307-321. 
Lasic, D. D. and D. Papahadjopoulos (1998). "Medical Applications of Liposomes." Elsevier. 
Lavon, I. and J. Kost (2004). "Ultrasound and transdermal drug delivery." Drug Discovery Today 9(15): 
670-676. 
Leamon, C. P. and P. S. Low (1991). "Delivery of macromolecules into living cells: a method that 
exploits folate receptor endocytosis." Proceedings of the National Academy of Sciences 88(13): 
5572-5576. 
Lee, C. C., J. A. MacKay, et al. (2005). "Designing dendrimers for biological applications." Nat Biotech 
23(12): 1517-1526. 
Lee, E. S., K. Na, et al. (2003). "Polymeric micelle for tumor pH and folate-mediated targeting." J 
Control Release 91(1-2): 103-113. 
Lee, H. M., J. H. Hong, et al. (2006). "High-intensity focused ultrasound therapy for clinically localized 
prostate cancer." Prostate Cancer Prostatic Dis 9(4): 439-443. 
Lee, I. O. S.-K. (1998). "Photoluminescent determination of oxygen using metalloporphyrin-polymer 
sensing systems." Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 54: 
91-100. 
Lee, R. J. and P. S. Low (1994). "Delivery of liposomes into cultured KB cells via folate 
receptor-mediated endocytosis." J Biol Chem 269(5): 3198-3204. 
Lee, S.-K. and I. Okura (1998). "Photoluminescent determination of oxygen using 
metalloporphyrin-polymer sensing systems." Spectrochimica Acta Part A 54: 91-100. 
Lee, S.-K., Y. B. Shin, et al. (2001). "Highly Sensitive Optical Oxygen Sensing Material: 
Thin Silica Xerogel Doped with Tris(4,7-diphenyl-1,10-phenanthroline)ruthenium." Chemistry Letters: 
310-311. 
Lefor, A. T., S. Makohon, et al. (1985). "The effects of hyperthermia on vascular permeability in 
experimental liver metastasis." J Surg Oncol 28(4): 297-300. 
Lehrer, S. S. (1971). "Solute Perturbation of Protein Fluorescence The Quenching of the Tryptophyl 
Fluorescence of Model Compounds and of Lysozyme by Iodide Ion." BIOCHEMISTRY 
A.xxviii 
10(17): 3254-3263. 
Leighton, T. G. (1994). The Acoustic Bubble, Academic Press. 
Leighton, T. G. (1994). "The Acoustic Bubble." London: Academic ed. 
Leighton, T. G., B. T. Cox, et al. (2000). "The Rayleigh-like collapse of a conical bubble." J Acoust Soc 
Am 107(1): 130-142. 
Lentacker, I., I. De Cock, et al. (2013). "Understanding ultrasound induced sonoporation: Definitions 
and underlying mechanisms." Adv Drug Deliv Rev 21(13): 00267-00266. 
Leong, T., M. Ashokkumar, et al. (2011). "THE FUNDAMENTALS OF POWER ULTRASOUND-A 
REVIEW." Acoustics Australia 39(2). 
Leong, T. S., T. J. Wooster, et al. (2009). "Minimising oil droplet size using ultrasonic emulsification." 
Ultrason Sonochem 16(6): 721-727. 
Leserman, L. D., J. N. Weinstein, et al. (1980). "Receptor-mediated endocytosis of antibody-opsonized 
liposomes by tumor cells." Proc Natl Acad Sci U S A 77(7): 4089-4093. 
Leskinen, J. J. and K. Hynynen (2012). "Study of factors affecting the magnitude and nature of 
ultrasound exposure with in vitro set-ups." Ultrasound Med Biol 38(5): 777-794. 
Li, C., M. Curreli, et al. (2005). "Complementary detection of prostate-specific antigen using In2O3 
nanowires and carbon nanotubes." J Am Chem Soc 127(36): 12484-12485. 
Li, L., M. Zhao, et al. (2012). "Self-complexation and complexation-controlled target cancer therapy." 
MedChemComm 3(9): 1059. 
Li, X., Y. P. Zhang, et al. (2005). "Gene therapy for prostate cancer by controlling adenovirus E1a and 
E4 gene expression with PSES enhancer." Cancer Res 65(5): 1941-1951. 
Li, Y. Y., W. H. Sha, et al. (2007). "Short and long term efficacy of high intensity focused ultrasound 
therapy for advanced hepatocellular carcinoma." J Gastroenterol Hepatol 22(12): 2148-2154. 
Li, Y. Y., X. Z. Zhang, et al. (2006). "Thermosensitive Y-Shaped Micelles of Poly(oleic 
acid-Y-N-isopropylacrylamide) for Drug Delivery." Small 2(7): 917-923. 
Lim, E.-K., Y.-M. Huh, et al. (2011). "pH-Triggered Drug-Releasing Magnetic Nanoparticles for Cancer 
Therapy Guided by Molecular Imaging by MRI." Advanced Materials 23(21): 2436-2442. 
Lim, J. and E. E. Simanek (2012). "Triazine dendrimers as drug delivery systems: from synthesis to 
therapy." Adv Drug Deliv Rev 64(9): 826-835. 
Lin, C.-Y., J.-R. Li, et al. (2012). "Enhancement of focused ultrasound with microbubbles on the 
treatments of anticancer nanodrug in mouse tumors." Nanomedicine: Nanotechnology, Biology 
and Medicine 8(6): 900-907. 
Lin, C. Y., Y. L. Huang, et al. (2010). "Effects of focused ultrasound and microbubbles on the vascular 
permeability of nanoparticles delivered into mouse tumors." Ultrasound Med Biol 36(9): 
1460-1469. 
Lindner, J. R. (2002). "Contrast echocardiography." Current Problems in Cardiology 27(11): 454-519. 
Liu, S.-Q., N. Wiradharmaa, et al. (2007). "Bio-functional micelles self-assembled from a 
folate-conjugated block copolymer for targeted intracellular delivery of anticancer drugs." 
Biomaterials 28(7): 1423-1433. 
Liu, Y., C.-W. Cho, et al. (2001). "Ultrasound-Induced hyperthermia increases cellular Uptake and 
Cytotoxicity of P-Glycoprotein 
Substrates in Multi-Drug 
Resistant Cells." Pharmaceutical Research 18(9). 
Liu, Y., D. A. Peterson, et al. (1997). "Mechanism of cellular 
A.xxix 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction." J Neurochem 
69(2): 581-593. 
Lo, Y.-L., C.-S. Chu, et al. (2008). "Temperature compensation of fluorescence intensity-based 
fiber-optic oxygen sensors using modified Stern–Volmer model." Sensors and Actuators B: 
Chemical 131(2): 479-488. 
Loftsson, T. and N. Bodor (1995). "Effect of cyclodextrins on percutaneous transport of drugs. In: Smith, 
E.W., 
Maibach, H.I. (Eds.),." Percutaneous Penetration Enhancers. CRC Press, Boca Raton, FL,: 335-342. 
Loftsson, T. and M. E. Brewster (1996). "Pharmaceutical applications of cyclodextrins. 1. Drug 
solubilization and stabilization." J Pharm Sci 85(10): 1017-1025. 
Loftsson, T. and D. Duchene (2007). "Cyclodextrins and their pharmaceutical applications." 
International Journal of Pharmaceutics 329(1-2): 1-11. 
Loftsson, T. and M. Masson (2001). "Cyclodextrins in topical drug formulations: theory and practice." 
International Journal of Pharmaceutics 225: 15-30. 
Low, P. S. and A. C. Antony (2004). "Folate receptor-targeted drugs for cancer and inflammatory 
diseases." Adv. Drug Deliv. Rev. 56(8): 1055-1058. 
Lu, Y. and K. Park (2013). "Polymeric micelles and alternative nanonized delivery vehicles for poorly 
soluble drugs." International Journal of Pharmaceutics 453(1): 198-214. 
Lukyanov, A. N., T. A. Elbayoumi, et al. (2004). "Tumor-targeted liposomes: doxorubicin-loaded 
long-circulating liposomes modified with anti-cancer antibody." J. Control. Rel. 100(1): 
135-144. 
Madersbacher, S. and M. Marberger (2003). "High-energy shockwaves and extracorporeal 
high-intensity focused ultrasound." J Endourol 17(8): 667-672. 
Martin, F. J., W. L. Hubbell, et al. (1981). "Immunospecific targeting of liposomes to cells: a novel and 
efficient method for covalent attachment of Fab' fragments via disulfide bonds." 
BIOCHEMISTRY 20(14): 4229-4238. 
Martone, R. L., H. Zhou, et al. (2009). "Begacestat (GSI-953): a novel, selective thiophene sulfonamide 
inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's 
disease." J Pharmacol Exp Ther 331(2): 598-608. 
Maruyama, K., T. Takizawa, et al. (1995). "Targetability of novel immunoliposomes modified with 
amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal 
antibodies." Biochim Biophys Acta 8(1): 74-80. 
Maruyama, K., T. Yuda, et al. (1991). "Effect of molecular weight in amphipathic polyethyleneglycol on 
prolonging the circulation time of large unilamellar liposomes." Chem Pharm Bull 39(6): 
1620-1622. 
Masayuki, Y., M. Mizue, et al. (1990). "Polymer micelles as novel drug carrier: Adriamycin-conjugated 
poly(ethylene glycol)-poly(aspartic acid) block copolymer." Journal of Controlled Release 
11(1–3): 269-278. 
Mason, T. J., J. P. Lorimer, et al. (1994). "Dosimetry in sonochemistry: the use of aqueous terephthalate 
ion as a fluorescence monitor." Ultrasonics Sonochemistry 1(2): S91-S95. 
Matsumura, Y., T. Hamaguchi, et al. (2004). "Phase I clinical trial and pharmacokinetic evaluation of 
NK911, a micelle-encapsulated doxorubicin." British Journal of Cancer 91(10): 1775-1781. 
Matsumura, Y. and K. Kataoka (2009). "Preclinical and clinical studies of anticancer 
agent-incorporating polymer micelles." Cancer Science 100(4): 572-579. 
A.xxx 
Mattheolabakis, G., B. Rigas, et al. (2012). "Nanodelivery strategies in cancer chemotherapy: biological 
rationale and pharmaceutical perspectives." Nanomedicine 7(10): 1577-1590. 
May, D. J., J. S. Allen, et al. (2002). "Dynamics and fragmentation of thick-shelled microbubbles." 
Ultrasonics, Ferroelectrics and Frequency Control, IEEE Transactions on 49(10): 1400-1410. 
May, J. P. and S.-D. Li (2013). "Hyperthermia-induced drug targeting." Expert Opinion on Drug 
Delivery 10(4): 511-527. 
Mayhew, E., D. Papahadjopoulos, et al. (1976). "Inhibition of tumor cell growth in vitro and in vivo by 
1-beta-D-arabinofuranosylcytosine entrapped within phospholipid vesicles." Cancer Res 36(12): 
4406-4411. 
Mayhew, E. G., D. Lasic, et al. (1992). "Pharmacokinetics and antitumor activity of epirubicin 
encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized 
phospholipid." Int J Cancer 51(2): 302-309. 
McDannold, N., C. D. Arvanitis, et al. (2012). "Temporary disruption of the blood-brain barrier by use 
of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques." Cancer 
Res 72(14): 3652-3663. 
McLean, J. R. and A. J. Mortimer (1988). "A cavitation and free radical dosimeter for ultrasound." 
Ultrasound Med Biol 14(1): 59-64. 
McNaught, A. D. and A. Wilkinson (2012). IUPAC. Compendium of Chemical Terminology, 2nd ed. 
(the "Gold Book"), WileyBlackwell; 2nd Revised edition edition. 
Merkus, F. W., J. C. Verhoef, et al. (1999). "Cyclodextrins in nasal drug delivery." Adv Drug Deliv Rev 
36(1): 41-57. 
Miller, M. W., D. L. Miller, et al. (1996). "A review of in vitro bioeffects of inertial ultrasonic cavitation 
from a mechanistic perspective." Ultrasound Med Biol 22(9): 1131-1154. 
Mills, J. K. and D. Needham (1999). "Targeted drug delivery." Expert Opinion on Therapeutic Patents 
9(11): 1499-1513. 
Mody, V., R. Siwale, et al. (2010). "Introduction to metallic nanoparticles." J Pharm Bioallied Sci 2(4): 
282-289. 
Mohammadi, A. and F. Bahrami (2014). "A nonlinear eigenvalue problem arising in a nanostructured 
quantum dot." Communications in Nonlinear Science and Numerical Simulation 19(9): 
3053-3062. 
Mohan, C. (2003). "Buffers." Calbiochem: 18-23. 
Mosmann, T. (1983). "Rapid colorimetric assay for cellular growth and survival: application to 
proliferation and cytotoxicity assays." J Immunol Methods 65(1-2): 55-63. 
Mousa, S. A. and D. J. Bharali (2011). "Nanotechnology-Based Detection and Targeted Therapy in 
Cancer: Nano-Bio Paradigms and Applications." Cancers 3(4): 2888-2903. 
Muggia, F. M. and M. D. Green (1991). "New anthracycline antitumor antibiotics." Crit. Rev. Oncol. 
Hematol. 11(1): 43-64. 
Myhr, G. and J. Moan (2006). "Synergistic and tumour selective effects of chemotherapy and ultrasound 
treatment." Cancer Lett 232(2): 206-213. 
Naji Meidani, A. R. and M. Hasan (2004). "Mathematical and physical modelling of bubble growth due 
to ultrasound." Applied Mathematical Modelling 28(4): 333-351. 
Nanjwade, B. K., H. M. Bechra, et al. (2009). "Dendrimers: Emerging polymers for drug-delivery 
systems." European Journal of Pharmaceutical Sciences 38(3): 185-196. 
Needham, D., G. Anyarambhatla, et al. (2000). "A new temperature-sensitive liposome for use with mild 
A.xxxi 
hyperthermia: characterization and testing in a human tumor xenograft model." Cancer Res 
60(5): 1197-1201. 
Negussie, A. H., P. S. Yarmolenko, et al. (2011). "Formulation and characterisation of magnetic 
resonance imageable thermally sensitive liposomes for use with magnetic resonance-guided 
high intensity focused ultrasound." Int J Hyperthermia 27(2): 140-155. 
Newkome, G. R., Z. Yao, et al. (1985). "Micelles. Part 1. Cascade molecules: a new approach to 
micelles. A [27]-arborol." The Journal of Organic Chemistry 50(11): 2003-2004. 
O'Neill, C. F., M. G. Ormerod, et al. (1996). "Apoptotic and non-apoptotic cell death induced by cis and 
trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) 
complex." Br J Cancer 74(7): 1037-1045. 
Oda, Y., N. Kobayashi, et al. (2008). "β-Cyclodextrin Conjugates with Glucose Moieties Designed as 
Drug Carriers: Their Syntheses, Evaluations Using Concanavalin A and Doxorubicin, and 
Structural Analyses by NMR Spectroscopy." Med. Chem. 4(3): 244-255. 
Oda, Y., M. Miura, et al. (2009). "Syntheses and Doxorubicin-Inclusion Abilities of β-Cyclodextrin 
Derivatives with a Hydroquinone α-Glycoside Residue Attached at the Primary Side." Chem. 
Pharm. Bull. 57(1): 74-78. 
Oda, Y., H. Yanagisawa, et al. (2008). "Design, synthesis and evaluation of d-galactose-β-cyclodextrin 
conjugates as drug-carrying molecules." Bioorg. Med. Chem. 16(19): 8830-8840. 
Okada, A., Y. Morita, et al. (2009). "Non-invasive magnetic resonance-guided focused ultrasound 
treatment of uterine fibroids in a large Japanese population: impact of the learning curve on 
patient outcome." Ultrasound Obstet Gynecol 34(5): 579-583. 
Paciotti, G. F., L. Myer, et al. (2004). "Colloidal gold: a novel nanoparticle vector for tumor directed 
drug delivery." Drug Deliv 11(3): 169-183. 
Pantarotto, D., R. Singh, et al. (2004). "Functionalized carbon nanotubes for plasmid DNA gene 
delivery." Angew Chem Int Ed Engl 43(39): 5242-5246. 
Papahadjopoulos, D., T. M. Allen, et al. (1991). "Sterically stabilized liposomes: improvements in 
pharmacokinetics and antitumor therapeutic efficacy." Proc Natl Acad Sci U S A 88(24): 
11460-11464. 
Papahadjopoulos, D. and A. Gabizon (1987). "Targeting of liposomes to tumor cells in vivo." Ann. N. Y. 
Acad. Sci 507: 64-74. 
Park, J. W. (2002). "Liposome-based drug delivery in breast cancer treatment." Breast Cancer Res 4(3): 
95-99. 
Park, J. W. (2006). Chapter 1 - Fluorescence Methods for Studies of Cyclodextrin Inclusion 
Complexation and Excitation Transfer in Cyclodextrin Complexes. Cyclodextrin Materials 
Photochemistry, Photophysics and Photobiology. A. Douhal. Amsterdam, Elsevier. 1: 1-26. 
Park, J. W. (2006). Cyclodextrin Materials Photochemistry, Photophysics and Photobiology. 
Patri, A. K., J. F. Kukowska-Latallo, et al. (2005). "Targeted drug delivery with dendrimers: comparison 
of the release kinetics of covalently conjugated drug and non-covalent drug inclusion 
complex." Adv Drug Deliv Rev 57(15): 2203-2214. 
Peer, D., J. M. Karp, et al. (2007). "Nanocarriers as an emerging platform for cancer therapy." Nat Nano 
2(12): 751-760. 
Pisanic, T. R., J. D. Blackwell, et al. (2007). "Nanotoxicity of iron oxide nanoparticle internalization in 
growing neurons." Biomaterials 28(16): 2572-2581. 
Pitt, W. G., G. A. Husseini, et al. (2004). "Ultrasonic drug delivery--a general review." Expert Opin 
A.xxxii 
Drug Deliv 1(1): 37-56. 
Pitt, W. G. and S. A. Ross (2003). "Ultrasound Increases the Rate of Bacterial Cell Growth." 
Biotechnology Progress 19(3): 1038-1044. 
Ponce, A. M., Z. Vujaskovic, et al. (2006). "Hyperthermia mediated liposomal drug delivery." Int J 
Hyperthermia 22(3): 205-213. 
Prentice, P., A. Cuschieri, et al. (2005). "Membrane disruption by optically controlled microbubble 
cavitation." Nat Phys 1(2): 107-110. 
Presant, C. A., D. Blayney, et al. (1990). "Preliminary report: imaging of Kaposi sarcoma and 
lymphoma in AIDS with indium-111-labelled liposomes." The Lancet 335(8701): 1307-1309. 
Presant, C. A., R. T. Proffitt, et al. (1988). "Successful Imaging of human cancer with 
Indium-111-labeled phospholipid vesiccles." Cancer 62: 905. 
Price, R., J. Chappell, et al. (2006). "Nanoparticle delivery into biological tissues by ultrasonic 
microbubble destruction." Nanomedicine 2(4): 273. 
Primeau, A. J., A. Rendon, et al. (2005). "The distribution of the anticancer drug Doxorubicin in relation 
to blood vessels in solid tumors." Clin Cancer Res 11(24 Pt 1): 8782-8788. 
Purushotham, S., P. E. Chang, et al. (2009). "Thermoresponsive core-shell magnetic nanoparticles for 
combined modalities of cancer therapy." Nanotechnology 20(30): 0957-4484. 
Qian, W. Y., D. M. Sun, et al. (2012). "pH-sensitive strontium carbonate nanoparticles as new 
anticancer vehicles for controlled etoposide release." Int J Nanomedicine 7: 5781-5792. 
Qian, X., X. Peng, et al. (2008). "In vivo tumor targeting and spectroscopic detection with 
surface-enhanced Raman nanoparticle tags." Nat Biotechnol 26(1): 83-90. 
Quate, C. and C. Gerber (1986). "Atomic Force Microscopy." 
Quintana, A., E. Raczka, et al. (2002). "Design and function of a dendrimer-based therapeutic 
nanodevice targeted to tumor cells through the folate receptor." Pharm Res 19(9): 1310-1316. 
Radmacher, M. (1997). "Measuring the elastic properties of biological samples with the AFM." IEEE 
Eng Med Biol Mag 16(2): 47-57. 
Rahimi, M., S. Kilaru, et al. (2008). "Synthesis and Characterization of Thermo-Sensitive Nanoparticles 
for Drug Delivery Applications." J Biomed Nanotechnol 4(4): 482-490. 
Rajewski, R. A. and V. J. Stella (1996). "Pharmaceutical applications of cyclodextrins. 2. In vivo drug 
delivery." J Pharm Sci 85(11): 1142-1169. 
Ranjan, A., G. C. Jacobs, et al. (2012). "Image-guided drug delivery with magnetic resonance guided 
high intensity focused ultrasound and temperature sensitive liposomes in a rabbit Vx2 tumor 
model." J Control Release 158(3): 487-494. 
Rapoport, N. Y., A. M. Kennedy, et al. (2009). "Controlled and targeted tumor chemotherapy by 
ultrasound-activated nanoemulsions/microbubbles." J Control Release 138(3): 268-276. 
Reeuwijk, H. J. E. M., H. Irth, et al. (1993). "Liquid chromatographic determination of β-cyclodextrin 
derivatives based on fluorescene enhancement after inclusion complexation." J. Chromatogr 
614: 95-101. 
Reilly, R. M. (2007). "Carbon nanotubes: potential benefits and risks of nanotechnology in nuclear 
medicine." J Nucl Med 48(7): 1039-1042. 
Rekharsky, M. V. and Y. Inoue (1998). "Complexation Thermodynamics of Cyclodextrins." Chem Rev 
98(5): 1875-1918. 
Rodriguez, M. A., R. Pytlik, et al. (2009). "Vincristine sulfate liposomes injection (Marqibo) in heavily 
pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal 
A.xxxiii 
phase 2 study." Cancer 115(15): 3475-3482. 
Saar, M., C. Körbel, et al. (2012). "Experimental orthotopic prostate tumor in nude mice: Techniques for 
local cell inoculation and three-dimensional ultrasound monitoring." Urologic Oncology: 
Seminars and Original Investigations 30(3): 330-338. 
Sætern, A. M., N. B. Nguyen, et al. (2004). "Effect of hydroxypropyl-β-cyclodextrin-complexation and 
pH on solubility of camptothecin." International Journal of Pharmaceutics 284(1–2): 61-68. 
Safinya, C. R. and K. K. Ewert (2012). "Materials chemistry: Liposomes derived from molecular vases." 
Nature 489(7416): 372-374. 
Saikawa, Y., C. B. Knight, et al. (1993). "Decreased expression of the human folate receptor mediates 
transport-defective methotrexate resistance in KB cells." J Biol Chem 268(7): 5293-5301. 
Sampathkumar, S.-G. and K. J. Yarema (2007). "Dendrimers in Cancer Treatment and Diagnosis, Edited 
by Challa S. S. R. Kumar " Nanomaterials for Cancer Diagnosis, Nanotechnologies for the Life 
Sciences 7: 1-43. 
Sarker, D. and P. Workman (2007). "Pharmacodynamic biomarkers for molecular cancer therapeutics." 
Adv Cancer Res 96: 213-268. 
Sarris, A. H., F. Hagemeister, et al. (2000). "Liposomal vincristine in relapsed non-Hodgkin's 
lymphomas: early results of an ongoing phase II trial." Ann Oncol 11(1): 69-72. 
Schaaf, A., S. Langbein, et al. (2003). "In vitro transfection of human bladder cancer cells by acoustic 
energy." Anticancer Res 23(6C): 4871-4875. 
Schardinger, F. (1903). "U  ¨ ber Thermophile Bakterien aus verschiedenen Speisen und Milch, 
sowie u¨ber einige Umsetzungsprodukte derselben in kohlenhydrathaltigen N a¨hrl o¨sungen, 
darunter krystallisierte Polysaccharide (Dextrine) aus St a¨rke." Z. Untersuch. Nahr. u. Genussm. 
6: 865-880. 
Schardinger, F. (1911). "Bildung kristallisierter Polysaccharide (Dextrine) aus St a¨rkekleister durch 
Microben. Zentralbl." Bakteriol. Parasitenk. Abt. II 29: 188-197. 
Schlicher, R. K., H. Radhakrishna, et al. (2006). "Mechanism of intracellular delivery by acoustic 
cavitation." Ultrasound Med Biol 32(6): 915-924. 
Schmaljohann, D. (2006). "Thermo- and pH-responsive polymers in drug delivery." Advanced Drug 
Delivery Reviews 58(15): 1655-1670. 
Schmaljohann, D. (2006). "Thermo- and pH-responsive polymers in drug delivery." Advanced Drug 
Delivery Reviews 58(15): 1655-1670. 
Schneider, H., F. Hacket, et al. (1998). "NMR Studies of Cyclodextrins and Cyclodextrin Complexes." 
Chem Rev 98(5): 1755-1786. 
Schülke, N., O. A. Varlamova, et al. (2003). "The homodimer of prostate-specific membrane antigen is a 
functional target for cancer therapy." Proceedings of the National Academy of Sciences of the 
United States of America 100(22): 12590-12595. 
Scudiero, D. A., R. H. Shoemaker, et al. (1988). "Evaluation of a soluble tetrazolium/formazan assay for 
cell growth and drug sensitivity in culture using human and other tumor cell lines." Cancer Res 
48(17): 4827-4833. 
Selvan, S. T., T. T. Y. Tan, et al. (2009). "Functional and Multifunctional Nanoparticles for Bioimaging 
and Biosensing." Langmuir 26(14): 11631-11641. 
Senior, J., C. Delgado, et al. (1991). "Influence of surface hydrophilicity of liposomes on their 
interaction with plasma protein and clearance from the circulation: studies with poly(ethylene 
glycol)-coated vesicles." Biochim Biophys Acta 11(1): 77-82. 
A.xxxiv 
Shen, D. W., Y. G. Lu, et al. (1991). "Human hepatocellular carcinoma cell lines exhibit multidrug 
resistance unrelated to MRD1 gene expression." J Cell Sci 98(Pt 3): 317-322. 
Shim, M., A. Javey, et al. (2001). "Polymer functionalization for air-stable n-type carbon nanotube 
field-effect transistors." J Am Chem Soc 123(46): 11512-11513. 
Shimamura, M., S. Kasai, et al. (2006). "Angiogenesis inhibition of arginine-rich dendrimers, TX-1943 
and TX-1944, which mimic the surface structure of endostatin." Vascul Pharmacol 45(3): 0-0. 
Singh, M., R. Sharma, et al. (2002). "Biotechnological applications of cyclodextrins." Biotechnology 
Advances 20: 341-359. 
Singh, R., Bharti, N., Madan, J. & Hiremath, S.N. (2010). "Characterization of cyclodextrin inclusion 
complexes – A review." Journal of Pharmaceutical Science and Technology 2(3): 171-183. 
Skoog, D. A. C. S. R. H. F. J. (2007). Principles of instrumental analysis. Belmont, CA, Thomson 
Brooks/Cole. 
Smith, A., H. Duan, et al. (2008). "Bioconjugated quantum dots for in vivo molecular and cellular 
imaging." Adv Drug Deliv Rev 60(11): 1226-1240. 
Son, S. J., X. Bai, et al. (2007). "Inorganic hollow nanoparticles and nanotubes in nanomedicine: Part 1. 
Drug/gene delivery applications." Drug Discovery Today 12(15–16): 650-656. 
Soppimath, K. S., C. W. Tan, et al. (2005). "pH-Triggered thermally responsive polymer core-shell 
nanoparticles for targeted drug delivery." Adv. Mater. 17: 318-323. 
Sorokin, A. V., I. I. Fylymonova, et al. (2012). "Exciton transport in amphi-PIC J-aggregates formed in 
polymer films." Optical Materials 34(12): 2091-2094. 
Sorokin, A. V., I. I. Fylymonova, et al. (2012). "Exciton transport in amphi-PIC J-aggregates formed in 
polymer films." Opt. Mater. 34: 2091-2094. 
Sparkman, O. D. (2000). Mass spectrometry desk reference. Pittsburgh, Pa., Global View Pub. 
Stella, V. J. and Q. He (2008). "Cyclodextrins." Toxicol Pathol 36(1): 30-42. 
Stella, V. J. and R. A. Rajewski (1997). "Cyclodextrins: their future in drug formulation and delivery." 
Pharm Res 14(5): 556-567. 
Stewart, M. J. and I. D. Watson (1983). "Standard units for expressing drug concentrations in biological 
fluids." British Journal of Clinical Pharmacology 16(1): 3-7. 
Straubinger, R. M., K. Hong, et al. (1983). "Endocytosis of liposomes and intracellular fate of 
encapsulated molecules: encounter with a low pH compartment after internalization in coated 
vesicles." Cell 32(4): 1069-1079. 
Sun, C., O. Veiseh, et al. (2008). "In vivo MRI detection of gliomas by chlorotoxin-conjugated 
superparamagnetic nanoprobes." Small 4(3): 372-379. 
Sundaram, J., B. R. Mellein, et al. (2003). "An experimental and theoretical analysis of 
ultrasound-induced permeabilization of cell membranes." Biophys J 84(5): 3087-3101. 
Suslick, K. S. and L. A. Crum (1998). Sonochemistry and sonoluminescence, Wiley-Interscience: New 
York. 
Suzuki, S., S. Watanabe, et al. (1995). "Preparation of long-circulating immunoliposomes containing 
adriamycin by a novel method to coat immunoliposomes with poly(ethylene glycol)." Biochim 
Biophys Acta 17(1): 9-16. 
Svenson, S. and D. A. Tomalia (2005). "Dendrimers in biomedical applications--reflections on the 
field." Adv Drug Deliv Rev 57(15): 2106-2129. 
Swiech, O., A. Mieczkowska, et al. (2012). "Intermolecular interactions between doxorubicin and 
beta-cyclodextrin 4-methoxyphenol conjugates." J Phys Chem B 116(6): 1765-1771. 
A.xxxv 
Szatmári, I. and Z. Vargay (1988). Pharmacokinetics of Dimethyl-Beta-Cyclodextrin in Rats. 
Proceedings of the Fourth International Symposium on Cyclodextrins. O. Huber and J. Szejtli, 
Springer Netherlands. 5: 407-413. 
Szejtli, J. (1988). Cyclodextrin Technology: 79-306. 
T.M. Allen, T. M., C.B. Hansen, Y.C. Chin (1992). "Stealth liposomes: an improved sustained release 
system for 1-b-D-arabinofuranosylcytosine." Cancer Res. 52: 2431-2439. 
Tabushi, I., Y. Kiyosuke, et al. (1978). "Approach to the aspects of driving force of inclusion by. 
alpha.-cyclodextrin." J. Am. Chem. Soc. 100(3): 916-919. 
Tacker, J. R. and R. U. Anderson (1982). "Delivery of antitumor drug to bladder cancer by use of phase 
transition liposomes and hyperthermia." J Urol 127(6): 1211-1214. 
Tafazzoli, M. and M. Ghiasi (2009). "Structure and conformation of α-, β- and γ-cyclodextrin in solution: 
Theoretical approaches and experimental validation." Carbohydrate Polymers 78(1): 10-15. 
Tanaka, M., Y. Iwata, et al. (1995). "Effect of 2-Hydroxypropyl-β-cyclodextrin on Percutaneous 
Absorption of Methyl Paraben." Journal of Pharmacy and Pharmacology 47(11): 897-900. 
ter Haar, G. (2007). "Therapeutic applications of ultrasound." Prog Biophys Mol Biol 93(1-3): 111-129. 
ter Haar, G., A. Shaw, et al. (2011). "Guidance on reporting ultrasound exposure conditions for 
bio-effects studies." Ultrasound Med Biol 37(2): 177-183. 
ter Haar, G. R. (2001). "High intensity focused ultrasound for the treatment of tumors." 
Echocardiography 18(4): 317-322. 
Thanou, M. and W. Gedroyc (2013). "MRI-Guided Focused Ultrasound as a New Method of Drug 
Delivery." Journal of Drug Delivery 2013: 12. 
Thomas, M. and A. M. Klibanov (2003). "Conjugation to gold nanoparticles enhances 
polyethylenimine's transfer of plasmid DNA into mammalian cells." Proceedings of the 
National Academy of Sciences 100(16): 9138-9143. 
Tinkov, S., R. Bekeredjian, et al. (2009). "Characterization of ultrasound-mediated destruction of 
drug-loaded microbubbles using an improved in vitro model." Applied Acoustics 70(10): 
1323-1329. 
Tiwari, G., R. Tiwari, et al. (2010). "Cyclodextrins in delivery systems: Applications." J Pharm 
Bioallied Sci 2(2): 72-79. 
Tomalia, D. A., H. Baker, et al. (1985). "A New Class of Polymers: Starburst-Dendritic 
Macromolecules." Polym J 17(1): 117-132. 
Tomalia, D. A., L. A. Reyna, et al. (2007). "Dendrimers as multi-purpose nanodevices for oncology 
drug delivery and diagnostic imaging." Biochem Soc Trans 35(Pt 1): 61-67. 
Tomayko, M. and C. P. Reynolds (1989). "Determination of subcutaneous tumor size in athymic (nude) 
mice." Cancer Chemotherapy and Pharmacology 24(3): 148-154. 
Torchilin, V. P. (2000). "Drug targeting." European Journal of Pharmaceutical Sciences 11, Supplement 
2(0): S81-S91. 
Totterman, A. M., N. G. Schipper, et al. (1997). "Intestinal safety of water-soluble β-cyclodextrins in 
paediatric oral solutions of spironolactone: effects on human intestinal epithelial Caco-2 cells." 
J. Pharm. Pharmacol. 49: 43-48. 
Treat, L. H., N. McDannold, et al. (2012). "Improved Anti-Tumor Effect of Liposomal Doxorubicin 
After Targeted Blood-Brain Barrier Disruption by MRI-Guided Focused Ultrasound in Rat 
Glioma." Ultrasound Med Biol 38(10): 1716-1725. 
Tuszynski, G. P. and A. Murphy (1990). "Spectrophotometric quantitation of anchorage-dependent cell 
A.xxxvi 
numbers using the bicinchoninic acid protein assay reagent." Anal Biochem 184(1): 189-191. 
Uekama, K. (2004). "Design and Evaluation of Cyclodextrin-Based Drug Formulation." 
Chem.Pharm.Bull. 52(8): 900-915. 
Uekama, K., H. Adachi, et al. (1992). "Improved transdermal delivery of prostaglandin E1 through 
hairless mouse skin: combined use of carboxymethyl-ethyl-beta-cyclodextrin and penetration 
enhancers." J Pharm Pharmacol 44(2): 119-121. 
Uekama, K., F. Hirayama, et al. (1998). "Cyclodextrin Drug Carrier Systems." Chem. Rev 98: 
2045-2076. 
Uekama, K., F. Hirayama, et al. (1998). "Cyclodextrin Drug Carrier Systems." Chem Rev 98(5): 
2045-2076. 
Vaage, J., E. Mayhew, et al. (1992). "Therapy of primary and metastatic mouse mammary carcinomas 
with doxorubicin encapsulated in long circulating liposomes." Int J Cancer 51(6): 942-948. 
van der Zee, J. (2002). "Heating the patient: a promising approach?" Ann Oncol 13(8): 1173-1184. 
van Wamel, A., K. Kooiman, et al. (2006). "Vibrating microbubbles poking individual cells: drug 
transfer into cells via sonoporation." J Control Release 112(2): 149-155. 
Vandyke, K., M. Y. White, et al. (2007). "Plant-derived MINA-05 inhibits human prostate cancer 
proliferation in vitro and lymph node spread in vivo." Neoplasia 9(4): 322-331. 
Vardharajula, S., S. Z. Ali, et al. (2012). "Functionalized carbon nanotubes: biomedical applications." 
Int J Nanomedicine 7: 5361-5374. 
Varga, G. (2011). "Alternative methods In vitro techniques: Cell and tissue cultures." Animal 
Experiments in Medicine. 
Vasir, J. K. and V. Labhasetwar (2005). "Targeted drug delivery in cancer therapy." Technology in 
cancer research & treatment 4(4): 363-374. 
Vaupel, P., F. Kallinowski, et al. (1989). "Blood flow, oxygen and nutrient supply, and metabolic 
microenvironment of human tumors: a review." Cancer Res 49(23): 6449-6465. 
Venditto, V. J. and F. C. Szoka Jr (2013). "Cancer nanomedicines: So many papers and so few drugs!" 
Advanced Drug Delivery Reviews 65(1): 80-88. 
Villeneuve, L., L. Alberti, et al. (2009). "Assay of hydroxyl radicals generated by focused ultrasound." 
Ultrason Sonochem 16(3): 339-344. 
Villiers, A. (1891). "Sur la fermentation de la f e´cule par l’action du ferment butyrique." Compt. Rend. 
Acad. Sci. 112: 536-538. 
Visaria, R. K., R. J. Griffin, et al. (2006). "Enhancement of tumor thermal therapy using gold 
nanoparticle-assisted tumor necrosis factor-alpha delivery." Mol Cancer Ther 5(4): 1014-1020. 
Vogelson, C. T. (2001). "Advances in drug delivery systems." Modern Drug Discovery 4(4): 49-50, 52. 
Vykhodtseva, N. (2010). Disruption of Blood–Brain Barrier by Focused Ultrasound for Targeted Drug 
Delivery to the Brain. 45: 35-62. 
Wagner, B. (2003). "Chapter 1 in Handbook of Photochemistry and Photobiology,." in: H. Nalwa (Ed.), 
Supramolecular Photochemistry, American Scientific Publishers, Stevenson 
Ranch, CA, 3. 
Wagner, B., S. Fitzpatrick, et al. (2003). "Fluorescence Suppression of 7-Methoxycoumarin upon 
Inclusion into Cyclodextrins." Journal of inclusion phenomena and macrocyclic chemistry 
47(3-4): 187-192. 
Wagner, B. D. (2006). Chapter 2 - The Effects of Cyclodextrins on Guest Fluorescence. Cyclodextrin 
Materials Photochemistry, Photophysics and Photobiology. A. Douhal. Amsterdam, Elsevier. 1: 
A.xxxvii 
27-59. 
Wang, P., C. Xu, et al. (2010). "Mitochondrial damage in nasopharyngeal carcinoma cells induced by 
ultrasound radiation in the presence of hypocrellin B." J Ultrasound Med 29(1): 43-50. 
Wang, Y., R. Wang, et al. (2010). "Pegylated phospholipids-based self-assembly with water-soluble 
drugs." Pharm Res 27(2): 361-370. 
Ward, M., J. Wu, et al. (2000). "Experimental study of the effects of Optison concentration on 
sonoporation in vitro." Ultrasound Med Biol 26(7): 1169-1175. 
Weidensteiner, C., W. Reichardt, et al. (2013). "Effects of the nitric oxide donor JS-K on the 
blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI." Nitric Oxide 30(0): 
17-25. 
Wiener, E. C., M. W. Brechbiel, et al. (1994). "Dendrimer-based metal chelates: a new class of magnetic 
resonance imaging contrast agents." Magn Reson Med 31(1): 1-8. 
Willis, M. and E. Forssen (1998). "Ligand-targeted liposomes." Adv. Drug Deliv. Rev. 29(3): 249-271. 
Wilson, I. D., R. Plumb, et al. (2005). "HPLC-MS-based methods for the study of metabonomics." 
Journal of Chromatography B 817(1): 67-76. 
Wolinsky, J. B. and M. W. Grinstaff (2008). "Therapeutic and diagnostic applications of dendrimers for 
cancer treatment." Adv Drug Deliv Rev 60(9): 1037-1055. 
Woodle, M. C., T. M. Allen, et al. (1992). "In vivo efficacy of vincristine entrapped in long-circulating 
liposomes." Proc. Am. Assoc. Cancer Res. 33: 447. 
Woodle, M. C., G. Storm, et al. (1992). "Prolonged systemic delivery of peptide drugs by 
long-circulating liposomes: illustration with vasopressin in the Brattleboro rat." Pharm Res 9(2): 
260-265. 
Wu, C., M. W. Brechbiel, et al. (1994). "Metal-chelate-dendrimer-antibody constructs for use in 
radioimmunotherapy and imaging." Bioorganic & Medicinal Chemistry Letters 4(3): 449-454. 
Wu, F., Z. B. Wang, et al. (2007). ""Wide local ablation" of localized breast cancer using high intensity 
focused ultrasound." J Surg Oncol 96(2): 130-136. 
Wu, F., Z. B. Wang, et al. (2003). "Preliminary experience using high intensity focused ultrasound for 
the treatment of patients with advanced stage renal malignancy." J Urol 170(6 Pt 1): 
2237-2240. 
Wu, F., Z. B. Wang, et al. (2005). "Feasibility of US-guided high-intensity focused ultrasound treatment 
in patients with advanced pancreatic cancer: initial experience." Radiology 236(3): 1034-1040. 
Wust, P., B. Hildebrandt, et al. (2002). "Hyperthermia in combined treatment of cancer." Lancet Oncol 
3(8): 487-497. 
Xiang, T.-x. and B. Anderson (2002). "Stable Supersaturated Aqueous Solutions of Silatecan 
7-t-Butyldimethylsilyl-10-Hydroxycamptothecin via Chemical Conversion in the Presence of a 
Chemically Modified β-Cyclodextrin." Pharmaceutical Research 19(8): 1215-1222. 
Xiong, L. L., J. H. Hwang, et al. (2009). "Early clinical experience using high intensity focused 
ultrasound for palliation of inoperable pancreatic cancer." Jop 10(2): 123-129. 
Xu, P., H. Tang, et al. (2004). "Enhanced stability of core-surface cross-linked micelles fabricated from 
amphiphilic brush copolymers." Biomacromolecules 5(5): 1736-1744. 
Yamanoi, T., N. Kobayashi, et al. (2006). "Preparation of a Cyclodextrin Conjugated With Two Arbutin 
Moieties as a Drug-Carrier Model, and its High Ability for the Inclusion of Doxorubicin." 
Letters in Drug Design & Discovery 3(3): 188-191. 
Yamanoi, T., N. Kobayashia, et al. (2006). "Preparation of a Cyclodextrin Conjugated With Two 
A.xxxviii 
Arbutin Moieties as a Drug-Carrier Model, and its High Ability for the Inclusion of 
Doxorubicin." Letters in Drug Design & Discovery(3): 188-191. 
Yamanoi, T., N. Yoshida, et al. (2005). "Synthesis of mono-glucose-branched cyclodextrins with a high 
inclusion ability for doxorubicin and their efficient glycosylation using Mucor hiemalis 
endo-β-N-acetylglucosaminidase." Bioorg. Medicin. Chem. Let. 15(4): 1009-1013. 
Yang, H. and W. J. Kao (2006). "Dendrimers for pharmaceutical and biomedical applications." J 
Biomater Sci Polym Ed 17(1-2): 3-19. 
Yokoyama, M., S. Inoue, et al. (1989). "Molecular design for missile drug: Synthesis of adriamycin 
conjugated with immunoglobulin G using poly(ethylene glycol)-block-poly(aspartic acid) as 
intermediate carrier." Die Makromolekulare Chemie 190(9): 2041-2054. 
Yokoyama, M., S. Inoue, et al. (1987). "Preparation of adriamycin-conjugated poly(ethylene 
glycol)-poly(aspartic acid) block copolymer. A new type of polymeric anticancer agent." Die 
Makromolekulare Chemie, Rapid Communications 8(9): 431-435. 
Yokoyama, M., T. Okano, et al. (1991). "Toxicity and antitumor activity against solid tumors of 
micelle-forming polymeric anticancer drug and its extremely long circulation in blood." Cancer 
Res 51(12): 3229-3236. 
Yokoyama, M., T. Okano, et al. (1999). "Selective Delivery of Adiramycin to a Solid Tumor Using a 
Polymeric Micelle Carrier System." Journal of Drug Targeting 7(3): 171-186. 
Yorozu, T., M. Hoshino, et al. (1982). "Fluorescence studies of pyrene inclusion complexes 
with .alpha.-, .beta.-, and .gamma.-cyclodextrins in aqueous solutions. Evidence for formation 
of pyrene dimer in .gamma.-cyclodextrin cavity." The Journal of Physical Chemistry 86(22): 
4426-4429. 
Yorozu, T., M. Hoshino, et al. (1982). "Photoexcited inclusion complexes of .beta.-naphthol 
with .alpha.-, .beta.-, and .gamma.-cyclodextrins in aqueous solutions." The Journal of Physical 
Chemistry 86(22): 4422-4426. 
Young, F. R. (1999). Cavitation, Imperial College Press. 
Yu, T., Z. Wang, et al. (2004). "A review of research into the uses of low level ultrasound in cancer 
therapy." Ultrasonics Sonochemistry 11(2): 95-103. 
Yudina, A., M. de Smet, et al. (2011). "Ultrasound-mediated intracellular drug delivery using 
microbubbles and temperature-sensitive liposomes." J Control Release 155(3): 442-448. 
Yudina, A., M. Lepetit-Coiffe, et al. (2011). "Evaluation of the temporal window for drug delivery 
following ultrasound-mediated membrane permeability enhancement." Mol Imaging Biol 13(2): 
239-249. 
Yurkovetskiy, A. F.-F., Robert J. and R. Fram (2009). "- XMT-1001, a novel polymeric camptothecin 
pro-drug in clinical development for patients with advanced cancer." Adv Drug Deliv Rev 
61(13): 1193-1202. 
Zhang, L., W. Z. Chen, et al. (2010). "Feasibility of magnetic resonance imaging-guided high intensity 
focused ultrasound therapy for ablating uterine fibroids in patients with bowel lies anterior to 
uterus." Eur J Radiol 73(2): 396-403. 
Zhang, L., H. Zhu, et al. (2009). "High-intensity focused ultrasound (HIFU): effective and safe therapy 
for hepatocellular carcinoma adjacent to major hepatic veins." Eur Radiol 19(2): 437-445. 
Zhu, H., K. Zhou, et al. (2009). "High intensity focused ultrasound (HIFU) therapy for local treatment of 
hepatocellular carcinoma: role of partial rib resection." Eur J Radiol 72(1): 160-166. 
 
A.xxxix 
 
 
